1
|
Wyrick DG, Cain N, Larsen RS, Lecoq J, Valley M, Ahmed R, Bowlus J, Boyer G, Caldejon S, Casal L, Chvilicek M, DePartee M, Groblewski PA, Huang C, Johnson K, Kato I, Larkin J, Lee E, Liang E, Luviano J, Mace K, Nayan C, Nguyen T, Reding M, Seid S, Sevigny J, Stoecklin M, Williford A, Choi H, Garrett M, Mazzucato L. Differential encoding of temporal context and expectation under representational drift across hierarchically connected areas. bioRxiv 2023:2023.06.02.543483. [PMID: 37333203 PMCID: PMC10274646 DOI: 10.1101/2023.06.02.543483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/20/2023]
Abstract
The classic view that neural populations in sensory cortices preferentially encode responses to incoming stimuli has been strongly challenged by recent experimental studies. Despite the fact that a large fraction of variance of visual responses in rodents can be attributed to behavioral state and movements, trial-history, and salience, the effects of contextual modulations and expectations on sensory-evoked responses in visual and association areas remain elusive. Here, we present a comprehensive experimental and theoretical study showing that hierarchically connected visual and association areas differentially encode the temporal context and expectation of naturalistic visual stimuli, consistent with the theory of hierarchical predictive coding. We measured neural responses to expected and unexpected sequences of natural scenes in the primary visual cortex (V1), the posterior medial higher order visual area (PM), and retrosplenial cortex (RSP) using 2-photon imaging in behaving mice collected through the Allen Institute Mindscope's OpenScope program. We found that information about image identity in neural population activity depended on the temporal context of transitions preceding each scene, and decreased along the hierarchy. Furthermore, our analyses revealed that the conjunctive encoding of temporal context and image identity was modulated by expectations of sequential events. In V1 and PM, we found enhanced and specific responses to unexpected oddball images, signaling stimulus-specific expectation violation. In contrast, in RSP the population response to oddball presentation recapitulated the missing expected image rather than the oddball image. These differential responses along the hierarchy are consistent with classic theories of hierarchical predictive coding whereby higher areas encode predictions and lower areas encode deviations from expectation. We further found evidence for drift in visual responses on the timescale of minutes. Although activity drift was present in all areas, population responses in V1 and PM, but not in RSP, maintained stable encoding of visual information and representational geometry. Instead we found that RSP drift was independent of stimulus information, suggesting a role in generating an internal model of the environment in the temporal domain. Overall, our results establish temporal context and expectation as substantial encoding dimensions in the visual cortex subject to fast representational drift and suggest that hierarchically connected areas instantiate a predictive coding mechanism.
Collapse
Affiliation(s)
- David G Wyrick
- Department of Biology and Institute of Neuroscience, University of Oregon
- Allen Institute, Mindscope program, University of Oregon
| | - Nicholas Cain
- Allen Institute, Mindscope program, University of Oregon
| | | | - Jérôme Lecoq
- Allen Institute, Mindscope program, University of Oregon
| | - Matthew Valley
- Allen Institute, Mindscope program, University of Oregon
| | - Ruweida Ahmed
- Allen Institute, Mindscope program, University of Oregon
| | - Jessica Bowlus
- Allen Institute, Mindscope program, University of Oregon
| | | | | | - Linzy Casal
- Allen Institute, Mindscope program, University of Oregon
| | | | | | | | - Cindy Huang
- Allen Institute, Mindscope program, University of Oregon
| | | | - India Kato
- Allen Institute, Mindscope program, University of Oregon
| | - Josh Larkin
- Allen Institute, Mindscope program, University of Oregon
| | - Eric Lee
- Allen Institute, Mindscope program, University of Oregon
| | | | | | - Kyla Mace
- Allen Institute, Mindscope program, University of Oregon
| | - Chelsea Nayan
- Allen Institute, Mindscope program, University of Oregon
| | | | - Melissa Reding
- Allen Institute, Mindscope program, University of Oregon
| | - Sam Seid
- Allen Institute, Mindscope program, University of Oregon
| | - Joshua Sevigny
- Allen Institute, Mindscope program, University of Oregon
| | | | - Ali Williford
- Allen Institute, Mindscope program, University of Oregon
| | - Hannah Choi
- Allen Institute, Mindscope program, University of Oregon
- School of Mathematics, Georgia Institute of Technology, University of Oregon
| | - Marina Garrett
- Allen Institute, Mindscope program, University of Oregon
| | - Luca Mazzucato
- Department of Biology and Institute of Neuroscience, University of Oregon
- Department of Mathematics and Physics, University of Oregon
| |
Collapse
|
2
|
Abratenko P, Aduszkiewicz A, Akbar F, Pons MA, Asaadi J, Aslin M, Babicz M, Badgett WF, Bagby LF, Baibussinov B, Behera B, Bellini V, Beltramello O, Benocci R, Berger J, Berkman S, Bertolucci S, Bertoni R, Betancourt M, Bettini M, Biagi S, Biery K, Bitter O, Bonesini M, Boone T, Bottino B, Braggiotti A, Brailsford D, Bremer J, Brice SJ, Brio V, Brizzolari C, Brown J, Budd HS, Calaon F, Campani A, Carber D, Carneiro M, Terrazas IC, Carranza H, Casazza D, Castellani L, Castro A, Centro S, Cerati G, Chalifour M, Chambouvet P, Chatterjee A, Cherdack D, Cherubini S, Chithirasreemadam N, Cicerchia M, Cicero V, Coan T, Cocco AG, Convery MR, Copello S, Cristaldo E, Dange AA, de Icaza Astiz I, De Roeck A, Di Domizio S, Di Noto L, Di Stefano C, Di Ferdinando D, Diwan M, Dolan S, Domine L, Donati S, Doubnik R, Drielsma F, Dyer J, Dytman S, Fabre C, Fabris F, Falcone A, Farnese C, Fava A, Ferguson H, Ferrari A, Ferraro F, Gallice N, Garcia FG, Geynisman M, Giarin M, Gibin D, Gigli SG, Gioiosa A, Gu W, Guerzoni M, Guglielmi A, Gurung G, Hahn S, Hardin K, Hausner H, Heggestuen A, Hilgenberg C, Hogan M, Howard B, Howell R, Hrivnak J, Iliescu M, Ingratta G, James C, Jang W, Jung M, Jwa YJ, Kashur L, Ketchum W, Kim JS, Koh DH, Kose U, Larkin J, Laurenti G, Lukhanin G, Marchini S, Marshall CM, Martynenko S, Mauri N, Mazzacane A, McFarland KS, Méndez DP, Menegolli A, Meng G, Miranda OG, Mladenov D, Mogan A, Moggi N, Montagna E, Montanari C, Montanari A, Mooney M, Moreno-Granados G, Mueller J, Naples D, Nebot-Guinot M, Nessi M, Nichols T, Nicoletto M, Norris B, Palestini S, Pallavicini M, Paolone V, Papaleo R, Pasqualini L, Patrizii L, Peghin R, Petrillo G, Petta C, Pia V, Pietropaolo F, Poirot J, Poppi F, Pozzato M, Prata MC, Prosser A, Putnam G, Qian X, Rampazzo G, Rappoldi A, Raselli GL, Rechenmacher R, Resnati F, Ricci AM, Riccobene G, Rice L, Richards E, Rigamonti A, Rosenberg M, Rossella M, Rubbia C, Sala P, Sapienza P, Savage G, Scaramelli A, Scarpelli A, Schmitz D, Schukraft A, Sergiampietri F, Sirri G, Smedley JS, Soha AK, Spanu M, Stanco L, Stewart J, Suarez NB, Sutera C, Tanaka HA, Tenti M, Terao K, Terranova F, Togo V, Torretta D, Torti M, Tortorici F, Tosi N, Tsai YT, Tufanli S, Turcato M, Usher T, Varanini F, Ventura S, Vercellati F, Vicenzi M, Vignoli C, Viren B, Warner D, Williams Z, Wilson RJ, Wilson P, Wolfs J, Wongjirad T, Wood A, Worcester E, Worcester M, Wospakrik M, Yu H, Yu J, Zani A, Zatti PG, Zennamo J, Zettlemoyer JC, Zhang C, Zucchelli S, Zuckerbrot M. ICARUS at the Fermilab Short-Baseline Neutrino program: initial operation. Eur Phys J C Part Fields 2023; 83:467. [PMID: 37303462 PMCID: PMC10239613 DOI: 10.1140/epjc/s10052-023-11610-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Accepted: 05/12/2023] [Indexed: 06/13/2023]
Abstract
The ICARUS collaboration employed the 760-ton T600 detector in a successful 3-year physics run at the underground LNGS laboratory, performing a sensitive search for LSND-like anomalous ν e appearance in the CERN Neutrino to Gran Sasso beam, which contributed to the constraints on the allowed neutrino oscillation parameters to a narrow region around 1 eV2 . After a significant overhaul at CERN, the T600 detector has been installed at Fermilab. In 2020 the cryogenic commissioning began with detector cool down, liquid argon filling and recirculation. ICARUS then started its operations collecting the first neutrino events from the booster neutrino beam (BNB) and the Neutrinos at the Main Injector (NuMI) beam off-axis, which were used to test the ICARUS event selection, reconstruction and analysis algorithms. ICARUS successfully completed its commissioning phase in June 2022. The first goal of the ICARUS data taking will be a study to either confirm or refute the claim by Neutrino-4 short-baseline reactor experiment. ICARUS will also perform measurement of neutrino cross sections with the NuMI beam and several Beyond Standard Model searches. After the first year of operations, ICARUS will search for evidence of sterile neutrinos jointly with the Short-Baseline Near Detector, within the Short-Baseline Neutrino program. In this paper, the main activities carried out during the overhauling and installation phases are highlighted. Preliminary technical results from the ICARUS commissioning data with the BNB and NuMI beams are presented both in terms of performance of all ICARUS subsystems and of capability to select and reconstruct neutrino events.
Collapse
Affiliation(s)
| | | | - F. Akbar
- University of Rochester, Rochester, NY 14627 USA
| | - M. Artero Pons
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - J. Asaadi
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - M. Aslin
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- Present Address: University of Wisconsin, Madison, USA
| | - M. Babicz
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
- INP-Polish Acad. Sci, Kraków, Poland
- Present Address: University of Zurich, Zurich, Switzerland
| | - W. F. Badgett
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - L. F. Bagby
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - B. Baibussinov
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - B. Behera
- Colorado State University, Fort Collins, CO 80523 USA
| | - V. Bellini
- INFN Sezione di Catania and University of Catania, Catania, Italy
| | - O. Beltramello
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - R. Benocci
- INFN Sezione di Milano Bicocca and University of Milano Bicocca, Milan, Italy
| | - J. Berger
- Colorado State University, Fort Collins, CO 80523 USA
| | - S. Berkman
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. Bertolucci
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - R. Bertoni
- INFN Sezione di Milano Bicocca and University of Milano Bicocca, Milan, Italy
| | - M. Betancourt
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. Bettini
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | | | - K. Biery
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - O. Bitter
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- Present Address: Northwestern University, Evanston, USA
| | - M. Bonesini
- INFN Sezione di Milano Bicocca and University of Milano Bicocca, Milan, Italy
| | - T. Boone
- Colorado State University, Fort Collins, CO 80523 USA
| | - B. Bottino
- INFN Sezione di Genova and University of Genova, Genoa, Italy
| | - A. Braggiotti
- INFN Sezione di Padova and University of Padova, Padua, Italy
- Istituto di Neuroscienze, CNR, Padua, Italy
| | - D. Brailsford
- SBND Collaboration, Lancaster University, Lancaster, UK
| | - J. Bremer
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - S. J. Brice
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - V. Brio
- INFN Sezione di Catania and University of Catania, Catania, Italy
| | - C. Brizzolari
- INFN Sezione di Milano Bicocca and University of Milano Bicocca, Milan, Italy
| | - J. Brown
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - H. S. Budd
- University of Rochester, Rochester, NY 14627 USA
| | - F. Calaon
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - A. Campani
- INFN Sezione di Genova and University of Genova, Genoa, Italy
| | - D. Carber
- Colorado State University, Fort Collins, CO 80523 USA
| | - M. Carneiro
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | - H. Carranza
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - D. Casazza
- INFN Sezione di Genova and University of Genova, Genoa, Italy
| | - L. Castellani
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - A. Castro
- Centro de Investigacion y de Estudios Avanzados del IPN (Cinvestav), Mexico City, Mexico
| | - S. Centro
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - G. Cerati
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. Chalifour
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - P. Chambouvet
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | | | - D. Cherdack
- University of Houston, Houston, TX 77204 USA
| | | | | | - M. Cicerchia
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - V. Cicero
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - T. Coan
- Southern Methodist University, Dallas, TX 75275 USA
| | | | - M. R. Convery
- SLAC National Acceleratory Laboratory, Menlo Park, CA 94025 USA
| | - S. Copello
- INFN Sezione di Pavia and University of Pavia, Pavia, Italy
| | - E. Cristaldo
- SBND Collaboration, Universidad Nacional de Asuncion, San Lorenzo, Paraguay
| | - A. A. Dange
- University of Texas at Arlington, Arlington, TX 76019 USA
| | | | - A. De Roeck
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - S. Di Domizio
- INFN Sezione di Genova and University of Genova, Genoa, Italy
| | - L. Di Noto
- INFN Sezione di Genova and University of Genova, Genoa, Italy
| | | | - D. Di Ferdinando
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - M. Diwan
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - S. Dolan
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - L. Domine
- SLAC National Acceleratory Laboratory, Menlo Park, CA 94025 USA
| | | | - R. Doubnik
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - F. Drielsma
- SLAC National Acceleratory Laboratory, Menlo Park, CA 94025 USA
| | - J. Dyer
- Colorado State University, Fort Collins, CO 80523 USA
| | - S. Dytman
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - C. Fabre
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - F. Fabris
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - A. Falcone
- INFN Sezione di Milano Bicocca and University of Milano Bicocca, Milan, Italy
| | - C. Farnese
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - A. Fava
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - H. Ferguson
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - F. Ferraro
- INFN Sezione di Genova and University of Genova, Genoa, Italy
| | | | - F. G. Garcia
- SLAC National Acceleratory Laboratory, Menlo Park, CA 94025 USA
| | - M. Geynisman
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. Giarin
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - D. Gibin
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - S. G. Gigli
- INFN Sezione di Pavia and University of Pavia, Pavia, Italy
| | | | - W. Gu
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Guerzoni
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - A. Guglielmi
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - G. Gurung
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - S. Hahn
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - K. Hardin
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - H. Hausner
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Heggestuen
- Colorado State University, Fort Collins, CO 80523 USA
| | - C. Hilgenberg
- Colorado State University, Fort Collins, CO 80523 USA
- Present Address: University of Minnesota, Minneapolis, USA
| | - M. Hogan
- Colorado State University, Fort Collins, CO 80523 USA
| | - B. Howard
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. Howell
- University of Rochester, Rochester, NY 14627 USA
| | - J. Hrivnak
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - M. Iliescu
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
- Present Address: INFN-LNF, Frascati, Italy
| | - G. Ingratta
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - C. James
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - W. Jang
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - M. Jung
- University of Chicago, Chicago, IL 60637 USA
- SBND Collaboration, Batavia, USA
| | - Y.-J. Jwa
- SLAC National Acceleratory Laboratory, Menlo Park, CA 94025 USA
| | - L. Kashur
- Colorado State University, Fort Collins, CO 80523 USA
| | - W. Ketchum
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. S. Kim
- University of Rochester, Rochester, NY 14627 USA
| | - D.-H. Koh
- SLAC National Acceleratory Laboratory, Menlo Park, CA 94025 USA
| | - U. Kose
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
- Present Address: ETH Zurich, Zurich, Switzerland
| | - J. Larkin
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - G. Laurenti
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - G. Lukhanin
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. Marchini
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | | | | | - N. Mauri
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - A. Mazzacane
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - D. P. Méndez
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - A. Menegolli
- INFN Sezione di Pavia and University of Pavia, Pavia, Italy
| | - G. Meng
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - O. G. Miranda
- Centro de Investigacion y de Estudios Avanzados del IPN (Cinvestav), Mexico City, Mexico
| | - D. Mladenov
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - A. Mogan
- Colorado State University, Fort Collins, CO 80523 USA
| | - N. Moggi
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - E. Montagna
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - C. Montanari
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- On leave of absence from INFN Pavia, Pavia, Italy
| | - A. Montanari
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - M. Mooney
- Colorado State University, Fort Collins, CO 80523 USA
| | - G. Moreno-Granados
- Centro de Investigacion y de Estudios Avanzados del IPN (Cinvestav), Mexico City, Mexico
| | - J. Mueller
- Colorado State University, Fort Collins, CO 80523 USA
| | - D. Naples
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | | | - M. Nessi
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - T. Nichols
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. Nicoletto
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - B. Norris
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. Palestini
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - M. Pallavicini
- INFN Sezione di Genova and University of Genova, Genoa, Italy
| | - V. Paolone
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | | | - L. Pasqualini
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - L. Patrizii
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - R. Peghin
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - G. Petrillo
- SLAC National Acceleratory Laboratory, Menlo Park, CA 94025 USA
| | - C. Petta
- INFN Sezione di Catania and University of Catania, Catania, Italy
| | - V. Pia
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - F. Pietropaolo
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
- On leave of absence from INFN Padova, Padua, Italy
| | - J. Poirot
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - F. Poppi
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - M. Pozzato
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - M. C. Prata
- INFN Sezione di Pavia and University of Pavia, Pavia, Italy
| | - A. Prosser
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. Putnam
- University of Chicago, Chicago, IL 60637 USA
| | - X. Qian
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - G. Rampazzo
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - A. Rappoldi
- INFN Sezione di Pavia and University of Pavia, Pavia, Italy
| | - G. L. Raselli
- INFN Sezione di Pavia and University of Pavia, Pavia, Italy
| | - R. Rechenmacher
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - F. Resnati
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | | | | | - L. Rice
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - E. Richards
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - A. Rigamonti
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | | | - M. Rossella
- INFN Sezione di Pavia and University of Pavia, Pavia, Italy
| | | | - P. Sala
- INFN Sezione di Milano, Milan, Italy
| | | | - G. Savage
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Scaramelli
- INFN Sezione di Pavia and University of Pavia, Pavia, Italy
| | - A. Scarpelli
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - D. Schmitz
- University of Chicago, Chicago, IL 60637 USA
| | - A. Schukraft
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - F. Sergiampietri
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
- Present Address: IPSI-INAF Torino, Turin, Italy
| | - G. Sirri
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | | | - A. K. Soha
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. Spanu
- INFN Sezione di Milano Bicocca and University of Milano Bicocca, Milan, Italy
| | - L. Stanco
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - J. Stewart
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - N. B. Suarez
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - C. Sutera
- INFN Sezione di Catania and University of Catania, Catania, Italy
| | - H. A. Tanaka
- SLAC National Acceleratory Laboratory, Menlo Park, CA 94025 USA
| | - M. Tenti
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - K. Terao
- SLAC National Acceleratory Laboratory, Menlo Park, CA 94025 USA
| | - F. Terranova
- INFN Sezione di Milano Bicocca and University of Milano Bicocca, Milan, Italy
| | - V. Togo
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - D. Torretta
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. Torti
- INFN Sezione di Milano Bicocca and University of Milano Bicocca, Milan, Italy
| | - F. Tortorici
- INFN Sezione di Catania and University of Catania, Catania, Italy
| | - N. Tosi
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - Y.-T. Tsai
- SLAC National Acceleratory Laboratory, Menlo Park, CA 94025 USA
| | - S. Tufanli
- CERN, European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - M. Turcato
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - T. Usher
- SLAC National Acceleratory Laboratory, Menlo Park, CA 94025 USA
| | - F. Varanini
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - S. Ventura
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - F. Vercellati
- INFN Sezione di Pavia and University of Pavia, Pavia, Italy
| | - M. Vicenzi
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | - B. Viren
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - D. Warner
- Colorado State University, Fort Collins, CO 80523 USA
| | - Z. Williams
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - R. J. Wilson
- Colorado State University, Fort Collins, CO 80523 USA
| | - P. Wilson
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Wolfs
- University of Rochester, Rochester, NY 14627 USA
| | | | - A. Wood
- University of Houston, Houston, TX 77204 USA
| | - E. Worcester
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Worcester
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Wospakrik
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - H. Yu
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - J. Yu
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - A. Zani
- INFN Sezione di Milano, Milan, Italy
| | - P. G. Zatti
- INFN Sezione di Padova and University of Padova, Padua, Italy
| | - J. Zennamo
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - C. Zhang
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - S. Zucchelli
- INFN Sezione di Bologna and University of Bologna, Bologna, Italy
| | - M. Zuckerbrot
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| |
Collapse
|
3
|
Haanen JBAG, Larkin J, Choueiri TK, Albiges L, Rini BI, Atkins MB, Schmidinger M, Penkov K, Michelon E, Wang J, Mariani M, di Pietro A, Motzer RJ. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open 2023; 8:101210. [PMID: 37104931 DOI: 10.1016/j.esmoop.2023.101210] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 03/03/2023] [Accepted: 03/07/2023] [Indexed: 04/29/2023] Open
Abstract
BACKGROUND We report updated data for avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma from the third interim analysis of the phase III JAVELIN Renal 101 trial. PATIENTS AND METHODS Progression-free survival (PFS), objective response rate (ORR), and duration of response per investigator assessment (RECIST version 1.1) and overall survival (OS) were evaluated in the overall population and in International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups; safety was also assessed. RESULTS Overall, median OS [95% confidence interval (CI)] was not reached [42.2 months-not estimable (NE)] with avelumab plus axitinib versus 37.8 months (31.4-NE) with sunitinib [hazard ratio (HR) 0.79, 95% CI 0.643-0.969; one-sided P = 0.0116], and median PFS (95% CI) was 13.9 months (11.1-16.6 months) versus 8.5 months (8.2-9.7 months), respectively (HR 0.67, 95% CI 0.568-0.785; one-sided P < 0.0001). In patients with IMDC favorable-, intermediate-, poor-, or intermediate plus poor-risk disease, respectively, HRs (95% CI) for OS with avelumab plus axitinib versus sunitinib were 0.66 (0.356-1.223), 0.84 (0.649-1.084), 0.60 (0.399-0.912), and 0.79 (0.636-0.983), and HRs (95% CIs) for PFS were 0.71 (0.490-1.016), 0.71 (0.578-0.866), 0.45 (0.304-0.678), and 0.66 (0.550-0.787), respectively. ORRs, complete response rates, and durations of response favored avelumab plus axitinib overall and across all risk groups. In the avelumab plus axitinib arm, 81.1% had a grade ≥3 treatment-emergent adverse event (TEAE), and incidences of TEAEs and immune-related AEs were highest <6 months after randomization. CONCLUSIONS Avelumab plus axitinib continues to show improved efficacy versus sunitinib and a tolerable safety profile overall and across IMDC risk groups. The OS trend favors avelumab plus axitinib versus sunitinib, but data remain immature; follow-up is ongoing. TRIAL REGISTRATION ClinicalTrials.govNCT02684006; https://clinicaltrials.gov/ct2/show/NCT02684006.
Collapse
Affiliation(s)
- J B A G Haanen
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
| | - J Larkin
- Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK
| | - T K Choueiri
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, USA
| | - L Albiges
- Department of Oncology, Institut Gustave Roussy, Villejuif, France
| | - B I Rini
- Hematology Oncology, Vanderbilt-Ingram Cancer Center, Nashville, USA
| | - M B Atkins
- Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA
| | - M Schmidinger
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - K Penkov
- Private Medical Institution Euromedservice, St. Petersburg, Russia
| | | | | | | | | | - R J Motzer
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| |
Collapse
|
4
|
Hassel J, Sarnaik A, Chesney J, Medina T, Hamid O, Thomas S, Wermke M, Domingo-Musibay E, Kirkwood J, Larkin J, Weber J, Arance Fernandez A, Rodriguez J, Thomas I, Corrie P, Gontcharova V, Wu X, Shi W, Kluger H. 35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
5
|
Zhang S, Cartwright E, Mullings S, Ferro Lopez L, Cunningham D, Chau I, Starling N, Popat S, O'Brien M, Bhosle J, Minchom A, Davidson M, Tokaca N, Lalondrelle S, Pickering L, Furness A, Turajlic S, Larkin J, José R, Young K. 87P Infliximab use in patients with checkpoint inhibitor toxicities: A tertiary centre experience. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
6
|
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33:1217-1238. [PMID: 36270461 DOI: 10.1016/j.annonc.2022.10.001] [Citation(s) in RCA: 170] [Impact Index Per Article: 85.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 09/30/2022] [Accepted: 10/02/2022] [Indexed: 11/17/2022] Open
Affiliation(s)
- J Haanen
- Division of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands
| | - M Obeid
- Immunology and Allergy Service, CHUV, Lausanne; Lausanne Center for Immuno-oncology Toxicities (LCIT), CHUV, Lausanne; Department of Oncology, CHUV, Lausanne, Switzerland
| | - L Spain
- Medical Oncology Department, Peter MacCallum Cancer Centre, Melbourne; Department of Medical Oncology, Eastern Health, Melbourne; Monash University Eastern Health Clinical School, Box Hill, Australia
| | - F Carbonnel
- Gastroenterology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, Le Kremlin Bicêtre, France; Université Paris Saclay 11, Le Kremlin-Bicêtre, France
| | - Y Wang
- Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - C Robert
- Department of Medicine, Gustave Roussy Cancer Centre, Villejuif; Paris-Saclay University, Villejuif, France
| | - A R Lyon
- Cardio-Oncology Service, Royal Brompton Hospital, London; National Heart and Lung Institute, Imperial College London, London, UK
| | - W Wick
- Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg; DKTK and Clinical Cooperation Unit NeuroOncology, DKFZ, Heidelberg, Germany
| | - M Kostine
- Department of Rheumatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - S Peters
- Department of Oncology, CHUV, Lausanne, Switzerland
| | - K Jordan
- Department of Haematology, Oncology and Palliative Medicine, Ernst von Bergmann Hospital Potsdam, Potsdam; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
| | - J Larkin
- Royal Marsden NHS Foundation Trust, London, UK
| |
Collapse
|
7
|
McGarvey C, Larkin J, Costello R, Connor MO. 164 OLDER PATIENTS AT THE PREOPERATIVE ASSESSMENT CLINIC: CHANGING THE FOCUS FROM FIT FOR SURGERY TO OPTIMISATION FOR SURGERY. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The Pre-operative Assessment Clinic (PAC) is run by the Anaesthetic Department and assesses older patients undergoing elective orthopaedic surgery. The aim of this study was to examine how PAC currently assesses older patients and how effective it is in assessing for likelihood of postoperative complications and requirement for rehabilitation.
Methods
A single-centre, retrospective study that received approval from the local ethics committee. Data were collected on all patients post elective orthopaedic surgery admitted to the on-site specialist rehabilitation unit for older persons, between 1st May 2020 and 31st December 2021. Data were collected from hospital Information Technology platform, Bluespiers.
Results
Seventy-six patients (58 female; median age: 80 years) were included. Median time from PAC to surgery was 95 days. Functional assessment was completed in 63.16% of cases, formal cognitive assessment was done in 13% of cases. Number of falls in the preceding year was recorded in 31% of patients. Baseline mobility was recorded in 93% of cases. Whilst smoking and alcohol history was recorded in 96% of cases, number of units was not calculated. 45% (n=34) of patients were correctly identified as likely to require post-operative inpatient rehabilitation. PAC did not record sarcopaenia, polypharmacy or delirium risk factors. From our dataset, at least 13% had sarcopaenia, 80% had polypharmacy and 23% required opiate medications. Post-operatively, 16% of patients developed a delirium and 12% had an acute kidney injury.
Conclusion
In its current format, PAC fails to optimally risk stratify frail, older patients. Attention concentrates on fitness for surgery rather than optimisation of patients. Failure to record frailty, sarcopenia, cognitive impairment and risk factors for delirium is leading to missed opportunities in terms of delirium prevention, and peri-operative optimisation of older patients as well as discharge planning before surgery. Collaboration with specialist geriatric services at PAC should improve patient outcomes.
Collapse
Affiliation(s)
- C McGarvey
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| | - J Larkin
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| | - R Costello
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| | - MO Connor
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| |
Collapse
|
8
|
McGarvey C, Larkin J, Costello R, Connor MO. 248 BENEFITS OF POST-OPERATIVE SPECIALIST GERIATRIC CARE FOR OLDER PATIENTS UNDERGOING ELECTIVE ORTHOPAEDIC SURGERY. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The Covid-19 pandemic changed work practices across many different healthcare institutions. The difficulties with cross-site transfers created an opportunity in our institution to provide on-site post-operative rehabilitation for older patients undergoing elective orthopaedic surgery. The aim of this study is to assess the impact of post-operative specialist geriatric care on older patients.
Methods
This is a single-centre, retrospective study that received approval from the local hospital ethics committee. Data were collected on all patients admitted to the on-site specialist rehabilitation unit post-elective orthopaedic surgery between 1st May 2020 and 31st December 2021. Two patients in this group were excluded as they had not attended a pre-operative assessment clinic. Data were collected from hospital Information Technology platform, Bluespiers.
Results
76 patients, 18 males and 58 females, were included in this study. The median age was 80 years. In the specialist rehabilitation unit, evidence of cognitive impairment was established in 40.79% of cases, there were 3 cases of newly diagnosed dementia, a history of falls was identified in 32.89% of patients and 13.16% of patients were found to have sarcopaenia. The median length of stay in the rehabilitation unit was 25 days. 51.32% of patients were discharged home independently, 23.68% of patients went home with a new Home-Care Package (HCP), 15.79% of patients were discharged home with an existing HCP, 6.58% of patients were transferred for further treatment and 2.63% patients were discharged to residential care units.
Conclusion
This data demonstrates a clear role for specialist geriatric care in elective rehabilitation, with a significant proportion of patients being discharged home independently. The benefits of a comprehensive geriatric assessment in the peri-operative setting include increased identification of cognitive impairment allowing appropriate implementation of brain health as well as identification of a history of falls, enabling falls risk assessment and management including bone health assessment.
Collapse
Affiliation(s)
- C McGarvey
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| | - J Larkin
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| | - R Costello
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| | - MO Connor
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| |
Collapse
|
9
|
Diab A, Gogas H, Sandhu S, Long G, Ascierto P, Larkin J, Sznol M, Franke F, Ciuleanu TE, Muñoz Couselo E, Perfetti A, Lebbe C, Meier F, Curti B, Rojas C, Yang H, Zhou M, Ravimohan S, Tagliaferri M, Khushanlani N. 785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
10
|
Larkin J, Squifflet P, Saad E, Mohr P, Kurt M, Moshyk A, Hamilton M, Kotapati S, Buyse M. 816P Investigating surrogate endpoints (SE) for overall survival (OS) in first-line (1L) advanced melanoma: A pooled-analysis of immune checkpoint inhibitor (ICI) trials. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
11
|
Tomita Y, Larkin J, Venugopal B, Haanen J, Kanayama H, Eto M, Grimm MO, Fujii Y, Umeyama Y, Huang B, Mariani M, di Pietro A, Choueiri TK. Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. ESMO Open 2022; 7:100564. [PMID: 36037566 PMCID: PMC9588905 DOI: 10.1016/j.esmoop.2022.100564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 07/13/2022] [Accepted: 07/15/2022] [Indexed: 11/17/2022] Open
Abstract
Background C-reactive protein (CRP) is an important prognostic and predictive factor in advanced renal cell carcinoma (aRCC). We report the association of CRP levels at baseline and early after treatment with efficacy of avelumab plus axitinib or sunitinib from the phase III JAVELIN Renal 101 trial. Patients and methods Patients were categorized into normal (baseline CRP <10 mg/l), normalized (baseline CRP ≥10 mg/l and ≥1 CRP value decreased to <10 mg/l during 6-week treatment), and non-normalized (CRP ≥10 mg/l at baseline and during 6-week treatment) CRP groups. Progression-free survival and best overall response from the second interim analysis and overall survival (OS) from the third interim analysis were assessed. Results In the avelumab plus axitinib and sunitinib arms, respectively, 234, 51, and 108 patients and 232, 36, and 128 patients were categorized into normal, normalized, and non-normalized CRP groups. In respective CRP groups, objective response rates [95% confidence interval (CI)] were 56.0% (49.4% to 62.4%), 66.7% (52.1% to 79.2%), and 45.4% (35.8% to 55.2%) with avelumab plus axitinib and 30.6% (24.7% to 37.0%), 41.7% (25.5% to 59.2%), and 19.5% (13.1% to 27.5%) with sunitinib; complete response rates were 3.8%, 11.8%, and 0.9% and 3.0%, 0%, and 1.6%, respectively. Median progression-free survival (95% CI) was 15.2 months (12.5-21.0 months), not reached (NR) [11.1 months-not estimable (NE)], and 7.0 months (5.6-9.9 months) with avelumab plus axitinib and 11.2 months (8.4-13.9 months), 11.2 months (6.7-13.8 months), and 4.2 months (2.8-5.6 months) with sunitinib; median OS (95% CI) was NR (42.2 months-NE), NR (30.4 months-NE), and 23.0 months (18.4-33.1 months) and NR (39.0 months-NE), 39.8 months (21.7-NE), and 19.1 months (16.3-25.3 months), respectively. Multivariate analyses demonstrated that normalized or non-normalized CRP levels were independent factors for the prediction of objective response rate or OS, respectively, with avelumab plus axitinib. Conclusions In patients with aRCC, CRP levels at baseline and early after treatment may predict efficacy with avelumab plus axitinib. C-reactive protein is an important prognostic and predictive factor in advanced renal cell carcinoma. The association between C-reactive protein levels and the efficacy of avelumab plus axitinib or sunitinib was evaluated. C-reactive protein levels at baseline and early after treatment might predict efficacy with avelumab plus axitinib.
Collapse
Affiliation(s)
- Y Tomita
- Department of Urology, Department of Molecular Oncology, Niigata University Graduate School of Medicine, Niigata, Japan.
| | - J Larkin
- Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK
| | - B Venugopal
- Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - J Haanen
- Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - H Kanayama
- Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - M Eto
- Department of Urology, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
| | - M-O Grimm
- Department of Urology, Jena University Hospital, Jena, Germany
| | - Y Fujii
- Pfizer R&D Japan, Tokyo, Japan
| | | | | | | | | | - T K Choueiri
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
12
|
Loef M, van de Stadt L, Böhringer S, Bay-Jensen AC, Mobasheri A, Larkin J, Lafeber FPJG, Blanco FJ, Haugen IK, Berenbaum F, Giera M, Ioan-Facsinay A, Kloppenburg M. The association of the lipid profile with knee and hand osteoarthritis severity: the IMI-APPROACH cohort. Osteoarthritis Cartilage 2022; 30:1062-1069. [PMID: 35644463 DOI: 10.1016/j.joca.2022.05.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 05/16/2022] [Accepted: 05/18/2022] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To investigate the association of the lipidomic profile with osteoarthritis (OA) severity, considering the outcomes radiographic knee and hand OA, pain and function. DESIGN We used baseline data from the Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH) cohort, comprising persons with knee OA fulfilling the clinical American College of Rheumatology classification criteria. Radiographic knee and hand OA severity was quantified with Kellgren-Lawrence sum scores. Knee and hand pain and function were assessed with validated questionnaires. We quantified fasted plasma higher order lipids and oxylipins with liquid chromatography with tandem mass spectrometry (LC-MS/MS)-based platforms. Using penalised linear regression, we assessed the variance in OA severity explained by lipidomics, with adjustment for clinical covariates (age, sex, body mass index (BMI) and lipid lowering medication), measurement batch and clinical centre. RESULTS In 216 participants (mean age 66 years, mean BMI 27.3 kg/m2, 75% women) we quantified 603 higher order lipids (triacylglycerols, diacylglycerols, cholesteryl esters, ceramides, free fatty acids, sphingomyelins, phospholipids) and 28 oxylipins. Lipidomics explained 3% and 2% of the variance in radiographic knee and hand OA severity, respectively. Lipids were not associated with knee pain or function. Lipidomics accounted for 12% and 6% of variance in hand pain and function, respectively. The investigated OA severity outcomes were associated with the lipidomic fraction of bound and free arachidonic acid, bound palmitoleic acid, oleic acid, linoleic acid and docosapentaenoic acid. CONCLUSIONS Within the APPROACH cohort lipidomics explained a minor portion of the variation in OA severity, which was most evident for the outcome hand pain. Our results suggest that eicosanoids may be involved in OA severity.
Collapse
Affiliation(s)
- M Loef
- Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
| | - L van de Stadt
- Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
| | - S Böhringer
- Medical Statistics, Leiden University Medical Center, Leiden, the Netherlands.
| | - A-C Bay-Jensen
- Biomarkers and Research, Nordic Bioscience, Herlev, Denmark.
| | - A Mobasheri
- Regenerative Medicine, State Research Institute Center of Innovative Medicine, Vilnius, Lithuania.
| | - J Larkin
- GlaxoSmithKline USA, Philadelphia, PA, USA.
| | - F P J G Lafeber
- Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, the Netherlands.
| | - F J Blanco
- Servicio de Reumatologia, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain.
| | - I K Haugen
- Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
| | - F Berenbaum
- Rheumatology, Sorbonne University, INSERM, AP-HP Saint-Antoine Hospital, Paris, France.
| | - M Giera
- Center of Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.
| | - A Ioan-Facsinay
- Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
| | - M Kloppenburg
- Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
| |
Collapse
|
13
|
Abud AA, Abi B, Acciarri R, Acero MA, Adames MR, Adamov G, Adamowski M, Adams D, Adinolfi M, Aduszkiewicz A, Aguilar J, Ahmad Z, Ahmed J, Aimard B, Ali-Mohammadzadeh B, Alion T, Allison K, Monsalve SA, AlRashed M, Alt C, Alton A, Alvarez R, Amedo P, Anderson J, Andreopoulos C, Andreotti M, Andrews M, Andrianala F, Andringa S, Anfimov N, Ankowski A, Antoniassi M, Antonova M, Antoshkin A, Antusch S, Aranda-Fernandez A, Arellano L, Arnold LO, Arroyave MA, Asaadi J, Asquith L, Aurisano A, Aushev V, Autiero D, Lara VA, Ayala-Torres M, Azfar F, Back A, Back H, Back JJ, Backhouse C, Bagaturia I, Bagby L, Balashov N, Balasubramanian S, Baldi P, Baller B, Bambah B, Barao F, Barenboim G, Alzas PB, Barker G, Barkhouse W, Barnes C, Barr G, Monarca JB, Barros A, Barros N, Barrow JL, Basharina-Freshville A, Bashyal A, Basque V, Batchelor C, Chagas EBD, Battat JBR, Battisti F, Bay F, Bazetto MCQ, Alba JLLB, Beacom JF, Bechetoille E, Behera B, Beigbeder C, Bellantoni L, Bellettini G, Bellini V, Beltramello O, Benekos N, Montiel CB, Neves FB, Berger J, Berkman S, Bernardini P, Berner RM, Bersani A, Bertolucci S, Betancourt M, Rodríguez AB, Bevan A, Bezawada Y, Bezerra TJC, Bhardwaj A, Bhatnagar V, Bhattacharjee M, Bhattarai D, Bhuller S, Bhuyan B, Biagi S, Bian J, Biassoni M, Biery K, Bilki B, Bishai M, Bitadze A, Blake A, Blaszczyk F, Blazey GC, Blucher E, Boissevain J, Bolognesi S, Bolton T, Bomben L, Bonesini M, Bongrand M, Bonilla-Diaz C, Bonini F, Booth A, Boran F, Bordoni S, Borkum A, Bostan N, Bour P, Bourgeois C, Boyden D, Bracinik J, Braga D, Brailsford D, Branca A, Brandt A, Bremer J, Breton D, Brew C, Brice SJ, Brizzolari C, Bromberg C, Brooke J, Bross A, Brunetti G, Brunetti M, Buchanan N, Budd H, Butorov I, Cagnoli I, Cai T, Caiulo D, Calabrese R, Calafiura P, Calcutt J, Calin M, Calvez S, Calvo E, Caminata A, Campanelli M, Caratelli D, Carber D, Carceller JC, Carini G, Carlus B, Carneiro MF, Carniti P, Terrazas IC, Carranza H, Carroll T, Forero JFC, Castillo A, Castromonte C, Catano-Mur E, Cattadori C, Cavalier F, Cavallaro G, Cavanna F, Centro S, Cerati G, Cervelli A, Villanueva AC, Chalifour M, Chappell A, Chardonnet E, Charitonidis N, Chatterjee A, Chattopadhyay S, Neyra MSSC, Chen H, Chen M, Chen Y, Chen Z, Chen-Wishart Z, Cheon Y, Cherdack D, Chi C, Childress S, Chirco R, Chiriacescu A, Chisnall G, Cho K, Choate S, Chokheli D, Chong PS, Christensen A, Christian D, Christodoulou G, Chukanov A, Chung M, Church E, Cicero V, Clarke P, Cline G, Coan TE, Cocco AG, Coelho JAB, Colton N, Conley E, Conley R, Conrad J, Convery M, Copello S, Cova P, Cremaldi L, Cremonesi L, Crespo-Anadón JI, Crisler M, Cristaldo E, Crnkovic J, Cross R, Cudd A, Cuesta C, Cui Y, Cussans D, Dalager O, da Motta H, Da Silva Peres L, David C, David Q, Davies GS, Davini S, Dawson J, De K, De S, Debbins P, De Bonis I, Decowski MP, De Gouvêa A, De Holanda PC, De Icaza Astiz IL, Deisting A, De Jong P, Delbart A, Delepine D, Delgado M, Dell’Acqua A, Delmonte N, De Lurgio P, de Mello Neto JRT, DeMuth DM, Dennis S, Densham C, Deptuch GW, De Roeck A, De Romeri V, De Souza G, Devi R, Dharmapalan R, Dias M, Diaz F, Díaz JS, Domizio SD, Giulio LD, Ding P, Noto LD, Dirkx G, Distefano C, Diurba R, Diwan M, Djurcic Z, Doering D, Dolan S, Dolek F, Dolinski M, Domine L, Donon Y, Douglas D, Douillet D, Dragone A, Drake G, Drielsma F, Duarte L, Duchesneau D, Duffy K, Dunne P, Dutta B, Duyang H, Dvornikov O, Dwyer D, Dyshkant A, Eads M, Earle A, Edmunds D, Eisch J, Emberger L, Emery S, Englezos P, Ereditato A, Erjavec T, Escobar C, Eurin G, Evans JJ, Ewart E, Ezeribe AC, Fahey K, Falcone A, Fani’ M, Farnese C, Farzan Y, Fedoseev D, Felix J, Feng Y, Fernandez-Martinez E, Menendez PF, Morales MF, Ferraro F, Fields L, Filip P, Filthaut F, Fiorini M, Fischer V, Fitzpatrick RS, Flanagan W, Fleming B, Flight R, Fogarty S, Foreman W, Fowler J, Fox W, Franc J, Francis K, Franco D, Freeman J, Freestone J, Fried J, Friedland A, Robayo FF, Fuess S, Furic IK, Furman K, Furmanski AP, Gabrielli A, Gago A, Gallagher H, Gallas A, Gallego-Ros A, Gallice N, Galymov V, Gamberini E, Gamble T, Ganacim F, Gandhi R, Gandrajula R, Gao F, Gao S, Garcia-Gamez D, García-Peris MÁ, Gardiner S, Gastler D, Gauvreau J, Ge G, Geffroy N, Gelli B, Gendotti A, Gent S, Ghorbani-Moghaddam Z, Giammaria P, Giammaria T, Giangiacomi N, Gibin D, Gil-Botella I, Gilligan S, Girerd C, Giri AK, Gnani D, Gogota O, Gold M, Gollapinni S, Gollwitzer K, Gomes RA, Bermeo LVG, Fajardo LSG, Gonnella F, Gonzalez-Diaz D, Gonzalez-Lopez M, Goodman MC, Goodwin O, Goswami S, Gotti C, Goudzovski E, Grace C, Gran R, Granados E, Granger P, Grant A, Grant C, Gratieri D, Green P, Greenler L, Greer J, Grenard J, Griffith WC, Groh M, Grudzinski J, Grzelak K, Gu W, Guardincerri E, Guarino V, Guarise M, Guenette R, Guerard E, Guerzoni M, Guffanti D, Guglielmi A, Guo B, Gupta A, Gupta V, Guthikonda KK, Gutierrez R, Guzowski P, Guzzo MM, Gwon S, Ha C, Haaf K, Habig A, Hadavand H, Haenni R, Hahn A, Haiston J, Hamacher-Baumann P, Hamernik T, Hamilton P, Han J, Harris DA, Hartnell J, Hartnett T, Harton J, Hasegawa T, Hasnip C, Hatcher R, Hatfield KW, Hatzikoutelis A, Hayes C, Hayrapetyan K, Hays J, Hazen E, He M, Heavey A, Heeger KM, Heise J, Henry S, Morquecho MAH, Herner K, Hewes J, Hilgenberg C, Hill T, Hillier SJ, Himmel A, Hinkle E, Hirsch LR, Ho J, Hoff J, Holin A, Hoppe E, Horton-Smith GA, Hostert M, Hourlier A, Howard B, Howell R, Hoyos J, Hristova I, Hronek MS, Huang J, Hulcher Z, Iles G, Ilic N, Iliescu AM, Illingworth R, Ingratta G, Ioannisian A, Irwin B, Isenhower L, Itay R, Jackson CM, Jain V, James E, Jang W, Jargowsky B, Jediny F, Jena D, Jeong YS, Jesús-Valls C, Ji X, Jiang L, Jiménez S, Jipa A, Johnson R, Johnson W, Johnston N, Jones B, Jones S, Judah M, Jung CK, Junk T, Jwa Y, Kabirnezhad M, Kaboth A, Kadenko I, Kakorin I, Kalitkina A, Kalra D, Kamiya F, Kaneshige N, Kaplan DM, Karagiorgi G, Karaman G, Karcher A, Karolak M, Karyotakis Y, Kasai S, Kasetti SP, Kashur L, Kazaryan N, Kearns E, Keener P, Kelly KJ, Kemp E, Kemularia O, Ketchum W, Kettell SH, Khabibullin M, Khotjantsev A, Khvedelidze A, Kim D, King B, Kirby B, Kirby M, Klein J, Klustova A, Kobilarcik T, Koehler K, Koerner LW, Koh DH, Kohn S, Koller PP, Kolupaeva L, Korablev D, Kordosky M, Kosc T, Kose U, Kostelecký VA, Kothekar K, Kralik R, Kreczko L, Krennrich F, Kreslo I, Kropp W, Kroupova T, Kubota S, Kudenko Y, Kudryavtsev VA, Kulagin S, Kumar J, Kumar P, Kunze P, Kurita N, Kuruppu C, Kus V, Kutter T, Kvasnicka J, Kwak D, Lambert A, Land B, Lane CE, Lang K, Langford T, Langstaff M, Larkin J, Lasorak P, Last D, Laundrie A, Laurenti G, Lawrence A, Lazanu I, LaZur R, Lazzaroni M, Le T, Leardini S, Learned J, LeBrun P, LeCompte T, Lee C, Lee SY, Miotto GL, Lehnert R, de Oliveira MAL, Leitner M, Lepin LM, Li SW, Li Y, Liao H, Lin CS, Lin Q, Lin S, Lineros RA, Ling J, Lister A, Littlejohn BR, Liu J, Liu Y, Lockwitz S, Loew T, Lokajicek M, Lomidze I, Long K, Lord T, LoSecco JM, Louis WC, Lu XG, Luk KB, Lunday B, Luo X, Luppi E, Lux T, Luzio VP, Maalmi J, MacFarlane D, Machado AA, Machado P, Macias CT, Macier JR, Maddalena A, Madera A, Madigan P, Magill S, Mahn K, Maio A, Major A, Maloney JA, Mandrioli G, Mandujano RC, Maneira J, Manenti L, Manly S, Mann A, Manolopoulos K, Plata MM, Manyam VN, Manzanillas L, Marchan M, Marchionni A, Marciano W, Marfatia D, Mariani C, Maricic J, Marie R, Marinho F, Marino AD, Marsden D, Marshak M, Marshall C, Marshall J, Marteau J, Martín-Albo J, Martinez N, Caicedo DAM, Miravé PM, Martynenko S, Mascagna V, Mason K, Mastbaum A, Matichard F, Matsuno S, Matthews J, Mauger C, Mauri N, Mavrokoridis K, Mawby I, Mazza R, Mazzacane A, Mazzucato E, McAskill T, McCluskey E, McConkey N, McFarland KS, McGrew C, McNab A, Mefodiev A, Mehta P, Melas P, Mena O, Mendez H, Mendez P, Méndez DP, Menegolli A, Meng G, Messier MD, Metcalf W, Mettler T, Mewes M, Meyer H, Miao T, Michna G, Miedema T, Mikola V, Milincic R, Miller G, Miller W, Mills J, Mineev O, Minotti A, Miranda OG, Miryala S, Mishra CS, Mishra SR, Mislivec A, Mitchell M, Mladenov D, Mocioiu I, Moffat K, Moggi N, Mohanta R, Mohayai TA, Mokhov N, Molina J, Bueno LM, Montagna E, Montanari A, Montanari C, Montanari D, Zetina LMM, Moon SH, Mooney M, Moor AF, Moreno D, Moretti D, Morris C, Mossey C, Mote M, Motuk E, Moura CA, Mousseau J, Mouster G, Mu W, Mualem L, Mueller J, Muether M, Mufson S, Muheim F, Muir A, Mulhearn M, Munford D, Muramatsu H, Murphy S, Musser J, Nachtman J, Nagu S, Nalbandyan M, Nandakumar R, Naples D, Narita S, Nath A, Navrer-Agasson A, Nayak N, Nebot-Guinot M, Negishi K, Nelson JK, Nesbit J, Nessi M, Newbold D, Newcomer M, Newton H, Nichol R, Nicolas-Arnaldos F, Nikolica A, Niner E, Nishimura K, Norman A, Norrick A, Northrop R, Novella P, Nowak JA, Oberling M, Ochoa-Ricoux J, Olivier A, Olshevskiy A, Onel Y, Onishchuk Y, Ott J, Pagani L, Palacio G, Palamara O, Palestini S, Paley JM, Pallavicini M, Palomares C, Vazquez WP, Pantic E, Paolone V, Papadimitriou V, Papaleo R, Papanestis A, Paramesvaran S, Parke S, Parozzi E, Parsa Z, Parvu M, Pascoli S, Pasqualini L, Pasternak J, Pater J, Patrick C, Patrizii L, Patterson RB, Patton SJ, Patzak T, Paudel A, Paulos B, Paulucci L, Pavlovic Z, Pawloski G, Payne D, Pec V, Peeters SJM, Perez AP, Pennacchio E, Penzo A, Peres OLG, Perry J, Pershey D, Pessina G, Petrillo G, Petta C, Petti R, Pia V, Piastra F, Pickering L, Pietropaolo F, Pimentel VL, Pinaroli G, Plows K, Plunkett R, Poling R, Pompa F, Pons X, Poonthottathil N, Poppi F, Pordes S, Porter J, Potekhin M, Potenza R, Potukuchi BVKS, Pozimski J, Pozzato M, Prakash S, Prakash T, Prest M, Prince S, Psihas F, Pugnere D, Qian X, Raaf JL, Radeka V, Rademacker J, Radics B, Rafique A, Raguzin E, Rai M, Rajaoalisoa M, Rakhno I, Rakotonandrasana A, Rakotondravohitra L, Rameika R, Delgado MAR, Ramson B, Rappoldi A, Raselli G, Ratoff P, Raut S, Razakamiandra RF, Rea EM, Real JS, Rebel B, Rechenmacher R, Reggiani-Guzzo M, Reichenbacher J, Reitzner SD, Sfar HR, Renshaw A, Rescia S, Resnati F, Ribas M, Riboldi S, Riccio C, Riccobene G, Rice LCJ, Ricol JS, Rigamonti A, Rigaut Y, Rincón EV, Ritchie-Yates H, Rivera D, Robert A, Rochester L, Roda M, Rodrigues P, Alonso MJR, Bonilla ER, Rondon JR, Rosauro-Alcaraz S, Rosenberg M, Rosier P, Roskovec B, Rossella M, Rossi M, Rout J, Roy P, Rubbia A, Rubbia C, Russell B, Ruterbories D, Rybnikov A, Saa-Hernandez A, Saakyan R, Sacerdoti S, Safford T, Sahu N, Sakashita K, Sala P, Samios N, Samoylov O, Sanchez MC, Sandberg V, Sanders DA, Sankey D, Santana S, Santos-Maldonado M, Saoulidou N, Sapienza P, Sarasty C, Sarcevic I, Savage G, Savinov V, Scaramelli A, Scarff A, Scarpelli A, Schefke T, Schellman H, Schifano S, Schlabach P, Schmitz D, Schneider AW, Scholberg K, Schukraft A, Segreto E, Selyunin A, Senise CR, Sensenig J, Sergi A, Sgalaberna D, Shaevitz MH, Shafaq S, Shaker F, Shamma M, Sharankova R, Sharma HR, Sharma R, Sharma RK, Shaw T, Shchablo K, Shepherd-Themistocleous C, Sheshukov A, Shin S, Shoemaker I, Shooltz D, Shrock R, Siegel H, Simard L, Sinclair J, Sinev G, Singh J, Singh J, Singh L, Singh P, Singh V, Sipos R, Sippach FW, Sirri G, Sitraka A, Siyeon K, Skarpaas K, Smith A, Smith E, Smith P, Smolik J, Smy M, Snider E, Snopok P, Snowden-Ifft D, Nunes MS, Sobel H, Soderberg M, Sokolov S, Salinas CJS, Söldner-Rembold S, Soleti SR, Solomey N, Solovov V, Sondheim WE, Sorel M, Sotnikov A, Soto-Oton J, Ugaldi FAS, Sousa A, Soustruznik K, Spagliardi F, Spanu M, Spitz J, Spooner NJC, Spurgeon K, Stancari M, Stanco L, Stanford C, Stein R, Steiner HM, Lisbôa AFS, Stewart J, Stillwell B, Stock J, Stocker F, Stokes T, Strait M, Strauss T, Strigari L, Stuart A, Suarez JG, Sunción JMS, Sullivan H, Summers D, Surdo A, Susic V, Suter L, Sutera CM, Svoboda R, Szczerbinska B, Szelc AM, Tanaka H, Tang S, Tapia A, Oregui BT, Tapper A, Tariq S, Tarpara E, Tata N, Tatar E, Tayloe R, Teklu AM, Tennessen P, Tenti M, Terao K, Ternes CA, Terranova F, Testera G, Thakore T, Thea A, Thompson JL, Thorn C, Timm SC, Tishchenko V, Tomassetti L, Tonazzo A, Torbunov D, Torti M, Tortola M, Tortorici F, Tosi N, Totani D, Toups M, Touramanis C, Travaglini R, Trevor J, Trilov S, Trzaska WH, Tsai Y, Tsai YT, Tsamalaidze Z, Tsang KV, Tsverava N, Tufanli S, Tull C, Tyley E, Tzanov M, Uboldi L, Uchida MA, Urheim J, Usher T, Uzunyan S, Vagins MR, Vahle P, Valder S, Valdiviesso GDA, Valencia E, Valentim R, Vallari Z, Vallazza E, Valle JWF, Vallecorsa S, Berg RV, de Water RGV, Forero DV, Vannerom D, Varanini F, Oliva DV, Varner G, Vasel J, Vasina S, Vasseur G, Vaughan N, Vaziri K, Ventura S, Verdugo A, Vergani S, Vermeulen MA, Verzocchi M, Vicenzi M, de Souza HV, Vignoli C, Vilela C, Viren B, Vrba T, Wachala T, Waldron AV, Wallbank M, Wallis C, Wang H, Wang J, Wang L, Wang MHLS, Wang X, Wang Y, Wang Y, Warburton K, Warner D, Wascko MO, Waters D, Watson A, Wawrowska K, Weatherly P, Weber A, Weber M, Wei H, Weinstein A, Wenman D, Wetstein M, White A, Whitehead LH, Whittington D, Wilking MJ, Wilkinson A, Wilkinson C, Williams Z, Wilson F, Wilson RJ, Wisniewski W, Wolcott J, Wongjirad T, Wood A, Wood K, Worcester E, Worcester M, Wresilo K, Wret C, Wu W, Wu W, Xiao Y, Xie F, Yaeggy B, Yandel E, Yang G, Yang K, Yang T, Yankelevich A, Yershov N, Yonehara K, Yoon YS, Young T, Yu B, Yu H, Yu H, Yu J, Yu Y, Yuan W, Zaki R, Zalesak J, Zambelli L, Zamorano B, Zani A, Zazueta L, Zeller GP, Zennamo J, Zeug K, Zhang C, Zhang S, Zhang Y, Zhao M, Zhivun E, Zhu G, Zimmerman ED, Zucchelli S, Zuklin J, Zutshi V, Zwaska R. Scintillation light detection in the 6-m drift-length ProtoDUNE Dual Phase liquid argon TPC. Eur Phys J C Part Fields 2022; 82:618. [PMID: 35859696 PMCID: PMC9288420 DOI: 10.1140/epjc/s10052-022-10549-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Accepted: 06/24/2022] [Indexed: 06/15/2023]
Abstract
DUNE is a dual-site experiment for long-baseline neutrino oscillation studies, neutrino astrophysics and nucleon decay searches. ProtoDUNE Dual Phase (DP) is a 6 × 6 × 6 m 3 liquid argon time-projection-chamber (LArTPC) that recorded cosmic-muon data at the CERN Neutrino Platform in 2019-2020 as a prototype of the DUNE Far Detector. Charged particles propagating through the LArTPC produce ionization and scintillation light. The scintillation light signal in these detectors can provide the trigger for non-beam events. In addition, it adds precise timing capabilities and improves the calorimetry measurements. In ProtoDUNE-DP, scintillation and electroluminescence light produced by cosmic muons in the LArTPC is collected by photomultiplier tubes placed up to 7 m away from the ionizing track. In this paper, the ProtoDUNE-DP photon detection system performance is evaluated with a particular focus on the different wavelength shifters, such as PEN and TPB, and the use of Xe-doped LAr, considering its future use in giant LArTPCs. The scintillation light production and propagation processes are analyzed and a comparison of simulation to data is performed, improving understanding of the liquid argon properties.
Collapse
Affiliation(s)
- A. Abed Abud
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
- University of Liverpool, Liverpool, L69 7ZE UK
| | - B. Abi
- University of Oxford, Oxford, OX1 3RH UK
| | - R. Acciarri
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. A. Acero
- Universidad del Atlántico, Barranquilla, Atlántico Colombia
| | - M. R. Adames
- Universidade Tecnológica Federal do Paraná, Curitiba, Brazil
| | - G. Adamov
- Georgian Technical University, Tbilisi, Georgia
| | - M. Adamowski
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - D. Adams
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | | | - J. Aguilar
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - Z. Ahmad
- Variable Energy Cyclotron Centre, Kolkata, West Bengal 700 064 India
| | - J. Ahmed
- University of Warwick, Coventry, CV4 7AL UK
| | - B. Aimard
- Laboratoire d’Annecy de Physique des Particules, Univ. Grenoble Alpes, Univ. Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - B. Ali-Mohammadzadeh
- Università di Catania, 2, 95131 Catania, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Catania, 95123 Catania, Italy
| | - T. Alion
- University of Sussex, Brighton, BN1 9RH UK
| | - K. Allison
- University of Colorado Boulder, Boulder, CO 80309 USA
| | - S. Alonso Monsalve
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
- ETH Zurich, Zurich, Switzerland
| | - M. AlRashed
- Kansas State University, Manhattan, KS 66506 USA
| | - C. Alt
- ETH Zurich, Zurich, Switzerland
| | - A. Alton
- Augustana University, Sioux Falls, SD 57197 USA
| | - R. Alvarez
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - P. Amedo
- Instituto Galego de Fisica de Altas Enerxias, A Coruña, Spain
| | - J. Anderson
- Argonne National Laboratory, Argonne, IL 60439 USA
| | - C. Andreopoulos
- University of Liverpool, Liverpool, L69 7ZE UK
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - M. Andreotti
- University of Ferrara, Ferrara, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Ferrara, 44122 Ferrara, Italy
| | - M. Andrews
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - F. Andrianala
- University of Antananarivo, 101 Antananarivo, Madagascar
| | - S. Andringa
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003 Lisboa, 3004-516 Coimbra, Portugal
| | - N. Anfimov
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - A. Ankowski
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - M. Antoniassi
- Universidade Tecnológica Federal do Paraná, Curitiba, Brazil
| | - M. Antonova
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - A. Antoshkin
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - S. Antusch
- University of Basel, 4056 Basel, Switzerland
| | | | - L. Arellano
- University of Manchester, Manchester, M13 9PL UK
| | | | | | - J. Asaadi
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - L. Asquith
- University of Sussex, Brighton, BN1 9RH UK
| | - A. Aurisano
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - V. Aushev
- Taras Shevchenko National University of Kyiv, Kyiv, 01601 Ukraine
| | - D. Autiero
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | | | - M. Ayala-Torres
- Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (Cinvestav), Mexico City, Mexico
| | - F. Azfar
- University of Oxford, Oxford, OX1 3RH UK
| | - A. Back
- Indiana University, Bloomington, IN 47405 USA
| | - H. Back
- Pacific Northwest National Laboratory, Richland, WA 99352 USA
| | - J. J. Back
- University of Warwick, Coventry, CV4 7AL UK
| | | | | | - L. Bagby
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - N. Balashov
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | | | - P. Baldi
- University of California Irvine, Irvine, CA 92697 USA
| | - B. Baller
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - B. Bambah
- University of Hyderabad, Gachibowli, Hyderabad, 500 046 India
| | - F. Barao
- Instituto Superior Técnico-IST, Universidade de Lisboa, 1049-001 Lisbon, Portugal
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003 Lisboa, 3004-516 Coimbra, Portugal
| | - G. Barenboim
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - P. Barham Alzas
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - G. Barker
- University of Warwick, Coventry, CV4 7AL UK
| | - W. Barkhouse
- University of North Dakota, Grand Forks, ND 58202-8357 USA
| | - C. Barnes
- University of Michigan, Ann Arbor, MI 48109 USA
| | - G. Barr
- University of Oxford, Oxford, OX1 3RH UK
| | | | - A. Barros
- Universidade Tecnológica Federal do Paraná, Curitiba, Brazil
| | - N. Barros
- Faculdade de Ciências da Universidade de Lisboa-FCUL, 1749-016 Lisbon, Portugal
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003 Lisboa, 3004-516 Coimbra, Portugal
| | - J. L. Barrow
- Massachusetts Institute of Technology, Cambridge, MA 02139 USA
| | | | - A. Bashyal
- Argonne National Laboratory, Argonne, IL 60439 USA
| | - V. Basque
- University of Manchester, Manchester, M13 9PL UK
| | | | | | | | | | - F. Bay
- Antalya Bilim University, 07190 Döşemealti/Antalya, Turkey
| | - M. C. Q. Bazetto
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | | | | | - E. Bechetoille
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - B. Behera
- Colorado State University, Fort Collins, CO 80523 USA
| | - C. Beigbeder
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - L. Bellantoni
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - V. Bellini
- Università di Catania, 2, 95131 Catania, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Catania, 95123 Catania, Italy
| | - O. Beltramello
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - N. Benekos
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | - F. Bento Neves
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003 Lisboa, 3004-516 Coimbra, Portugal
| | - J. Berger
- Colorado State University, Fort Collins, CO 80523 USA
| | - S. Berkman
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - P. Bernardini
- Istituto Nazionale di Fisica Nucleare Sezione di Lecce, 73100 Lecce, Italy
- Università del Salento, 73100 Lecce, Italy
| | | | - A. Bersani
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - S. Bertolucci
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - M. Betancourt
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - A. Bevan
- Queen Mary University of London, London, E1 4NS UK
| | - Y. Bezawada
- University of California Davis, Davis, CA 95616 USA
| | | | - A. Bhardwaj
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - V. Bhatnagar
- Panjab University, Chandigarh, U.T. 160014 India
| | - M. Bhattacharjee
- Indian Institute of Technology Guwahati, Guwahati, 781 039 India
| | - D. Bhattarai
- University of Mississippi, University, MS 38677 USA
| | - S. Bhuller
- University of Bristol, Bristol, BS8 1TL UK
| | - B. Bhuyan
- Indian Institute of Technology Guwahati, Guwahati, 781 039 India
| | - S. Biagi
- Istituto Nazionale di Fisica Nucleare Laboratori Nazionali del Sud, 95123 Catania, Italy
| | - J. Bian
- University of California Irvine, Irvine, CA 92697 USA
| | - M. Biassoni
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - K. Biery
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - B. Bilki
- Beykent University, Istanbul, Turkey
- University of Iowa, Iowa City, IA 52242 USA
| | - M. Bishai
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - A. Bitadze
- University of Manchester, Manchester, M13 9PL UK
| | - A. Blake
- Lancaster University, Lancaster, LA1 4YB UK
| | - F. Blaszczyk
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. C. Blazey
- Northern Illinois University, DeKalb, IL 60115 USA
| | - E. Blucher
- University of Chicago, Chicago, IL 60637 USA
| | - J. Boissevain
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - S. Bolognesi
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - T. Bolton
- Kansas State University, Manhattan, KS 66506 USA
| | - L. Bomben
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- University of Insubria, Via Ravasi, 2, 21100 Varese, VA Italy
| | - M. Bonesini
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - M. Bongrand
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | | | - F. Bonini
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - A. Booth
- Queen Mary University of London, London, E1 4NS UK
| | - F. Boran
- Beykent University, Istanbul, Turkey
| | - S. Bordoni
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - A. Borkum
- University of Sussex, Brighton, BN1 9RH UK
| | - N. Bostan
- University of Notre Dame, Notre Dame, IN 46556 USA
| | - P. Bour
- Czech Technical University, 115 19 Prague 1, Czech Republic
| | - C. Bourgeois
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - D. Boyden
- Northern Illinois University, DeKalb, IL 60115 USA
| | - J. Bracinik
- University of Birmingham, Birmingham, B15 2TT UK
| | - D. Braga
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - A. Branca
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - A. Brandt
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - J. Bremer
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - D. Breton
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - C. Brew
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - S. J. Brice
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - C. Brizzolari
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - C. Bromberg
- Michigan State University, East Lansing, MI 48824 USA
| | - J. Brooke
- University of Bristol, Bristol, BS8 1TL UK
| | - A. Bross
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. Brunetti
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | | | - N. Buchanan
- Colorado State University, Fort Collins, CO 80523 USA
| | - H. Budd
- University of Rochester, Rochester, NY 14627 USA
| | - I. Butorov
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - I. Cagnoli
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - T. Cai
- York University, Toronto, M3J 1P3 Canada
| | - D. Caiulo
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - R. Calabrese
- University of Ferrara, Ferrara, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Ferrara, 44122 Ferrara, Italy
| | - P. Calafiura
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - J. Calcutt
- Oregon State University, Corvallis, OR 97331 USA
| | - M. Calin
- University of Bucharest, Bucharest, Romania
| | - S. Calvez
- Colorado State University, Fort Collins, CO 80523 USA
| | - E. Calvo
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - A. Caminata
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | | | - D. Caratelli
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - D. Carber
- Colorado State University, Fort Collins, CO 80523 USA
| | | | - G. Carini
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - B. Carlus
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | | | - P. Carniti
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | | | - H. Carranza
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - T. Carroll
- University of Wisconsin Madison, Madison, WI 53706 USA
| | | | - A. Castillo
- Universidad Sergio Arboleda, 11022 Bogotá, Colombia
| | | | - E. Catano-Mur
- College of William and Mary, Williamsburg, VA 23187 USA
| | - C. Cattadori
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - F. Cavalier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - G. Cavallaro
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - F. Cavanna
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. Centro
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
- Universtà degli Studi di Padova, 35131 Padua, Italy
| | - G. Cerati
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Cervelli
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - A. Cervera Villanueva
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - M. Chalifour
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | - E. Chardonnet
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | - N. Charitonidis
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | - S. Chattopadhyay
- Variable Energy Cyclotron Centre, Kolkata, West Bengal 700 064 India
| | | | - H. Chen
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Chen
- University of California Irvine, Irvine, CA 92697 USA
| | - Y. Chen
- University of Bern, 3012 Bern, Switzerland
| | - Z. Chen
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | | | - Y. Cheon
- Ulsan National Institute of Science and Technology, Ulsan, 689-798 South Korea
| | - D. Cherdack
- University of Houston, Houston, TX 77204 USA
| | - C. Chi
- Columbia University, New York, NY 10027 USA
| | - S. Childress
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. Chirco
- Illinois Institute of Technology, Chicago, IL 60616 USA
| | | | | | - K. Cho
- Korea Institute of Science and Technology Information, Daejeon, 34141 South Korea
| | - S. Choate
- Northern Illinois University, DeKalb, IL 60115 USA
| | - D. Chokheli
- Georgian Technical University, Tbilisi, Georgia
| | - P. S. Chong
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | | | - D. Christian
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. Christodoulou
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - A. Chukanov
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - M. Chung
- Ulsan National Institute of Science and Technology, Ulsan, 689-798 South Korea
| | - E. Church
- Pacific Northwest National Laboratory, Richland, WA 99352 USA
| | - V. Cicero
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - P. Clarke
- University of Edinburgh, Edinburgh, EH8 9YL UK
| | - G. Cline
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - T. E. Coan
- Southern Methodist University, Dallas, TX 75275 USA
| | - A. G. Cocco
- Istituto Nazionale di Fisica Nucleare Sezione di Napoli, 80126 Naples, Italy
| | - J. A. B. Coelho
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | - N. Colton
- Colorado State University, Fort Collins, CO 80523 USA
| | - E. Conley
- Duke University, Durham, NC 27708 USA
| | - R. Conley
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - J. Conrad
- Massachusetts Institute of Technology, Cambridge, MA 02139 USA
| | - M. Convery
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - S. Copello
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - P. Cova
- Istituto Nazionale di Fisica Nucleare Sezione di Milano, 20133 Milan, Italy
- University of Parma, 43121 Parma, PR Italy
| | - L. Cremaldi
- University of Mississippi, University, MS 38677 USA
| | - L. Cremonesi
- Queen Mary University of London, London, E1 4NS UK
| | - J. I. Crespo-Anadón
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - M. Crisler
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - E. Cristaldo
- Universidad Nacional de Asunción, San Lorenzo, Paraguay
| | - J. Crnkovic
- University of Mississippi, University, MS 38677 USA
| | - R. Cross
- Lancaster University, Lancaster, LA1 4YB UK
| | - A. Cudd
- University of Colorado Boulder, Boulder, CO 80309 USA
| | - C. Cuesta
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - Y. Cui
- University of California Riverside, Riverside, CA 92521 USA
| | - D. Cussans
- University of Bristol, Bristol, BS8 1TL UK
| | - O. Dalager
- University of California Irvine, Irvine, CA 92697 USA
| | - H. da Motta
- Centro Brasileiro de Pesquisas Físicas, Rio de Janeiro, RJ 22290-180 Brazil
| | - L. Da Silva Peres
- Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-901 Brazil
| | - C. David
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- York University, Toronto, M3J 1P3 Canada
| | - Q. David
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - G. S. Davies
- University of Mississippi, University, MS 38677 USA
| | - S. Davini
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - J. Dawson
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | - K. De
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - S. De
- University of Albany, SUNY, Albany, NY 12222 USA
| | - P. Debbins
- University of Iowa, Iowa City, IA 52242 USA
| | - I. De Bonis
- Laboratoire d’Annecy de Physique des Particules, Univ. Grenoble Alpes, Univ. Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - M. P. Decowski
- University of Amsterdam, 1098 XG Amsterdam, The Netherlands
- Nikhef National Institute of Subatomic Physics, 1098 XG Amsterdam, The Netherlands
| | | | - P. C. De Holanda
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | | | | | - P. De Jong
- University of Amsterdam, 1098 XG Amsterdam, The Netherlands
- Nikhef National Institute of Subatomic Physics, 1098 XG Amsterdam, The Netherlands
| | - A. Delbart
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - D. Delepine
- Universidad de Guanajuato, C.P. 37000 Guanajuato, Mexico
| | - M. Delgado
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - A. Dell’Acqua
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - N. Delmonte
- Istituto Nazionale di Fisica Nucleare Sezione di Milano, 20133 Milan, Italy
- University of Parma, 43121 Parma, PR Italy
| | - P. De Lurgio
- Argonne National Laboratory, Argonne, IL 60439 USA
| | | | - D. M. DeMuth
- Valley City State University, Valley City, ND 58072 USA
| | - S. Dennis
- University of Cambridge, Cambridge, CB3 0HE UK
| | - C. Densham
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | | | - A. De Roeck
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - V. De Romeri
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - G. De Souza
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - R. Devi
- University of Jammu, Jammu, 180006 India
| | | | - M. Dias
- Universidade Federal de São Paulo, São Paulo, 09913-030 Brazil
| | - F. Diaz
- Pontificia Universidad Católica del Perú, Lima, Peru
| | - J. S. Díaz
- Indiana University, Bloomington, IN 47405 USA
| | - S. Di Domizio
- Università degli Studi di Genova, Genoa, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - L. Di Giulio
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - P. Ding
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - L. Di Noto
- Università degli Studi di Genova, Genoa, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - G. Dirkx
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - C. Distefano
- Istituto Nazionale di Fisica Nucleare Laboratori Nazionali del Sud, 95123 Catania, Italy
| | - R. Diurba
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - M. Diwan
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - Z. Djurcic
- Argonne National Laboratory, Argonne, IL 60439 USA
| | - D. Doering
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - S. Dolan
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - F. Dolek
- Beykent University, Istanbul, Turkey
| | - M. Dolinski
- Drexel University, Philadelphia, PA 19104 USA
| | - L. Domine
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - Y. Donon
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - D. Douglas
- Michigan State University, East Lansing, MI 48824 USA
| | - D. Douillet
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - A. Dragone
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - G. Drake
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - F. Drielsma
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - L. Duarte
- Universidade Federal de São Paulo, São Paulo, 09913-030 Brazil
| | - D. Duchesneau
- Laboratoire d’Annecy de Physique des Particules, Univ. Grenoble Alpes, Univ. Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - K. Duffy
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - P. Dunne
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - B. Dutta
- Texas A &M University, College Station, 77840 USA
| | - H. Duyang
- University of South Carolina, Columbia, SC 29208 USA
| | | | - D. Dwyer
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - A. Dyshkant
- Northern Illinois University, DeKalb, IL 60115 USA
| | - M. Eads
- Northern Illinois University, DeKalb, IL 60115 USA
| | - A. Earle
- University of Sussex, Brighton, BN1 9RH UK
| | - D. Edmunds
- Michigan State University, East Lansing, MI 48824 USA
| | - J. Eisch
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - L. Emberger
- University of Manchester, Manchester, M13 9PL UK
- Max-Planck-Institut, 80805 Munich, Germany
| | - S. Emery
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - P. Englezos
- Rutgers University, Piscataway, NJ 08854 USA
| | | | - T. Erjavec
- University of California Davis, Davis, CA 95616 USA
| | - C. Escobar
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. Eurin
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - J. J. Evans
- University of Manchester, Manchester, M13 9PL UK
| | - E. Ewart
- Indiana University, Bloomington, IN 47405 USA
| | | | - K. Fahey
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Falcone
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - M. Fani’
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - C. Farnese
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | - Y. Farzan
- Institute for Research in Fundamental Sciences, Tehran, Iran
| | - D. Fedoseev
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - J. Felix
- Universidad de Guanajuato, C.P. 37000 Guanajuato, Mexico
| | - Y. Feng
- Iowa State University, Ames, IA 50011 USA
| | | | - P. Fernandez Menendez
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | | | - F. Ferraro
- Università degli Studi di Genova, Genoa, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - L. Fields
- University of Notre Dame, Notre Dame, IN 46556 USA
| | - P. Filip
- Institute of Physics, Czech Academy of Sciences, 182 00 Prague 8, Czech Republic
| | - F. Filthaut
- Nikhef National Institute of Subatomic Physics, 1098 XG Amsterdam, The Netherlands
- Radboud University, 6525 AJ Nijmegen, The Netherlands
| | - M. Fiorini
- University of Ferrara, Ferrara, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Ferrara, 44122 Ferrara, Italy
| | - V. Fischer
- Iowa State University, Ames, IA 50011 USA
| | | | - W. Flanagan
- University of Dallas, Irving, TX 75062-4736 USA
| | - B. Fleming
- Yale University, New Haven, CT 06520 USA
| | - R. Flight
- University of Rochester, Rochester, NY 14627 USA
| | - S. Fogarty
- Colorado State University, Fort Collins, CO 80523 USA
| | - W. Foreman
- Illinois Institute of Technology, Chicago, IL 60616 USA
| | - J. Fowler
- Duke University, Durham, NC 27708 USA
| | - W. Fox
- Indiana University, Bloomington, IN 47405 USA
| | - J. Franc
- Czech Technical University, 115 19 Prague 1, Czech Republic
| | - K. Francis
- Northern Illinois University, DeKalb, IL 60115 USA
| | - D. Franco
- Yale University, New Haven, CT 06520 USA
| | - J. Freeman
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Freestone
- University of Manchester, Manchester, M13 9PL UK
| | - J. Fried
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - A. Friedland
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | | | - S. Fuess
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - I. K. Furic
- University of Florida, Gainesville, FL 32611-8440 USA
| | - K. Furman
- Queen Mary University of London, London, E1 4NS UK
| | - A. P. Furmanski
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - A. Gabrielli
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - A. Gago
- Pontificia Universidad Católica del Perú, Lima, Peru
| | | | - A. Gallas
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - A. Gallego-Ros
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - N. Gallice
- Istituto Nazionale di Fisica Nucleare Sezione di Milano, 20133 Milan, Italy
- Università degli Studi di Milano, 20133 Milan, Italy
| | - V. Galymov
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - E. Gamberini
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - T. Gamble
- University of Sheffield, Sheffield, S3 7RH UK
| | - F. Ganacim
- Universidade Tecnológica Federal do Paraná, Curitiba, Brazil
| | - R. Gandhi
- Harish-Chandra Research Institute, Jhunsi, Allahabad, 211 019 India
| | - R. Gandrajula
- Michigan State University, East Lansing, MI 48824 USA
| | - F. Gao
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - S. Gao
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | - M. Á. García-Peris
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - S. Gardiner
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - J. Gauvreau
- Occidental College, Los Angeles, CA 90041 USA
| | - G. Ge
- Columbia University, New York, NY 10027 USA
| | - N. Geffroy
- Laboratoire d’Annecy de Physique des Particules, Univ. Grenoble Alpes, Univ. Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - B. Gelli
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | | | - S. Gent
- South Dakota State University, Brookings, SD 57007 USA
| | | | - P. Giammaria
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - T. Giammaria
- University of Ferrara, Ferrara, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Ferrara, 44122 Ferrara, Italy
| | | | - D. Gibin
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
- Universtà degli Studi di Padova, 35131 Padua, Italy
| | - I. Gil-Botella
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - S. Gilligan
- Oregon State University, Corvallis, OR 97331 USA
| | - C. Girerd
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - A. K. Giri
- Indian Institute of Technology Hyderabad, Hyderabad, 502285 India
| | - D. Gnani
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - O. Gogota
- Taras Shevchenko National University of Kyiv, Kyiv, 01601 Ukraine
| | - M. Gold
- University of New Mexico, Albuquerque, NM 87131 USA
| | - S. Gollapinni
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - K. Gollwitzer
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. A. Gomes
- Universidade Federal de Goias, Goiania, GO 74690-900 Brazil
| | | | | | - F. Gonnella
- University of Birmingham, Birmingham, B15 2TT UK
| | | | | | | | - O. Goodwin
- University of Manchester, Manchester, M13 9PL UK
| | - S. Goswami
- Physical Research Laboratory, Ahmedabad, 380 009 India
| | - C. Gotti
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | | | - C. Grace
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - R. Gran
- University of Minnesota Duluth, Duluth, MN 55812 USA
| | - E. Granados
- Universidad de Guanajuato, C.P. 37000 Guanajuato, Mexico
| | - P. Granger
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A. Grant
- Daresbury Laboratory, Cheshire, WA4 4AD UK
| | - C. Grant
- Boston University, Boston, MA 02215 USA
| | - D. Gratieri
- Fluminense Federal University, 9 Icaraí, Niterói, RJ 24220-900 Brazil
| | - P. Green
- University of Manchester, Manchester, M13 9PL UK
| | - L. Greenler
- University of Wisconsin Madison, Madison, WI 53706 USA
| | - J. Greer
- University of Bristol, Bristol, BS8 1TL UK
| | - J. Grenard
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | - M. Groh
- Colorado State University, Fort Collins, CO 80523 USA
| | | | - K. Grzelak
- University of Warsaw, 02-093 Warsaw, Poland
| | - W. Gu
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | - V. Guarino
- Argonne National Laboratory, Argonne, IL 60439 USA
| | - M. Guarise
- University of Ferrara, Ferrara, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Ferrara, 44122 Ferrara, Italy
| | | | - E. Guerard
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - M. Guerzoni
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - D. Guffanti
- Istituto Nazionale di Fisica Nucleare Sezione di Milano, 20133 Milan, Italy
| | - A. Guglielmi
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | - B. Guo
- University of South Carolina, Columbia, SC 29208 USA
| | - A. Gupta
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - V. Gupta
- Nikhef National Institute of Subatomic Physics, 1098 XG Amsterdam, The Netherlands
| | | | | | - P. Guzowski
- University of Manchester, Manchester, M13 9PL UK
| | - M. M. Guzzo
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - S. Gwon
- Chung-Ang University, Seoul, 06974 South Korea
| | - C. Ha
- Chung-Ang University, Seoul, 06974 South Korea
| | - K. Haaf
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Habig
- University of Minnesota Duluth, Duluth, MN 55812 USA
| | - H. Hadavand
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - R. Haenni
- University of Bern, 3012 Bern, Switzerland
| | - A. Hahn
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Haiston
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | | | - T. Hamernik
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - P. Hamilton
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - J. Han
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - D. A. Harris
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- York University, Toronto, M3J 1P3 Canada
| | | | - T. Hartnett
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - J. Harton
- Colorado State University, Fort Collins, CO 80523 USA
| | - T. Hasegawa
- High Energy Accelerator Research Organization (KEK), Ibaraki, 305-0801 Japan
| | - C. Hasnip
- University of Oxford, Oxford, OX1 3RH UK
| | - R. Hatcher
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | | | - C. Hayes
- Indiana University, Bloomington, IN 47405 USA
| | | | - J. Hays
- Queen Mary University of London, London, E1 4NS UK
| | - E. Hazen
- Boston University, Boston, MA 02215 USA
| | - M. He
- University of Houston, Houston, TX 77204 USA
| | - A. Heavey
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - J. Heise
- Sanford Underground Research Facility, Lead, SD 57754 USA
| | - S. Henry
- University of Rochester, Rochester, NY 14627 USA
| | | | - K. Herner
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Hewes
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - C. Hilgenberg
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - T. Hill
- Idaho State University, Pocatello, ID 83209 USA
| | | | - A. Himmel
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - E. Hinkle
- University of Chicago, Chicago, IL 60637 USA
| | - L. R. Hirsch
- Universidade Tecnológica Federal do Paraná, Curitiba, Brazil
| | - J. Ho
- Harvard University, Cambridge, MA 02138 USA
| | - J. Hoff
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Holin
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - E. Hoppe
- Pacific Northwest National Laboratory, Richland, WA 99352 USA
| | | | - M. Hostert
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - A. Hourlier
- Massachusetts Institute of Technology, Cambridge, MA 02139 USA
| | - B. Howard
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. Howell
- University of Rochester, Rochester, NY 14627 USA
| | - J. Hoyos
- University of Medellín, Medellín, 050026 Colombia
| | - I. Hristova
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - M. S. Hronek
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Huang
- University of California Davis, Davis, CA 95616 USA
| | - Z. Hulcher
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - G. Iles
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - N. Ilic
- University of Toronto, Toronto, ON M5S 1A1 Canada
| | - A. M. Iliescu
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - R. Illingworth
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. Ingratta
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - A. Ioannisian
- Yerevan Institute for Theoretical Physics and Modeling, Yerevan, 0036 Armenia
| | - B. Irwin
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - L. Isenhower
- Abilene Christian University, Abilene, TX 79601 USA
| | - R. Itay
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - C. M. Jackson
- Pacific Northwest National Laboratory, Richland, WA 99352 USA
| | - V. Jain
- University of Albany, SUNY, Albany, NY 12222 USA
| | - E. James
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - W. Jang
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - B. Jargowsky
- University of California Irvine, Irvine, CA 92697 USA
| | - F. Jediny
- Czech Technical University, 115 19 Prague 1, Czech Republic
| | - D. Jena
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - Y. S. Jeong
- Chung-Ang University, Seoul, 06974 South Korea
- University of Iowa, Iowa City, IA 52242 USA
| | - C. Jesús-Valls
- Institut de Física d’Altes Energies (IFAE)-Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
| | - X. Ji
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - L. Jiang
- Virginia Tech, Blacksburg, VA 24060 USA
| | - S. Jiménez
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - A. Jipa
- University of Bucharest, Bucharest, Romania
| | - R. Johnson
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - W. Johnson
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | - N. Johnston
- Indiana University, Bloomington, IN 47405 USA
| | - B. Jones
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - S. Jones
- University College London, London, WC1E 6BT UK
| | - M. Judah
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - C. K. Jung
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - T. Junk
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - Y. Jwa
- Columbia University, New York, NY 10027 USA
| | | | - A. Kaboth
- Royal Holloway College, London, TW20 0EX UK
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - I. Kadenko
- Taras Shevchenko National University of Kyiv, Kyiv, 01601 Ukraine
| | - I. Kakorin
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - A. Kalitkina
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - D. Kalra
- Columbia University, New York, NY 10027 USA
| | - F. Kamiya
- Universidade Federal do ABC, Santo André, SP 09210-580 Brazil
| | - N. Kaneshige
- University of California Santa Barbara, Santa Barbara, CA 93106 USA
| | - D. M. Kaplan
- Illinois Institute of Technology, Chicago, IL 60616 USA
| | | | - G. Karaman
- University of Iowa, Iowa City, IA 52242 USA
| | - A. Karcher
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - M. Karolak
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - Y. Karyotakis
- Laboratoire d’Annecy de Physique des Particules, Univ. Grenoble Alpes, Univ. Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - S. Kasai
- National Institute of Technology, Kure College, Hiroshima, 737-8506 Japan
| | - S. P. Kasetti
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - L. Kashur
- Colorado State University, Fort Collins, CO 80523 USA
| | - N. Kazaryan
- Yerevan Institute for Theoretical Physics and Modeling, Yerevan, 0036 Armenia
| | - E. Kearns
- Boston University, Boston, MA 02215 USA
| | - P. Keener
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - K. J. Kelly
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - E. Kemp
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | | | - W. Ketchum
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - M. Khabibullin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | - A. Khotjantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | | | - D. Kim
- Texas A &M University, College Station, 77840 USA
| | - B. King
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - B. Kirby
- Columbia University, New York, NY 10027 USA
| | - M. Kirby
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Klein
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - A. Klustova
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - T. Kobilarcik
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - K. Koehler
- University of Wisconsin Madison, Madison, WI 53706 USA
| | | | - D. H. Koh
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - S. Kohn
- University of California Berkeley, Berkeley, CA 94720 USA
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | | | - L. Kolupaeva
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - D. Korablev
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - M. Kordosky
- College of William and Mary, Williamsburg, VA 23187 USA
| | - T. Kosc
- University Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - U. Kose
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | | | - R. Kralik
- University of Sussex, Brighton, BN1 9RH UK
| | - L. Kreczko
- University of Bristol, Bristol, BS8 1TL UK
| | | | - I. Kreslo
- University of Bern, 3012 Bern, Switzerland
| | - W. Kropp
- University of California Irvine, Irvine, CA 92697 USA
| | - T. Kroupova
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - S. Kubota
- Harvard University, Cambridge, MA 02138 USA
| | - Y. Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | | | - S. Kulagin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | - J. Kumar
- University of Hawaii, Honolulu, HI 96822 USA
| | - P. Kumar
- University of Sheffield, Sheffield, S3 7RH UK
| | - P. Kunze
- Laboratoire d’Annecy de Physique des Particules, Univ. Grenoble Alpes, Univ. Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - N. Kurita
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - C. Kuruppu
- University of South Carolina, Columbia, SC 29208 USA
| | - V. Kus
- Czech Technical University, 115 19 Prague 1, Czech Republic
| | - T. Kutter
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - J. Kvasnicka
- Institute of Physics, Czech Academy of Sciences, 182 00 Prague 8, Czech Republic
| | - D. Kwak
- Ulsan National Institute of Science and Technology, Ulsan, 689-798 South Korea
| | - A. Lambert
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - B. Land
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - C. E. Lane
- Drexel University, Philadelphia, PA 19104 USA
| | - K. Lang
- University of Texas at Austin, Austin, TX 78712 USA
| | | | - M. Langstaff
- University of Manchester, Manchester, M13 9PL UK
| | - J. Larkin
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - P. Lasorak
- University of Sussex, Brighton, BN1 9RH UK
| | - D. Last
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - A. Laundrie
- University of Wisconsin Madison, Madison, WI 53706 USA
| | - G. Laurenti
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - A. Lawrence
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - I. Lazanu
- University of Bucharest, Bucharest, Romania
| | - R. LaZur
- Colorado State University, Fort Collins, CO 80523 USA
| | - M. Lazzaroni
- Istituto Nazionale di Fisica Nucleare Sezione di Milano, 20133 Milan, Italy
- Università degli Studi di Milano, 20133 Milan, Italy
| | - T. Le
- Tufts University, Medford, MA 02155 USA
| | - S. Leardini
- Instituto Galego de Fisica de Altas Enerxias, A Coruña, Spain
| | - J. Learned
- University of Hawaii, Honolulu, HI 96822 USA
| | - P. LeBrun
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - T. LeCompte
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - C. Lee
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. Y. Lee
- Jeonbuk National University, Jeonrabuk-do, 54896 South Korea
| | - G. Lehmann Miotto
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - R. Lehnert
- Indiana University, Bloomington, IN 47405 USA
| | | | - M. Leitner
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - L. M. Lepin
- University of Manchester, Manchester, M13 9PL UK
| | - S. W. Li
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - Y. Li
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - H. Liao
- Kansas State University, Manhattan, KS 66506 USA
| | - C. S. Lin
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - Q. Lin
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - S. Lin
- Louisiana State University, Baton Rouge, LA 70803 USA
| | | | - J. Ling
- Sun Yat-Sen University, Guangzhou, 510275 China
| | - A. Lister
- University of Wisconsin Madison, Madison, WI 53706 USA
| | | | - J. Liu
- University of California Irvine, Irvine, CA 92697 USA
| | - Y. Liu
- University of Chicago, Chicago, IL 60637 USA
| | - S. Lockwitz
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - T. Loew
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - M. Lokajicek
- Institute of Physics, Czech Academy of Sciences, 182 00 Prague 8, Czech Republic
| | - I. Lomidze
- Georgian Technical University, Tbilisi, Georgia
| | - K. Long
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - T. Lord
- University of Warwick, Coventry, CV4 7AL UK
| | | | - W. C. Louis
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - X.-G. Lu
- University of Warwick, Coventry, CV4 7AL UK
| | - K. B. Luk
- University of California Berkeley, Berkeley, CA 94720 USA
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - B. Lunday
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - X. Luo
- University of California Santa Barbara, Santa Barbara, CA 93106 USA
| | - E. Luppi
- University of Ferrara, Ferrara, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Ferrara, 44122 Ferrara, Italy
| | - T. Lux
- Institut de Física d’Altes Energies (IFAE)-Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
| | - V. P. Luzio
- Universidade Federal do ABC, Santo André, SP 09210-580 Brazil
| | - J. Maalmi
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - D. MacFarlane
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - A. A. Machado
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - P. Machado
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - J. R. Macier
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Maddalena
- Laboratori Nazionali del Gran Sasso, L’Aquila, AQ Italy
| | - A. Madera
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - P. Madigan
- University of California Berkeley, Berkeley, CA 94720 USA
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - S. Magill
- Argonne National Laboratory, Argonne, IL 60439 USA
| | - K. Mahn
- Michigan State University, East Lansing, MI 48824 USA
| | - A. Maio
- Faculdade de Ciências da Universidade de Lisboa-FCUL, 1749-016 Lisbon, Portugal
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003 Lisboa, 3004-516 Coimbra, Portugal
| | - A. Major
- Duke University, Durham, NC 27708 USA
| | | | - G. Mandrioli
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | | | - J. Maneira
- Faculdade de Ciências da Universidade de Lisboa-FCUL, 1749-016 Lisbon, Portugal
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003 Lisboa, 3004-516 Coimbra, Portugal
| | - L. Manenti
- University College London, London, WC1E 6BT UK
| | - S. Manly
- University of Rochester, Rochester, NY 14627 USA
| | - A. Mann
- Tufts University, Medford, MA 02155 USA
| | | | | | - V. N. Manyam
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - L. Manzanillas
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - M. Marchan
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Marchionni
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - W. Marciano
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - D. Marfatia
- University of Hawaii, Honolulu, HI 96822 USA
| | | | - J. Maricic
- University of Hawaii, Honolulu, HI 96822 USA
| | - R. Marie
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - F. Marinho
- Universidade Federal de São Carlos, Araras, SP 13604-900 Brazil
| | - A. D. Marino
- University of Colorado Boulder, Boulder, CO 80309 USA
| | - D. Marsden
- University of Manchester, Manchester, M13 9PL UK
| | - M. Marshak
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - C. Marshall
- University of Rochester, Rochester, NY 14627 USA
| | | | - J. Marteau
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - J. Martín-Albo
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - N. Martinez
- Kansas State University, Manhattan, KS 66506 USA
| | | | - P. Martínez Miravé
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - S. Martynenko
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - V. Mascagna
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- University of Insubria, Via Ravasi, 2, 21100 Varese, VA Italy
| | - K. Mason
- Tufts University, Medford, MA 02155 USA
| | - A. Mastbaum
- Rutgers University, Piscataway, NJ 08854 USA
| | - F. Matichard
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - S. Matsuno
- University of Hawaii, Honolulu, HI 96822 USA
| | - J. Matthews
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - C. Mauger
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - N. Mauri
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | | | - I. Mawby
- University of Warwick, Coventry, CV4 7AL UK
| | - R. Mazza
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - A. Mazzacane
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - E. Mazzucato
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | | | - E. McCluskey
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - N. McConkey
- University of Manchester, Manchester, M13 9PL UK
| | | | - C. McGrew
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - A. McNab
- University of Manchester, Manchester, M13 9PL UK
| | - A. Mefodiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | - P. Mehta
- Jawaharlal Nehru University, New Delhi, 110067 India
| | - P. Melas
- University of Athens, 157 84 Zografou, Greece
| | - O. Mena
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - H. Mendez
- University of Puerto Rico, Mayaguez, PR 00681 USA
| | - P. Mendez
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - D. P. Méndez
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - A. Menegolli
- Istituto Nazionale di Fisica Nucleare Sezione di Pavia, 27100 Pavia, Italy
- Università degli Studi di Pavia, 27100 Pavia, PV Italy
| | - G. Meng
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | | | - W. Metcalf
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - T. Mettler
- University of Bern, 3012 Bern, Switzerland
| | - M. Mewes
- Indiana University, Bloomington, IN 47405 USA
| | - H. Meyer
- Wichita State University, Wichita, KS 67260 USA
| | - T. Miao
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. Michna
- South Dakota State University, Brookings, SD 57007 USA
| | - T. Miedema
- Nikhef National Institute of Subatomic Physics, 1098 XG Amsterdam, The Netherlands
- Radboud University, 6525 AJ Nijmegen, The Netherlands
| | - V. Mikola
- University College London, London, WC1E 6BT UK
| | - R. Milincic
- University of Hawaii, Honolulu, HI 96822 USA
| | - G. Miller
- University of Manchester, Manchester, M13 9PL UK
| | - W. Miller
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - J. Mills
- Tufts University, Medford, MA 02155 USA
| | - O. Mineev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | - A. Minotti
- Istituto Nazionale di Fisica Nucleare Sezione di Milano, 20133 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - O. G. Miranda
- Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (Cinvestav), Mexico City, Mexico
| | - S. Miryala
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - C. S. Mishra
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. R. Mishra
- University of South Carolina, Columbia, SC 29208 USA
| | - A. Mislivec
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - M. Mitchell
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - D. Mladenov
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - I. Mocioiu
- Pennsylvania State University, University Park, PA 16802 USA
| | - K. Moffat
- Durham University, Durham, DH1 3LE UK
| | - N. Moggi
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - R. Mohanta
- University of Hyderabad, Gachibowli, Hyderabad, 500 046 India
| | - T. A. Mohayai
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - N. Mokhov
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Molina
- Universidad Nacional de Asunción, San Lorenzo, Paraguay
| | - L. Molina Bueno
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - E. Montagna
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - A. Montanari
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - C. Montanari
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- Istituto Nazionale di Fisica Nucleare Sezione di Pavia, 27100 Pavia, Italy
- Università degli Studi di Pavia, 27100 Pavia, PV Italy
| | - D. Montanari
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - L. M. Montañno Zetina
- Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (Cinvestav), Mexico City, Mexico
| | - S. H. Moon
- Ulsan National Institute of Science and Technology, Ulsan, 689-798 South Korea
| | - M. Mooney
- Colorado State University, Fort Collins, CO 80523 USA
| | - A. F. Moor
- University of Cambridge, Cambridge, CB3 0HE UK
| | - D. Moreno
- Universidad Antonio Nariño, Bogotá, Colombia
| | - D. Moretti
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - C. Morris
- University of Houston, Houston, TX 77204 USA
| | - C. Mossey
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. Mote
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - E. Motuk
- University College London, London, WC1E 6BT UK
| | - C. A. Moura
- Universidade Federal do ABC, Santo André, SP 09210-580 Brazil
| | - J. Mousseau
- University of Michigan, Ann Arbor, MI 48109 USA
| | - G. Mouster
- Lancaster University, Lancaster, LA1 4YB UK
| | - W. Mu
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - L. Mualem
- California Institute of Technology, Pasadena, CA 91125 USA
| | - J. Mueller
- Colorado State University, Fort Collins, CO 80523 USA
| | - M. Muether
- Wichita State University, Wichita, KS 67260 USA
| | - S. Mufson
- Indiana University, Bloomington, IN 47405 USA
| | - F. Muheim
- University of Edinburgh, Edinburgh, EH8 9YL UK
| | - A. Muir
- Daresbury Laboratory, Cheshire, WA4 4AD UK
| | - M. Mulhearn
- University of California Davis, Davis, CA 95616 USA
| | - D. Munford
- University of Houston, Houston, TX 77204 USA
| | - H. Muramatsu
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | | | - J. Musser
- Indiana University, Bloomington, IN 47405 USA
| | | | - S. Nagu
- University of Lucknow, Lucknow, Uttar Pradesh 226007 India
| | - M. Nalbandyan
- Yerevan Institute for Theoretical Physics and Modeling, Yerevan, 0036 Armenia
| | - R. Nandakumar
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - D. Naples
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - S. Narita
- Iwate University, Morioka, Iwate 020-8551 Japan
| | - A. Nath
- Indian Institute of Technology Guwahati, Guwahati, 781 039 India
| | | | - N. Nayak
- University of California Irvine, Irvine, CA 92697 USA
| | | | - K. Negishi
- Iwate University, Morioka, Iwate 020-8551 Japan
| | - J. K. Nelson
- College of William and Mary, Williamsburg, VA 23187 USA
| | - J. Nesbit
- University of Wisconsin Madison, Madison, WI 53706 USA
| | - M. Nessi
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - D. Newbold
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - M. Newcomer
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - H. Newton
- Daresbury Laboratory, Cheshire, WA4 4AD UK
| | - R. Nichol
- University College London, London, WC1E 6BT UK
| | | | - A. Nikolica
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - E. Niner
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - A. Norman
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Norrick
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. Northrop
- University of Chicago, Chicago, IL 60637 USA
| | - P. Novella
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | | | - M. Oberling
- Argonne National Laboratory, Argonne, IL 60439 USA
| | | | - A. Olivier
- University of Rochester, Rochester, NY 14627 USA
| | - A. Olshevskiy
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - Y. Onel
- University of Iowa, Iowa City, IA 52242 USA
| | - Y. Onishchuk
- Taras Shevchenko National University of Kyiv, Kyiv, 01601 Ukraine
| | - J. Ott
- University of California Irvine, Irvine, CA 92697 USA
| | - L. Pagani
- University of California Davis, Davis, CA 95616 USA
| | - G. Palacio
- Universidad EIA, Envigado, Antioquia, Colombia
| | - O. Palamara
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. Palestini
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - J. M. Paley
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. Pallavicini
- Università degli Studi di Genova, Genoa, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - C. Palomares
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | | | - E. Pantic
- University of California Davis, Davis, CA 95616 USA
| | - V. Paolone
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | | | - R. Papaleo
- Istituto Nazionale di Fisica Nucleare Laboratori Nazionali del Sud, 95123 Catania, Italy
| | - A. Papanestis
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | | | - S. Parke
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - E. Parozzi
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - Z. Parsa
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Parvu
- University of Bucharest, Bucharest, Romania
| | - S. Pascoli
- Università del Bologna, 40127 Bologna, Italy
- Durham University, Durham, DH1 3LE UK
| | - L. Pasqualini
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - J. Pasternak
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - J. Pater
- University of Manchester, Manchester, M13 9PL UK
| | - C. Patrick
- University College London, London, WC1E 6BT UK
| | - L. Patrizii
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | | | - S. J. Patton
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - T. Patzak
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | - A. Paudel
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - B. Paulos
- University of Wisconsin Madison, Madison, WI 53706 USA
| | - L. Paulucci
- Universidade Federal do ABC, Santo André, SP 09210-580 Brazil
| | - Z. Pavlovic
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. Pawloski
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - D. Payne
- University of Liverpool, Liverpool, L69 7ZE UK
| | - V. Pec
- Institute of Physics, Czech Academy of Sciences, 182 00 Prague 8, Czech Republic
| | | | - A. Pena Perez
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - E. Pennacchio
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - A. Penzo
- University of Iowa, Iowa City, IA 52242 USA
| | - O. L. G. Peres
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - J. Perry
- University of Edinburgh, Edinburgh, EH8 9YL UK
| | | | - G. Pessina
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - G. Petrillo
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - C. Petta
- Università di Catania, 2, 95131 Catania, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Catania, 95123 Catania, Italy
| | - R. Petti
- University of South Carolina, Columbia, SC 29208 USA
| | - V. Pia
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - F. Piastra
- University of Bern, 3012 Bern, Switzerland
| | - L. Pickering
- Michigan State University, East Lansing, MI 48824 USA
| | - F. Pietropaolo
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | - V. L. Pimentel
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
- Centro de Tecnologia da Informacao Renato Archer, Amarais, Campinas, SP CEP 13069-901 Brazil
| | - G. Pinaroli
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - K. Plows
- University of Oxford, Oxford, OX1 3RH UK
| | - R. Plunkett
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. Poling
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - F. Pompa
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - X. Pons
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | - F. Poppi
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - S. Pordes
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Porter
- University of Sussex, Brighton, BN1 9RH UK
| | - M. Potekhin
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - R. Potenza
- Università di Catania, 2, 95131 Catania, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Catania, 95123 Catania, Italy
| | | | - J. Pozimski
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - M. Pozzato
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - S. Prakash
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - T. Prakash
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - M. Prest
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - S. Prince
- Harvard University, Cambridge, MA 02138 USA
| | - F. Psihas
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - D. Pugnere
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - X. Qian
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - J. L. Raaf
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - V. Radeka
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | | | - A. Rafique
- Argonne National Laboratory, Argonne, IL 60439 USA
| | - E. Raguzin
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Rai
- University of Warwick, Coventry, CV4 7AL UK
| | | | - I. Rakhno
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | | | - R. Rameika
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - B. Ramson
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Rappoldi
- Istituto Nazionale di Fisica Nucleare Sezione di Pavia, 27100 Pavia, Italy
- Università degli Studi di Pavia, 27100 Pavia, PV Italy
| | - G. Raselli
- Istituto Nazionale di Fisica Nucleare Sezione di Pavia, 27100 Pavia, Italy
- Università degli Studi di Pavia, 27100 Pavia, PV Italy
| | - P. Ratoff
- Lancaster University, Lancaster, LA1 4YB UK
| | - S. Raut
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | | | - E. M. Rea
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - J. S. Real
- University Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - B. Rebel
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- University of Wisconsin Madison, Madison, WI 53706 USA
| | - R. Rechenmacher
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - J. Reichenbacher
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | - S. D. Reitzner
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - H. Rejeb Sfar
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - A. Renshaw
- University of Houston, Houston, TX 77204 USA
| | - S. Rescia
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - F. Resnati
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - M. Ribas
- Universidade Tecnológica Federal do Paraná, Curitiba, Brazil
| | - S. Riboldi
- Istituto Nazionale di Fisica Nucleare Sezione di Milano, 20133 Milan, Italy
| | - C. Riccio
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - G. Riccobene
- Istituto Nazionale di Fisica Nucleare Laboratori Nazionali del Sud, 95123 Catania, Italy
| | | | - J. S. Ricol
- University Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - A. Rigamonti
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | | | | | - D. Rivera
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - A. Robert
- University Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - L. Rochester
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - M. Roda
- University of Liverpool, Liverpool, L69 7ZE UK
| | | | | | | | | | | | - M. Rosenberg
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - P. Rosier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - B. Roskovec
- University of California Irvine, Irvine, CA 92697 USA
| | - M. Rossella
- Istituto Nazionale di Fisica Nucleare Sezione di Pavia, 27100 Pavia, Italy
- Università degli Studi di Pavia, 27100 Pavia, PV Italy
| | - M. Rossi
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - J. Rout
- Jawaharlal Nehru University, New Delhi, 110067 India
| | - P. Roy
- Wichita State University, Wichita, KS 67260 USA
| | | | - C. Rubbia
- Gran Sasso Science Institute, L’Aquila, Italy
| | - B. Russell
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | | | - A. Rybnikov
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | | | - R. Saakyan
- University College London, London, WC1E 6BT UK
| | - S. Sacerdoti
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | - T. Safford
- Michigan State University, East Lansing, MI 48824 USA
| | - N. Sahu
- Indian Institute of Technology Hyderabad, Hyderabad, 502285 India
| | - K. Sakashita
- High Energy Accelerator Research Organization (KEK), Ibaraki, 305-0801 Japan
| | - P. Sala
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
- Istituto Nazionale di Fisica Nucleare Sezione di Milano, 20133 Milan, Italy
| | - N. Samios
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - O. Samoylov
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | | | - V. Sandberg
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | | | - D. Sankey
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - S. Santana
- University of Puerto Rico, Mayaguez, PR 00681 USA
| | | | | | - P. Sapienza
- Istituto Nazionale di Fisica Nucleare Laboratori Nazionali del Sud, 95123 Catania, Italy
| | - C. Sarasty
- University of Cincinnati, Cincinnati, OH 45221 USA
| | | | - G. Savage
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - V. Savinov
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - A. Scaramelli
- Istituto Nazionale di Fisica Nucleare Sezione di Pavia, 27100 Pavia, Italy
| | - A. Scarff
- University of Sheffield, Sheffield, S3 7RH UK
| | - A. Scarpelli
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - T. Schefke
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - H. Schellman
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- Oregon State University, Corvallis, OR 97331 USA
| | - S. Schifano
- University of Ferrara, Ferrara, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Ferrara, 44122 Ferrara, Italy
| | - P. Schlabach
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - D. Schmitz
- University of Chicago, Chicago, IL 60637 USA
| | - A. W. Schneider
- Massachusetts Institute of Technology, Cambridge, MA 02139 USA
| | | | - A. Schukraft
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - E. Segreto
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - A. Selyunin
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - C. R. Senise
- Universidade Federal de São Paulo, São Paulo, 09913-030 Brazil
| | - J. Sensenig
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - A. Sergi
- University of Birmingham, Birmingham, B15 2TT UK
| | | | | | - S. Shafaq
- Jawaharlal Nehru University, New Delhi, 110067 India
| | - F. Shaker
- York University, Toronto, M3J 1P3 Canada
| | - M. Shamma
- University of California Riverside, Riverside, CA 92521 USA
| | | | | | - R. Sharma
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - R. K. Sharma
- Punjab Agricultural University, Ludhiana, 141004 India
| | - T. Shaw
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - K. Shchablo
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | | | - A. Sheshukov
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - S. Shin
- Jeonbuk National University, Jeonrabuk-do, 54896 South Korea
| | | | - D. Shooltz
- Michigan State University, East Lansing, MI 48824 USA
| | - R. Shrock
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - H. Siegel
- Columbia University, New York, NY 10027 USA
| | - L. Simard
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - J. Sinclair
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - G. Sinev
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | - J. Singh
- University of Lucknow, Lucknow, Uttar Pradesh 226007 India
| | - J. Singh
- University of Lucknow, Lucknow, Uttar Pradesh 226007 India
| | - L. Singh
- Central University of South Bihar, Gaya, 824236 India
| | - P. Singh
- Queen Mary University of London, London, E1 4NS UK
| | - V. Singh
- Banaras Hindu University, Varanasi, 221 005 India
- Central University of South Bihar, Gaya, 824236 India
| | - R. Sipos
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | - G. Sirri
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - A. Sitraka
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | - K. Siyeon
- Chung-Ang University, Seoul, 06974 South Korea
| | - K. Skarpaas
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - A. Smith
- University of Cambridge, Cambridge, CB3 0HE UK
| | - E. Smith
- Indiana University, Bloomington, IN 47405 USA
| | - P. Smith
- Indiana University, Bloomington, IN 47405 USA
| | - J. Smolik
- Czech Technical University, 115 19 Prague 1, Czech Republic
| | - M. Smy
- University of California Irvine, Irvine, CA 92697 USA
| | - E. Snider
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - P. Snopok
- Illinois Institute of Technology, Chicago, IL 60616 USA
| | | | | | - H. Sobel
- University of California Irvine, Irvine, CA 92697 USA
| | | | - S. Sokolov
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | | | | | - S. R. Soleti
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - N. Solomey
- Wichita State University, Wichita, KS 67260 USA
| | - V. Solovov
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003 Lisboa, 3004-516 Coimbra, Portugal
| | - W. E. Sondheim
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - M. Sorel
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - A. Sotnikov
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - J. Soto-Oton
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | | | - A. Sousa
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - K. Soustruznik
- Institute of Particle and Nuclear Physics of the Faculty of Mathematics and Physics of the Charles University, 180 00 Prague 8, Czech Republic
| | | | - M. Spanu
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - J. Spitz
- University of Michigan, Ann Arbor, MI 48109 USA
| | | | | | - M. Stancari
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - L. Stanco
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
- Universtà degli Studi di Padova, 35131 Padua, Italy
| | | | - R. Stein
- University of Bristol, Bristol, BS8 1TL UK
| | - H. M. Steiner
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | | | - J. Stewart
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | - J. Stock
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | - F. Stocker
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - T. Stokes
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - M. Strait
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - T. Strauss
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - L. Strigari
- Texas A &M University, College Station, 77840 USA
| | - A. Stuart
- Universidad de Colima, Colima, Mexico
| | | | | | - H. Sullivan
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - D. Summers
- University of Mississippi, University, MS 38677 USA
| | - A. Surdo
- Istituto Nazionale di Fisica Nucleare Sezione di Lecce, 73100 Lecce, Italy
| | - V. Susic
- University of Basel, 4056 Basel, Switzerland
| | - L. Suter
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - C. M. Sutera
- Università di Catania, 2, 95131 Catania, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Catania, 95123 Catania, Italy
| | - R. Svoboda
- University of California Davis, Davis, CA 95616 USA
| | - B. Szczerbinska
- Texas A &M University-Corpus Christi, Corpus Christi, TX 78412 USA
| | - A. M. Szelc
- University of Edinburgh, Edinburgh, EH8 9YL UK
| | - H. Tanaka
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - S. Tang
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - A. Tapia
- University of Medellín, Medellín, 050026 Colombia
| | | | - A. Tapper
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - S. Tariq
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - E. Tarpara
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - N. Tata
- Harvard University, Cambridge, MA 02138 USA
| | - E. Tatar
- Idaho State University, Pocatello, ID 83209 USA
| | - R. Tayloe
- Indiana University, Bloomington, IN 47405 USA
| | - A. M. Teklu
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - P. Tennessen
- Antalya Bilim University, 07190 Döşemealti/Antalya, Turkey
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - M. Tenti
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - K. Terao
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - C. A. Ternes
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - F. Terranova
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - G. Testera
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - T. Thakore
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - A. Thea
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | | | - C. Thorn
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - S. C. Timm
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - L. Tomassetti
- University of Ferrara, Ferrara, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Ferrara, 44122 Ferrara, Italy
| | - A. Tonazzo
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | - D. Torbunov
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - M. Torti
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - M. Tortola
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - F. Tortorici
- Università di Catania, 2, 95131 Catania, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Catania, 95123 Catania, Italy
| | - N. Tosi
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - D. Totani
- University of California Santa Barbara, Santa Barbara, CA 93106 USA
| | - M. Toups
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - R. Travaglini
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - J. Trevor
- California Institute of Technology, Pasadena, CA 91125 USA
| | - S. Trilov
- University of Bristol, Bristol, BS8 1TL UK
| | | | - Y. Tsai
- University of California Irvine, Irvine, CA 92697 USA
| | - Y.-T. Tsai
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | | | - K. V. Tsang
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - N. Tsverava
- Georgian Technical University, Tbilisi, Georgia
| | - S. Tufanli
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - C. Tull
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - E. Tyley
- University of Sheffield, Sheffield, S3 7RH UK
| | - M. Tzanov
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - L. Uboldi
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | - J. Urheim
- Indiana University, Bloomington, IN 47405 USA
| | - T. Usher
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - S. Uzunyan
- Northern Illinois University, DeKalb, IL 60115 USA
| | - M. R. Vagins
- Kavli Institute for the Physics and Mathematics of the Universe, Kashiwa, Chiba 277-8583 Japan
| | - P. Vahle
- College of William and Mary, Williamsburg, VA 23187 USA
| | - S. Valder
- University of Sussex, Brighton, BN1 9RH UK
| | | | - E. Valencia
- Universidad de Guanajuato, C.P. 37000 Guanajuato, Mexico
| | - R. Valentim
- Universidade Federal de São Paulo, São Paulo, 09913-030 Brazil
| | - Z. Vallari
- California Institute of Technology, Pasadena, CA 91125 USA
| | - E. Vallazza
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - J. W. F. Valle
- Instituto de Física Corpuscular, CSIC and Universitat de València, 46980 Paterna, Valencia Spain
| | - S. Vallecorsa
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - R. Van Berg
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | | | | | - D. Vannerom
- Massachusetts Institute of Technology, Cambridge, MA 02139 USA
| | - F. Varanini
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | - D. Vargas Oliva
- Institut de Física d’Altes Energies (IFAE)-Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
| | - G. Varner
- University of Hawaii, Honolulu, HI 96822 USA
| | - J. Vasel
- Indiana University, Bloomington, IN 47405 USA
| | - S. Vasina
- Joint Institute for Nuclear Research, Dzhelepov Laboratory of Nuclear Problems 6 Joliot-Curie, Dubna, Moscow Region 141980 Russia
| | - G. Vasseur
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - N. Vaughan
- Oregon State University, Corvallis, OR 97331 USA
| | - K. Vaziri
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. Ventura
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | - A. Verdugo
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - S. Vergani
- University of Cambridge, Cambridge, CB3 0HE UK
| | - M. A. Vermeulen
- Nikhef National Institute of Subatomic Physics, 1098 XG Amsterdam, The Netherlands
| | - M. Verzocchi
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. Vicenzi
- Università degli Studi di Genova, Genoa, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - H. Vieira de Souza
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | - C. Vignoli
- Laboratori Nazionali del Gran Sasso, L’Aquila, AQ Italy
| | - C. Vilela
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - B. Viren
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - T. Vrba
- Czech Technical University, 115 19 Prague 1, Czech Republic
| | - T. Wachala
- H. Niewodniczański Institute of Nuclear Physics, Polish Academy of Sciences, Kraków, Poland
| | - A. V. Waldron
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - M. Wallbank
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - C. Wallis
- Colorado State University, Fort Collins, CO 80523 USA
| | - H. Wang
- University of California Los Angeles, Los Angeles, CA 90095 USA
| | - J. Wang
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | - L. Wang
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | | | - X. Wang
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - Y. Wang
- University of California Los Angeles, Los Angeles, CA 90095 USA
| | - Y. Wang
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | | | - D. Warner
- Colorado State University, Fort Collins, CO 80523 USA
| | - M. O. Wascko
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - D. Waters
- University College London, London, WC1E 6BT UK
| | - A. Watson
- University of Birmingham, Birmingham, B15 2TT UK
| | - K. Wawrowska
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
- University of Sussex, Brighton, BN1 9RH UK
| | | | - A. Weber
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- Johannes Gutenberg-Universität Mainz, 55122 Mainz, Germany
| | - M. Weber
- University of Bern, 3012 Bern, Switzerland
| | - H. Wei
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | - D. Wenman
- University of Wisconsin Madison, Madison, WI 53706 USA
| | | | - A. White
- University of Texas at Arlington, Arlington, TX 76019 USA
| | | | | | - M. J. Wilking
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | | | - C. Wilkinson
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - Z. Williams
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - F. Wilson
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - R. J. Wilson
- Colorado State University, Fort Collins, CO 80523 USA
| | - W. Wisniewski
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | | | | | - A. Wood
- University of Houston, Houston, TX 77204 USA
| | - K. Wood
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - E. Worcester
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Worcester
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - K. Wresilo
- University of Cambridge, Cambridge, CB3 0HE UK
| | - C. Wret
- University of Rochester, Rochester, NY 14627 USA
| | - W. Wu
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - W. Wu
- University of California Irvine, Irvine, CA 92697 USA
| | - Y. Xiao
- University of California Irvine, Irvine, CA 92697 USA
| | - F. Xie
- University of Sussex, Brighton, BN1 9RH UK
| | - B. Yaeggy
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - E. Yandel
- University of California Santa Barbara, Santa Barbara, CA 93106 USA
| | - G. Yang
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - K. Yang
- University of Oxford, Oxford, OX1 3RH UK
| | - T. Yang
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - N. Yershov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | - K. Yonehara
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - Y. S. Yoon
- Chung-Ang University, Seoul, 06974 South Korea
| | - T. Young
- University of North Dakota, Grand Forks, ND 58202-8357 USA
| | - B. Yu
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - H. Yu
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - H. Yu
- Sun Yat-Sen University, Guangzhou, 510275 China
| | - J. Yu
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - Y. Yu
- Illinois Institute of Technology, Chicago, IL 60616 USA
| | - W. Yuan
- University of Edinburgh, Edinburgh, EH8 9YL UK
| | - R. Zaki
- York University, Toronto, M3J 1P3 Canada
| | - J. Zalesak
- Institute of Physics, Czech Academy of Sciences, 182 00 Prague 8, Czech Republic
| | - L. Zambelli
- Laboratoire d’Annecy de Physique des Particules, Univ. Grenoble Alpes, Univ. Savoie Mont Blanc, CNRS, LAPP-IN2P3, 74000 Annecy, France
| | - B. Zamorano
- University of Granada & CAFPE, 18002 Granada, Spain
| | - A. Zani
- Istituto Nazionale di Fisica Nucleare Sezione di Milano, 20133 Milan, Italy
| | - L. Zazueta
- College of William and Mary, Williamsburg, VA 23187 USA
| | - G. P. Zeller
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Zennamo
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - K. Zeug
- University of Wisconsin Madison, Madison, WI 53706 USA
| | - C. Zhang
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - S. Zhang
- Indiana University, Bloomington, IN 47405 USA
| | - Y. Zhang
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - M. Zhao
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - E. Zhivun
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - G. Zhu
- Ohio State University, Columbus, OH 43210 USA
| | | | - S. Zucchelli
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - J. Zuklin
- Institute of Physics, Czech Academy of Sciences, 182 00 Prague 8, Czech Republic
| | - V. Zutshi
- Northern Illinois University, DeKalb, IL 60115 USA
| | - R. Zwaska
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | |
Collapse
|
14
|
Ruiz-Romero C, Önnerfjord P, Calamia V, Fernández Puente P, Lourido L, Paz González R, Widera P, Bacardit J, Bay-Jensen AC, Berenbaum F, Haugen IK, Kloppenburg M, Mastbergen S, Larkin J, Mobasheri A, Blanco FJ. OP0224 DISCOVERY PROTEOMICS ANALYSIS IN THE IMI-APPROACH COHORT SHOWS THE DIFFERENTIAL MODULATION AT 24 MONTHS OF PROTEIN PROFILES ASSOCIATED WITH STRUCTURAL OR PAIN PROGRESSION IN OSTEOARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThe characterization of differential molecular endotypes in osteoarthritis (OA) is essential for enabling patient stratification to enhance clinical trials, facilitate the development of targeted and individualized treatments.ObjectivesThis study aimed to characterize the profile and dynamics over 24 months (24M) of proteins present in the sera from patients in the IMI-Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH) cohort who exhibited structural (radiographic) and pain progression compared to participants who did not progressed during this period.MethodsForty-five patients enrolled in the IMI-APPROACH cohort were selected for the proteomic analysis. Among these, 15 showed the highest structural progression (group S) and 15 the highest pain progression (group P) at 24M, according to the APPROACH criteria [1], while 15 did not progressed neither in S nor in P. Baseline (BL) and 24M serum samples were depleted of the top 14 most abundant proteins and then analysed by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) on a nanoElute-LC coupled to a high-resolution TIMS-QTOF (timsTOF Pro, Bruker Daltonics). Proteins were identified and quantified using the LFQ algorithm of MaxQuant software. Further statistical and bioinformatic analyses were performed using Perseus and OmicsAnalyst software.ResultsThe proteomic analysis resulted in the identification of 558 proteins (10,466 peptides) in the serum samples. A label-free quantification algorithm was employed to quantify 468 proteins in the samples. Hierarchical clustering of the data showed the differences in protein abundance were more relevant longitudinally (BL to 24M) than in cross-sectional comparisons between the three groups under study (N, P or S). Sixty-three proteins were significantly altered (fold change >=1.5, p<0.05) when comparing BL to 24M in the N group (15 increased and 48 decreased), 53 in the P group (20 increased and 33 decreased) and 93 in the S group (19 increased and 74 decreased). Interestingly, two different endotypes were detected at baseline in the N and S groups, based on these protein modulations.The overlapping of these proteomic profiles was analyzed between groups and is shown in the Figure 1. Proteins modulated specifically in the N group may be associated with mechanisms related with joint repair. On the other hand, six proteins (including two apolipoproteins) were increased at 24M only in the P group. Finally, 30 proteins were modulated only in the S group: five of them increased and 25 decreased. Remarkably, this latter group includes lubricin, chaperones and proteins related with proteoglycan binding, such as COMP, fibronectin or histidine-rich glycoprotein.Figure 1.Circulating proteins identified as modulated after 24M follow-up in 45 patients from the APPROACH cohort that progressed in structure (S group; n=15), pain (P group; n=15) or did not progressed (N group; n=15). The numbers with arrows indicate those proteins that decrease (arrow pointing down) or increase (arrow pointing up) compared to baseline.ConclusionThe modulation of specific protein profiles in serum were identified as associated with the progression in structure, pain or non-progression in patients from the APPROACH cohort. Proteomic changes found specifically in the S group may be interesting circulating markers of the structural affectation occurring in the joint.References[1]van Helvoort EM, et al., BMJ Open. 2020 Jul 28;10(7):e035101. doi: 10.1136/bmjopen-2019-035101.Disclosure of InterestsCristina Ruiz-Romero: None declared, Patrik Önnerfjord: None declared, Valentina Calamia: None declared, Patricia Fernández Puente: None declared, Lucía Lourido: None declared, Rocío Paz González: None declared, Pawel Widera: None declared, Jaume Bacardit: None declared, Anne-Christine Bay-Jensen Shareholder of: Nordic Bioscience, Employee of: Nordic Bioscience, Francis Berenbaum Consultant of: AstraZeneca, Boehringer, Bone Therapeutics, CellProthera, Expanscience, Galapagos, Gilead, Grunenthal, GSK, Eli Lilly, Merck Sereno, MSD, Nordic, Nordic Bioscience, Novartis, Pfizer, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, 4P Pharma, 4Moving Biotech, Grant/research support from: TRB Chemedica, Ida K. Haugen Consultant of: Abbvie and Novartis, Grant/research support from: Pfizer, Margreet Kloppenburg Consultant of: Abbvie, Pfizer, Levicept, GlaxoSmithKline, Merck-Serono, Kiniksa, Flexion, Galapagos, Jansen, CHDR, Novartis, UCB, Simon Mastbergen: None declared, Jonathan Larkin Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline, Ali Mobasheri Consultant of: Merck KGaA, Kolon TissueGene, Pfizer Inc., Galapagos-Servier, Image Analysis Group (IAG), Artialis SA, Aché Laboratórios Farmacêuticos, AbbVie, Guidepoint Global, Alphasights, Science Branding Communications, GSK, Flexion Therapeutics, Pacira Biosciences, Sterifarma, Bioiberica, SANOFI, Genacol, Kolon Life Science, BRASIT/BRASOS, GEOS, MCI Group, Alcimed, Abbot, Laboratoires Expansciences, SPRIM Communications, Frontiers Media and University Health Network (UHN) Toronto, Grant/research support from: Merck KGaA, Kolon TissueGene, Pfizer Inc., Galapagos-Servier, Image Analysis Group (IAG), Artialis SA, Aché Laboratórios Farmacêuticos, AbbVie, Guidepoint Global, Alphasights, Science Branding Communications, GSK, Flexion Therapeutics, Pacira Biosciences, Sterifarma, Bioiberica, SANOFI, Genacol, Kolon Life Science, BRASIT/BRASOS, GEOS, MCI Group, Alcimed, Abbot, Laboratoires Expansciences, SPRIM Communications, Frontiers Media and University Health Network (UHN) Toronto, Francisco J. Blanco Consultant of: Gedeon Richter Plc., Bristol-Myers Squibb International Corporation (BMSIC), Sun Pharma Global FZE, Celgene Corporation, Janssen Cilag International N.V, Janssen Research & Development, Viela Bio, Inc., Astrazeneca AB, UCB BIOSCIENCES GMBH, UCB BIOPHARMA SPRL, AbbVie Deutschland GmbH & Co.KG, Merck KGaA, Amgen, Inc., Novartis Farmacéutica, S.A., Boehringer Ingelheim España, S.A, CSL Behring, LLC, Glaxosmithkline Research & Development Limited, Pfizer Inc, Lilly S.A., Corbus Pharmaceuticals Inc., Biohope Scientific Solutions for Human Health S.L., Centrexion Therapeutics Corp., Sanofi, TEDEC-MEIJI FARMA S.A., Kiniksa Pharmaceuticals, Ltd., Fundación para la Investigación Biomédica Del Hospital Clínico San Carlos, Grünenthal and Galapagos, Grant/research support from: Pfizer
Collapse
|
15
|
Hussain K, Kawsar A, Weir J, Au L, Turajlic S, Larkin J, Fearfield L. Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit? Clin Exp Dermatol 2022; 47:149-151. [PMID: 34260095 PMCID: PMC8444809 DOI: 10.1111/ced.14852] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Accepted: 07/09/2021] [Indexed: 12/01/2022]
Affiliation(s)
- K. Hussain
- Department of DermatologyChelsea and Westminster HospitalLondonUK
| | - A. Kawsar
- Department of DermatologyChelsea and Westminster HospitalLondonUK
| | - J. Weir
- Department of HistopathologyImperial College Healthcare NHS TrustLondonUK
| | - L. Au
- Skin and Melanoma UnitRoyal Marsden HospitalLondonUK
| | - S. Turajlic
- Skin and Melanoma UnitRoyal Marsden HospitalLondonUK
| | - J. Larkin
- Skin and Melanoma UnitRoyal Marsden HospitalLondonUK
| | - L. Fearfield
- Department of DermatologyChelsea and Westminster HospitalLondonUK
- Skin and Melanoma UnitRoyal Marsden HospitalLondonUK
| |
Collapse
|
16
|
Broderick N, Fawsitt CG, Tyner B, Larkin J, McCarthy M, Walsh KA, O'Neill M, Ryan M. COVID-19 Public Health Guidance Database. Eur J Public Health 2021. [DOI: 10.1093/eurpub/ckab164.738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Since March 2020, members of the Health Technology Assessment (HTA) team in HIQA have been identifying, reviewing and presenting COVID-19 public health guidance produced by international organisations. The aim of this work has been to inform the development of public health guidance and policy by the Health Protection Surveillance Centre (HPSC), Department of Health and Health Service Executive (HSE), using international evidence and best practice.
Methods
International resources are searched on a weekly basis to identify new or updated public health guidance on COVID-19. The three distinct steps in the process include, searching relevant international resources, reviewing identified relevant public health guidance for COVID-19, and presenting new or updated guidance in a COVID-19 Public Health Guidance Database, which was created by the team using Microsoft Excel. The international organisations reviewed include the World Health Organisation, European Centre for Disease Prevention and Control and Centers for Disease Control and Prevention, as well as a range of ministries of health and public health agencies from 10 countries. These were chosen, based on guidance being available in English, widespread use of the organisation's advice, and/or the working constraints of the HTA team.
Results
The COVID-19 Public Health Guidance Database is updated weekly and provided to the relevant individuals within HPSC, Department of Health, and HSE, who are responsible for developing public health and infection, prevention and control guidance related to COVID-19 in Ireland. Following this the database is published online and may be utilised by the public or other international organisations.
Conclusions
The COVID-19 Public Health Guidance Database is used to inform the ongoing response to the COVID-19 pandemic, specifically, to inform the development of public health and infection, prevention and control guidance to prevent the spread of COVID-19.
Collapse
Affiliation(s)
- N Broderick
- Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland
| | - CG Fawsitt
- Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland
| | - B Tyner
- Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland
| | - J Larkin
- Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland
| | - M McCarthy
- Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland
| | - KA Walsh
- Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland
| | - M O'Neill
- Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland
| | - M Ryan
- Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland
- Department of Pharmacology & Therapeutics, Trinity College Dublin, Dublin, Ireland
| |
Collapse
|
17
|
Abbasi Asl R, Muslim A, Larkin J, Takasaki K, Millman D, Denman D, Lecoq J, Arkhipov A, Gouwens NW, Waters J, Reid RC, de Vries SEJ. A large-scale standardized survey of neural receptive fields in an entire column in mouse V1. J Vis 2021. [DOI: 10.1167/jov.21.9.2901] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
18
|
Choueiri TK, Larkin J, Pal S, Motzer RJ, Rini BI, Venugopal B, Alekseev B, Miyake H, Gravis G, Bilen MA, Hariharan S, Chudnovsky A, Ching KA, Mu XJ, Mariani M, Robbins PB, Huang B, di Pietro A, Albiges L. Erratum to 'Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial': [ESMO Open Volume 6, Issue 3, June 2021, 100101]. ESMO Open 2021; 6:100177. [PMID: 34474809 PMCID: PMC8411062 DOI: 10.1016/j.esmoop.2021.100177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Affiliation(s)
- T K Choueiri
- Department of Medical Oncology, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA.
| | - J Larkin
- Renal and Skin Units, The Royal Marsden NHS Foundation Trust, Chelsea, London, UK
| | - S Pal
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, USA
| | - R J Motzer
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - B I Rini
- Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, USA
| | - B Venugopal
- Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK
| | - B Alekseev
- P. Hertsen Moscow Oncology Research Institute, Moscow, Russia
| | - H Miyake
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - G Gravis
- Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Université, Inserm, CNRS, CRCM, Marseille, France
| | - M A Bilen
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA
| | | | | | - K A Ching
- Computational Biology, Pfizer, San Diego, USA
| | - X J Mu
- Computational Biology, Pfizer, San Diego, USA
| | - M Mariani
- Immuno-Oncology, Pfizer, Milan, Lombardia, Italy
| | - P B Robbins
- Translational Oncology, Pfizer, San Diego, USA
| | - B Huang
- Biostatistics, Pfizer, Groton, USA
| | - A di Pietro
- Immuno-Oncology, Pfizer, Milan, Lombardia, Italy
| | - L Albiges
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| |
Collapse
|
19
|
McDermott D, Lee JL, Bjarnason G, Larkin J, Gafanov R, Kochenderfer M, Jensen N, Donskov F, Malik J, Poprach A, Tykodi S, Alonso-Gordoa T, Cho D, Geertsen P, Climent Duran M, Di Simone C, Liu H, Burgents J, Rodriguez-Lopez K, Atkins M. 666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
20
|
Acciarri R, Adams C, Andreopoulos C, Asaadi J, Babicz M, Backhouse C, Badgett W, Bagby L, Barker D, Basque V, Bazetto MCQ, Betancourt M, Bhanderi A, Bhat A, Bonifazi C, Brailsford D, Brandt AG, Brooks T, Carneiro MF, Chen Y, Chen H, Chisnall G, Crespo-Anadón JI, Cristaldo E, Cuesta C, de Icaza Astiz IL, De Roeck A, de Sá Pereira G, Del Tutto M, Di Benedetto V, Ereditato A, Evans JJ, Ezeribe AC, Fitzpatrick RS, Fleming BT, Foreman W, Franco D, Furic I, Furmanski AP, Gao S, Garcia-Gamez D, Frandini H, Ge G, Gil-Botella I, Gollapinni S, Goodwin O, Green P, Griffith WC, Guenette R, Guzowski P, Ham T, Henzerling J, Holin A, Howard B, Jones RS, Kalra D, Karagiorgi G, Kashur L, Ketchum W, Kim MJ, Kudryavtsev VA, Larkin J, Lay H, Lepetic I, Littlejohn BR, Louis WC, Machado AA, Malek M, Mardsen D, Mariani C, Marinho F, Mastbaum A, Mavrokoridis K, McConkey N, Meddage V, Méndez DP, Mettler T, Mistry K, Mogan A, Molina J, Mooney M, Mora L, Moura CA, Mousseau J, Navrer-Agasson A, Nicolas-Arnaldos FJ, Nowak JA, Palamara O, Pandey V, Pater J, Paulucci L, Pimentel VL, Psihas F, Putnam G, Qian X, Raguzin E, Ray H, Reggiani-Guzzo M, Rivera D, Roda M, Ross-Lonergan M, Scanavini G, Scarff A, Schmitz DW, Schukraft A, Segreto E, Soares Nunes M, Soderberg M, Söldner-Rembold S, Spitz J, Spooner NJC, Stancari M, Stenico GV, Szelc A, Tang W, Tena Vidal J, Torretta D, Toups M, Touramanis C, Tripathi M, Tufanli S, Tyley E, Valdiviesso GA, Worcester E, Worcester M, Yarbrough G, Yu J, Zamorano B, Zennamo J, Zglam A. Cosmic Ray Background Removal With Deep Neural Networks in SBND. Front Artif Intell 2021; 4:649917. [PMID: 34505055 PMCID: PMC8421797 DOI: 10.3389/frai.2021.649917] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Accepted: 03/23/2021] [Indexed: 11/13/2022] Open
Abstract
In liquid argon time projection chambers exposed to neutrino beams and running on or near surface levels, cosmic muons, and other cosmic particles are incident on the detectors while a single neutrino-induced event is being recorded. In practice, this means that data from surface liquid argon time projection chambers will be dominated by cosmic particles, both as a source of event triggers and as the majority of the particle count in true neutrino-triggered events. In this work, we demonstrate a novel application of deep learning techniques to remove these background particles by applying deep learning on full detector images from the SBND detector, the near detector in the Fermilab Short-Baseline Neutrino Program. We use this technique to identify, on a pixel-by-pixel level, whether recorded activity originated from cosmic particles or neutrino interactions.
Collapse
Affiliation(s)
- R. Acciarri
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - C. Adams
- Argonne National Laboratory, Lemont, IL, United States
| | - C. Andreopoulos
- University of Liverpool, Liverpool, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell, United Kingdom
| | - J. Asaadi
- University of Texas at Arlington, Arlington, TX, United States
| | - M. Babicz
- CERN, European Organization for Nuclear Research, Geneva, Switzerland
| | - C. Backhouse
- University College London, London, United Kingdom
| | - W. Badgett
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - L. Bagby
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - D. Barker
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - V. Basque
- University of Manchester, Manchester, United Kingdom
| | - M. C. Q. Bazetto
- Universidade Estadual de Campinas, Campinas, Brazil
- Center for Information Technology Renato Archer Campinas, Campinas, Brazil
| | - M. Betancourt
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - A. Bhanderi
- University of Manchester, Manchester, United Kingdom
| | - A. Bhat
- Syracuse University, Syracuse, NY, United States
| | - C. Bonifazi
- Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | | | - A. G. Brandt
- University of Texas at Arlington, Arlington, TX, United States
| | - T. Brooks
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - M. F. Carneiro
- Brookhaven National Laboratory, Upton, NY, United States
| | - Y. Chen
- Universität Bern, Bern, Switzerland
| | - H. Chen
- Brookhaven National Laboratory, Upton, NY, United States
| | - G. Chisnall
- University of Sussex, Brighton, United Kingdom
| | - J. I. Crespo-Anadón
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain
| | - E. Cristaldo
- FIUNA Facultad de Ingeniería, Universidad Nacional de Asunción, San Lorenzo, Paraguay
| | - C. Cuesta
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain
| | | | - A. De Roeck
- CERN, European Organization for Nuclear Research, Geneva, Switzerland
| | - G. de Sá Pereira
- University of Liverpool, Liverpool, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell, United Kingdom
| | - M. Del Tutto
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - V. Di Benedetto
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | | | - J. J. Evans
- University of Manchester, Manchester, United Kingdom
| | - A. C. Ezeribe
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | | | - B. T. Fleming
- Wright Laboratory, Department of Physics, Yale University, New Haven, CT, United States
| | - W. Foreman
- Illinois Institute of Technology, Chicago, IL, United States
| | - D. Franco
- Wright Laboratory, Department of Physics, Yale University, New Haven, CT, United States
| | - I. Furic
- University of Florida, Gainesville, FL, United States
| | | | - S. Gao
- Brookhaven National Laboratory, Upton, NY, United States
| | | | - H. Frandini
- Universidade Estadual de Campinas, Campinas, Brazil
| | - G. Ge
- Columbia University, New York, NY, United States
| | - I. Gil-Botella
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain
| | - S. Gollapinni
- Los Alamos National Laboratory, Los Alamos, NM, United States
- University of Tennessee, Knoxville, TN, United States
| | - O. Goodwin
- University of Manchester, Manchester, United Kingdom
| | - P. Green
- University of Manchester, Manchester, United Kingdom
| | | | - R. Guenette
- Harvard University, Cambridge, MA, United States
| | - P. Guzowski
- University of Manchester, Manchester, United Kingdom
| | - T. Ham
- University of Liverpool, Liverpool, United Kingdom
| | | | - A. Holin
- University College London, London, United Kingdom
| | - B. Howard
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - R. S. Jones
- University of Liverpool, Liverpool, United Kingdom
| | - D. Kalra
- Columbia University, New York, NY, United States
| | | | - L. Kashur
- Colorado State University, Fort Collins, CO, United States
| | - W. Ketchum
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - M. J. Kim
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - V. A. Kudryavtsev
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - J. Larkin
- Brookhaven National Laboratory, Upton, NY, United States
| | - H. Lay
- Lancaster University, Lancaster, United Kingdom
| | - I. Lepetic
- Rutgers University, Piscataway, NJ, United States
| | | | - W. C. Louis
- Los Alamos National Laboratory, Los Alamos, NM, United States
| | | | - M. Malek
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - D. Mardsen
- University of Manchester, Manchester, United Kingdom
| | - C. Mariani
- Center for Neutrino Physics, Virginia Tech, Blacksburg, VA, United States
| | - F. Marinho
- Universidade Federal de São Carlos, Araras, Brazil
| | - A. Mastbaum
- Rutgers University, Piscataway, NJ, United States
| | | | - N. McConkey
- University of Manchester, Manchester, United Kingdom
| | - V. Meddage
- University of Florida, Gainesville, FL, United States
| | - D. P. Méndez
- Brookhaven National Laboratory, Upton, NY, United States
| | | | - K. Mistry
- University of Manchester, Manchester, United Kingdom
| | - A. Mogan
- University of Tennessee, Knoxville, TN, United States
| | - J. Molina
- FIUNA Facultad de Ingeniería, Universidad Nacional de Asunción, San Lorenzo, Paraguay
| | - M. Mooney
- Colorado State University, Fort Collins, CO, United States
| | - L. Mora
- University of Manchester, Manchester, United Kingdom
| | - C. A. Moura
- Universidade Federal do ABC, Santo André, Brazil
| | - J. Mousseau
- University of Michigan, Ann Arbor, MI, United States
| | | | | | - J. A. Nowak
- Lancaster University, Lancaster, United Kingdom
| | - O. Palamara
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - V. Pandey
- University of Florida, Gainesville, FL, United States
| | - J. Pater
- University of Manchester, Manchester, United Kingdom
| | - L. Paulucci
- Universidade Federal do ABC, Santo André, Brazil
| | - V. L. Pimentel
- Universidade Estadual de Campinas, Campinas, Brazil
- Center for Information Technology Renato Archer Campinas, Campinas, Brazil
| | - F. Psihas
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - G. Putnam
- Enrico Fermi Institute, University of Chicago, Chicago, IL, United States
| | - X. Qian
- Brookhaven National Laboratory, Upton, NY, United States
| | - E. Raguzin
- Brookhaven National Laboratory, Upton, NY, United States
| | - H. Ray
- University of Florida, Gainesville, FL, United States
| | | | - D. Rivera
- University of Pennsylvania, Philadelphia, PA, United States
| | - M. Roda
- University of Liverpool, Liverpool, United Kingdom
| | | | - G. Scanavini
- Wright Laboratory, Department of Physics, Yale University, New Haven, CT, United States
| | - A. Scarff
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - D. W. Schmitz
- Enrico Fermi Institute, University of Chicago, Chicago, IL, United States
| | - A. Schukraft
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - E. Segreto
- Universidade Estadual de Campinas, Campinas, Brazil
| | | | - M. Soderberg
- Syracuse University, Syracuse, NY, United States
| | | | - J. Spitz
- University of Michigan, Ann Arbor, MI, United States
| | - N. J. C. Spooner
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | - M. Stancari
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | | | - A. Szelc
- University of Manchester, Manchester, United Kingdom
| | - W. Tang
- University of Tennessee, Knoxville, TN, United States
| | | | - D. Torretta
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - M. Toups
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | | | - M. Tripathi
- University of Florida, Gainesville, FL, United States
| | - S. Tufanli
- CERN, European Organization for Nuclear Research, Geneva, Switzerland
| | - E. Tyley
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| | | | - E. Worcester
- Brookhaven National Laboratory, Upton, NY, United States
| | - M. Worcester
- Brookhaven National Laboratory, Upton, NY, United States
| | - G. Yarbrough
- University of Tennessee, Knoxville, TN, United States
| | - J. Yu
- University of Texas at Arlington, Arlington, TX, United States
| | | | - J. Zennamo
- Fermi National Accelerator Laboratory, Batavia, IL, United States
| | - A. Zglam
- Department of Physics and Astronomy, University of Sheffield, Sheffield, United Kingdom
| |
Collapse
|
21
|
Rzeniewicz K, Larkin J, Menzies AM, Turajlic S. Immunotherapy use outside clinical trial populations: never say never? Ann Oncol 2021; 32:866-880. [PMID: 33771665 PMCID: PMC9246438 DOI: 10.1016/j.annonc.2021.03.199] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Revised: 03/02/2021] [Accepted: 03/05/2021] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Based on favourable outcomes in clinical trials, immune checkpoint inhibitors (ICIs), most notably programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitors, are now widely used across multiple cancer types. However, due to their strict inclusion and exclusion criteria, clinical studies often do not address challenges presented by non-trial populations. DESIGN This review summarises available data on the efficacy and safety of ICIs in trial-ineligible patients, including those with autoimmune disease, chronic viral infections, organ transplants, organ dysfunction, poor performance status, and brain metastases, as well as the elderly, children, and those who are pregnant. In addition, we review data concerning other real-world challenges with ICIs, including timing of therapy switch, relationships to radiotherapy or surgery, re-treatment after an immune-related toxicity, vaccinations in patients on ICIs, and current experience around ICI and coronavirus disease-19. Where possible, we provide recommendations to aid the often-difficult decision-making process in those settings. CONCLUSIONS Data suggest that ICIs are often active and have an acceptable safety profile in the populations described above, with the exception of PD-1 inhibitors in solid organ transplant recipients. Decisions about whether to treat with ICIs should be personalised and require multidisciplinary input and careful counselling of patients with respect to potential risks and benefits. Clinical judgements need to be carefully weighed, considering factors such as underlying cancer type, feasibility of alternative treatment options, or activity in trial-eligible patients.
Collapse
Affiliation(s)
- K Rzeniewicz
- Warwick Medical School, University of Warwick, Warwick, UK; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK
| | - J Larkin
- Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK
| | - A M Menzies
- Melanoma Institute Australia and The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia
| | - S Turajlic
- Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK; Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK.
| |
Collapse
|
22
|
Giles R, Maskens D, Martinez R, Kastrati K, Castro C, Julián Mauro J, Bick R, Packer M, Heng D, Larkin J, Bex A, Jonasch E, Maclennan S, Jewett M. Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 41 countries. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)00586-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Choueiri TK, Larkin J, Pal S, Motzer RJ, Rini BI, Venugopal B, Alekseev B, Miyake H, Gravis G, Bilen MA, Hariharan S, Chudnovsky A, Ching KA, Mu XJ, Mariani M, Robbins PB, Huang B, di Pietro A, Albiges L. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open 2021; 6:100101. [PMID: 33901870 PMCID: PMC8099757 DOI: 10.1016/j.esmoop.2021.100101] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 03/01/2021] [Accepted: 03/02/2021] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Among patients with advanced renal cell carcinoma (RCC), those with sarcomatoid histology (sRCC) have the poorest prognosis. This analysis assessed the efficacy of avelumab plus axitinib versus sunitinib in patients with treatment-naive advanced sRCC. METHODS The randomized, open-label, multicenter, phase III JAVELIN Renal 101 trial (NCT02684006) enrolled patients with treatment-naive advanced RCC. Patients were randomized 1 : 1 to receive either avelumab plus axitinib or sunitinib following standard doses and schedules. Assessments in this post hoc analysis of patients with sRCC included efficacy (including progression-free survival) and biomarker analyses. RESULTS A total of 108 patients had sarcomatoid histology and were included in this post hoc analysis; 47 patients in the avelumab plus axitinib arm and 61 in the sunitinib arm. Patients in the avelumab plus axitinib arm had improved progression-free survival [stratified hazard ratio, 0.57 (95% confidence interval, 0.325-1.003)] and a higher objective response rate (46.8% versus 21.3%; complete response in 4.3% versus 0%) versus those in the sunitinib arm. Correlative gene expression analyses of patients with sRCC showed enrichment of gene pathway scores for cancer-associated fibroblasts and regulatory T cells, CD274 and CD8A expression, and tumors with The Cancer Genome Atlas m3 classification. CONCLUSIONS In this subgroup analysis of JAVELIN Renal 101, patients with sRCC in the avelumab plus axitinib arm had improved efficacy outcomes versus those in the sunitinib arm. Correlative analyses provide insight into this subtype of RCC and suggest that avelumab plus axitinib may increase the chance of overcoming the aggressive features of sRCC.
Collapse
Affiliation(s)
- T K Choueiri
- Department of Medical Oncology, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA.
| | - J Larkin
- Renal and Skin Units, The Royal Marsden NHS Foundation Trust, Chelsea, London, UK
| | - S Pal
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, USA
| | - R J Motzer
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - B I Rini
- Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, USA
| | - B Venugopal
- Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK
| | - B Alekseev
- P. Hertsen Moscow Oncology Research Institute, Moscow, Russia
| | - H Miyake
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - G Gravis
- Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Université, Inserm, CNRS, CRCM, Marseille, France
| | - M A Bilen
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA
| | | | | | - K A Ching
- Computational Biology, Pfizer, San Diego, USA
| | - X J Mu
- Computational Biology, Pfizer, San Diego, USA
| | - M Mariani
- Immuno-Oncology, Pfizer, Milan, Lombardia, Italy
| | - P B Robbins
- Translational Oncology, Pfizer, San Diego, USA
| | - B Huang
- Biostatistics, Pfizer, Groton, USA
| | - A di Pietro
- Immuno-Oncology, Pfizer, Milan, Lombardia, Italy
| | - L Albiges
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| |
Collapse
|
24
|
Lidington E, Darlington AS, Vlooswijk C, Beardsworth S, McCaffrey S, Tang S, Stallard K, Younger E, Edwards P, Ali AI, Nandhabalan M, Din A, Starling N, Larkin J, Stanway S, Nobbenhuis M, Banerjee S, Szucs Z, Gonzalez M, Sirohi B, Husson O, van der Graaf WTA. Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25-39 Years Old in the UK National Health Service. Clin Oncol (R Coll Radiol) 2021; 33:494-506. [PMID: 33722412 DOI: 10.1016/j.clon.2021.02.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 02/04/2021] [Accepted: 02/17/2021] [Indexed: 11/17/2022]
Abstract
AIMS Adolescents and young adults aged 15-39 years with cancer face unique medical, practical and psychosocial issues. In the UK, principal treatment centres and programmes have been designed to care for teenage and young adult patients aged 13-24 years in an age-appropriate manner. However, for young adults (YAs) aged 25-39 years with cancer, little access to age-specific support is available. The aim of this study was to examine this possible gap by qualitatively exploring YA care experiences, involving patients as research partners in the analysis to ensure robust results. MATERIALS AND METHODS We conducted a phenomenological qualitative study with YAs diagnosed with any cancer type between ages 25 and 39 years old in the last 5 years. Participants took part in interviews or focus groups and data were analysed using inductive thematic analysis. Results were shaped in an iterative process with the initial coders and four YA patients who did not participate in the study to improve the rigor of the results. RESULTS Sixty-five YAs with a range of tumour types participated. We identified seven themes and 13 subthemes. YAs found navigating the healthcare system difficult and commonly experienced prolonged diagnostic pathways. Participants felt under-informed about clinical details and the long-term implications of side-effects on daily life. YAs found online resources overwhelming but also a source of information and treatment support. Some patients regretted not discussing fertility before cancer treatment or felt uninformed or rushed when making fertility preservation decisions. A lack of age-tailored content or age-specific groups deterred YAs from accessing psychological support and rehabilitation services. CONCLUSIONS YAs with cancer may miss some benefits provided to teenagers and young adults in age-tailored cancer services. Improving services for YAs in adult settings should focus on provision of age-specific information and access to existing relevant support.
Collapse
Affiliation(s)
- E Lidington
- Royal Marsden NHS Foundation Trust, London, UK
| | | | - C Vlooswijk
- The Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands
| | | | | | - S Tang
- Imperial College Healthcare NHS Trust, London, UK; Public Health England, London, UK
| | | | - E Younger
- Royal Marsden NHS Foundation Trust, London, UK; Radboud University Medical Center, Nijmegen, the Netherlands
| | - P Edwards
- Royal Marsden NHS Foundation Trust, London, UK
| | - A I Ali
- St George's University Hospital NHS Foundation Trust, London, UK
| | | | - A Din
- University of Southampton, Southampton, UK
| | - N Starling
- Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK
| | - J Larkin
- Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK
| | - S Stanway
- Royal Marsden NHS Foundation Trust, London, UK
| | | | - S Banerjee
- Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK
| | - Z Szucs
- East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK
| | - M Gonzalez
- Imperial College Healthcare NHS Trust, London, UK
| | - B Sirohi
- Barts Health NHS Trust, London, UK; Apollo Proton Cancer Centre, Chennai, India
| | - O Husson
- Institute of Cancer Research, London, UK; Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
| | - W T A van der Graaf
- Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK; Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands
| |
Collapse
|
25
|
Ferguson L, Ho B, Weir J, Francis N, West K, Rathbone B, Larkin J, Heelan K. Extensive mucocutaneous, oesophageal and otic lichen planus secondary to nivolumab therapy. Skin Health Dis 2021; 1:e8. [PMID: 35664814 PMCID: PMC9060137 DOI: 10.1002/ski2.8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Revised: 10/19/2020] [Accepted: 10/23/2020] [Indexed: 02/01/2023]
Abstract
We report a 73-year-old female with metastatic renal cell carcinoma who developed a widespread lichenoid reaction following nivolumab treatment. The timeline of the reaction strongly correlated with the nivolumab treatment and subsequent cessation. Our patient had cutaneous, mucosal, otic, ophthalmic and oesophageal involvement, demonstrating the potentially extensive nature of lichenoid reactions to anti-programmed cell death receptor-1 (anti-PD1) therapies. Although lichenoid reactions to anti-PD1 therapies are now well recognized, there have been no previous reports of otic or oesophageal involvement in the literature. Although cutaneous lichenoid reactions do not tend to be severe or treatment limiting, more widespread systemic lichenoid reactions are challenging to manage, particularly in the context of malignancy. This very unusual case highlights the importance of considering involvement beyond the skin in all lichenoid skin reactions.
Collapse
Affiliation(s)
| | - B. Ho
- Dermatology DepartmentSt George's University Hospitals NHS Foundation TrustLondonUK
| | - J. Weir
- Department of HistopathologyImperial College Healthcare NHS TrustLondonUK
| | - N. Francis
- Department of HistopathologyImperial College Healthcare NHS TrustLondonUK
| | - K. West
- Histopathology DepartmentLeicester Royal InfirmaryLeicesterUK
| | - B. Rathbone
- Gastroenterology DepartmentLeicester Royal InfirmaryLeicesterUK
| | - J. Larkin
- Royal Marsden Hospital NHS TrustLondonUK
| | - K. Heelan
- Royal Marsden Hospital NHS TrustLondonUK
| |
Collapse
|
26
|
Edwards CL, Comito F, Agraso Busto S, Harland C, Turajlic S, Larkin J, Heelan K, Fearfield L. Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution. Clin Exp Dermatol 2021; 46:338-341. [PMID: 33010053 DOI: 10.1111/ced.14469] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Revised: 09/22/2020] [Accepted: 09/26/2020] [Indexed: 01/19/2023]
Abstract
Checkpoint inhibitor (CPI) therapy has significantly improved overall survival for metastatic melanoma, and is now approved for use in the adjuvant setting. Modulating the immune system is recognized to cause cutaneous immune-related adverse events (irAEs). We conducted a retrospective observational cohort study of adult patients with melanoma at our tertiary referral centre, who received CPI therapy from 2006 to March 2018. This is the single largest study of cutaneous irAEs occurring on CPI therapy in patients with melanoma to date and encompasses 12 years. The results showed that cutaneous toxicity occurs in 24% of patients but is generally manageable, with < 5% patients discontinuing treatment.
Collapse
Affiliation(s)
- C L Edwards
- Department of Dermatology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
- Departments of, Department of, Dermatology, Royal Marsden NHS Foundation Trust, London, UK
| | - F Comito
- Departments of, Department of, Dermatology, Royal Marsden NHS Foundation Trust, London, UK
| | - S Agraso Busto
- Departments of, Department of, Dermatology, Royal Marsden NHS Foundation Trust, London, UK
| | - C Harland
- Departments of, Department of, Dermatology, Royal Marsden NHS Foundation Trust, London, UK
| | - S Turajlic
- Department of, Cancer Dynamics Laboratory, Francis Crick Institute, London, UK
| | - J Larkin
- Departments of, Department of, Dermatology, Royal Marsden NHS Foundation Trust, London, UK
| | - K Heelan
- Departments of, Department of, Dermatology, Royal Marsden NHS Foundation Trust, London, UK
| | - L Fearfield
- Department of Dermatology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
- Departments of, Department of, Dermatology, Royal Marsden NHS Foundation Trust, London, UK
| |
Collapse
|
27
|
Tarhini AA, Toor K, Chan K, McDermott DF, Mohr P, Larkin J, Hodi FS, Lee CH, Rizzo JI, Johnson H, Moshyk A, Rao S, Kotapati S, Atkins MB. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma ☆. ESMO Open 2021; 6:100050. [PMID: 33556898 PMCID: PMC7872980 DOI: 10.1016/j.esmoop.2021.100050] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 12/18/2020] [Accepted: 01/05/2021] [Indexed: 12/21/2022] Open
Abstract
Background Approved first-line treatments for patients with BRAF V600–mutant advanced melanoma include nivolumab (a programmed cell death protein 1 inhibitor) plus ipilimumab (a cytotoxic T lymphocyte antigen-4 inhibitor; NIVO+IPI) and the BRAF/MEK inhibitors dabrafenib plus trametinib (DAB+TRAM), encorafenib plus binimetinib (ENCO+BINI), and vemurafenib plus cobimetinib (VEM+COBI). Results from prospective randomized clinical trials (RCTs) comparing these treatments have not yet been reported. This analysis evaluated the relative efficacy and safety of NIVO+IPI versus DAB+TRAM, ENCO+BINI, and VEM+COBI in patients with BRAF-mutant advanced melanoma using a matching-adjusted indirect comparison (MAIC). Patients and methods A systematic literature review identified RCTs for DAB+TRAM, ENCO+BINI, and VEM+COBI in patients with BRAF-mutant advanced melanoma. Individual patient-level data for NIVO+IPI were derived from the phase III CheckMate 067 trial (BRAF-mutant cohort) and restricted to match the inclusion/exclusion criteria of the comparator trials. Treatment effects for overall survival (OS) and progression-free survival (PFS) were estimated using Cox proportional hazards and time-varying hazard ratio (HR) models. Safety outcomes (grade 3 or 4 treatment-related adverse events) with NIVO+IPI and the comparators were compared. Results In the Cox proportional hazards analysis, NIVO+IPI showed improved OS compared with DAB+TRAM (HR = 0.53; 95% confidence interval [CI], 0.39-0.73), ENCO+BINI (HR = 0.60; CI, 0.42-0.85), and VEM+COBI (HR = 0.50; CI, 0.36-0.70) for the overall study period. In the time-varying analysis, NIVO+IPI was associated with significant improvements in OS and PFS compared with the BRAF/MEK inhibitors 12 months after treatment initiation. There were no significant differences between NIVO+IPI and BRAF/MEK inhibitor treatment from 0 to 12 months. Safety outcomes favored DAB+TRAM over NIVO+IPI, whereas NIVO+IPI was comparable to VEM+COBI. Conclusion Results of this MAIC demonstrated durable OS and PFS benefits for patients with BRAF-mutant advanced melanoma treated with NIVO+IPI compared with BRAF/MEK inhibitors, with the greatest benefits noted after 12 months. First-line treatments for BRAF V600-mutant melanoma include NIVO+IPI and BRAF/MEK inhibitors. Results from prospective RCTs comparing NIVO+IPI and BRAF/MEK inhibitors have not yet been reported. This MAIC evaluated NIVO+IPI versus BRAF/MEK inhibitors for BRAF-mutant advanced melanoma. OS and PFS benefits were noted with NIVO+IPI versus BRAF/MEK inhibitors beginning at 12 months. These findings may provide information relevant to the selection of treatments for BRAF-mutant advanced melanoma.
Collapse
Affiliation(s)
- A A Tarhini
- Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
| | - K Toor
- Evidence Synthesis and Decision Modeling, Precision HEOR, Vancouver, Canada
| | - K Chan
- Evidence Synthesis and Decision Modeling, Precision HEOR, Vancouver, Canada
| | - D F McDermott
- Medical Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
| | - P Mohr
- Department of Dermatology, Elbe Kliniken Buxtehude, Buxtehude, Germany
| | - J Larkin
- Medical Oncology, The Royal Marsden Hospital, London, UK
| | - F S Hodi
- Medical Oncology, Dana-Farber/Harvard Cancer Center, Boston, USA
| | - C-H Lee
- US Health Economics and Outcome Research, Metastatic Melanoma, Bristol Myers Squibb, Princeton, USA
| | - J I Rizzo
- Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA
| | - H Johnson
- Worldwide Health Economics and Outcomes Research, Melanoma, Bristol Myers Squibb, Uxbridge, UK
| | - A Moshyk
- Worldwide Health Economics and Outcomes Research, Melanoma, Bristol Myers Squibb, Princeton, USA
| | - S Rao
- US Health Economics and Outcome Research, Metastatic Melanoma, Bristol Myers Squibb, Princeton, USA
| | - S Kotapati
- Worldwide Medical, Melanoma, Bristol Myers Squibb, Princeton, USA
| | - M B Atkins
- Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA
| |
Collapse
|
28
|
Saturno G, Lopes F, Niculescu-Duvaz I, Niculescu-Duvaz D, Zambon A, Davies L, Johnson L, Preece N, Lee R, Viros A, Holovanchuk D, Pedersen M, McLeary R, Lorigan P, Dhomen N, Fisher C, Banerji U, Dean E, Krebs MG, Gore M, Larkin J, Marais R, Springer C. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. Ann Oncol 2021; 32:269-278. [PMID: 33130216 PMCID: PMC7839839 DOI: 10.1016/j.annonc.2020.10.483] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 09/21/2020] [Accepted: 10/18/2020] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting G12CKRAS specifically, but therapeutic options for other mutant forms of KRAS are limited, largely because the complexity of downstream signaling and feedback mechanisms mean that targeting individual pathway components is ineffective. DESIGN The protein kinases RAF and SRC are validated therapeutic targets in KRAS-mutant pancreatic ductal adenocarcinomas, colorectal cancers and non-small-cell lung cancers and we show that both must be inhibited to block growth of these cancers. We describe CCT3833, a new drug that inhibits both RAF and SRC, which may be effective in KRAS-mutant cancers. RESULTS We show that CCT3833 inhibits RAF and SRC in KRAS-mutant tumors in vitro and in vivo, and that it inhibits tumor growth at well-tolerated doses in mice. CCT3833 has been evaluated in a phase I clinical trial (NCT02437227) and we report here that it significantly prolongs progression-free survival of a patient with a G12VKRAS spindle cell sarcoma who did not respond to a multikinase inhibitor and therefore had limited treatment options. CONCLUSIONS New drug CCT3833 elicits significant preclinical therapeutic efficacy in KRAS-mutant colorectal, lung and pancreatic tumor xenografts, demonstrating a treatment option for several areas of unmet clinical need. Based on these preclinical data and the phase I clinical unconfirmed response in a patient with KRAS-mutant spindle cell sarcoma, CCT3833 requires further evaluation in patients with other KRAS-mutant cancers.
Collapse
Affiliation(s)
- G Saturno
- Molecular Oncology Group, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK
| | - F Lopes
- Drug Discovery Unit, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK; Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - I Niculescu-Duvaz
- Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - D Niculescu-Duvaz
- Drug Discovery Unit, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK; Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - A Zambon
- Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - L Davies
- Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - L Johnson
- Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - N Preece
- Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - R Lee
- Molecular Oncology Group, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK
| | - A Viros
- Molecular Oncology Group, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK
| | - D Holovanchuk
- Molecular Oncology Group, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK
| | - M Pedersen
- Targeted Therapy Team, the Institute of Cancer Research, London, UK
| | - R McLeary
- Drug Discovery Unit, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK; Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK
| | - P Lorigan
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - N Dhomen
- Molecular Oncology Group, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK
| | - C Fisher
- The Royal Marsden NHS Foundation Trust, London, UK
| | - U Banerji
- The Royal Marsden NHS Foundation Trust, London, UK
| | - E Dean
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - M G Krebs
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - M Gore
- The Royal Marsden NHS Foundation Trust, London, UK
| | - J Larkin
- The Royal Marsden NHS Foundation Trust, London, UK
| | - R Marais
- Molecular Oncology Group, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK.
| | - C Springer
- Drug Discovery Unit, Cancer Research UK Manchester Institute, the University of Manchester, Alderley Park, Manchester, UK; Gene and Oncogene Targeting Team, CR-UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK.
| |
Collapse
|
29
|
Aeppli S, Schmaus M, Eisen T, Escudier B, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini BI, Schmidinger M, Sternberg CN, Rothermundt C, Putora PM. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO Open 2021; 6:100030. [PMID: 33460963 PMCID: PMC7815472 DOI: 10.1016/j.esmoop.2020.100030] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Revised: 12/01/2020] [Accepted: 12/02/2020] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC) has been transformed by targeted therapies with tyrosine kinase inhibitors (TKI) and more recently by the incorporation of immune checkpoint inhibitors (ICI). Today, a spectrum of single agent TKI to TKI/ICI and ICI/ICI combinations can be considered and the choice of the best regimen is complex. MATERIALS AND METHODS We performed an updated decision-making analysis among 11 international kidney cancer experts. Each expert provided their treatment strategy and relevant decision criteria in the first line treatment of mccRCC. After the collection of all input a list of unified decision criteria was determined and compatible decision trees were created. We used a methodology based on diagnostic nodes, which allows for an automated cross-comparison of decision trees, to determine the most common treatment recommendations as well as deviations. RESULTS Diverse parameters were considered relevant for treatment selection, various drugs and drug combinations were recommended by the experts. The parameters, chosen by the experts, were performance status, International Metastatic renal cell carcinoma Database Consortium (IMDC) risk group, PD-L1 status, zugzwang and contraindication to immunotherapy. The systemic therapies selected for first line treatment were sunitinib, pazopanib, tivozanib, cabozantinib, ipilimumab/nivolumab or pembrolizumab/axitinib. CONCLUSION A wide spectrum of treatment recommendations based on multiple decision criteria was demonstrated. Significant inter-expert variations were observed. This demonstrates how data from randomized trials are implemented differently when transferred into daily practice.
Collapse
Affiliation(s)
- S Aeppli
- Division of Oncology and Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
| | - M Schmaus
- Department of Radiotherapy and Radiation Oncology, University Medical Centre Hamburg Eppendorf, Hamburg, Germany
| | - T Eisen
- Department of Oncology, Cambridge University Hospitals National Health Service Foundation, Cambridge, UK
| | | | - V Grünwald
- Interdisciplinary GU Oncology, Clinic for Urology and Clinic for Tumour Research, University Hospital Essen, Essen, Germany
| | - J Larkin
- The Royal Marsden Hospital, London, UK
| | - D McDermott
- Beth Israel Deaconess Medical Centre, Boston, USA
| | - J Oldenburg
- Department of Oncology, Akershus University Hospital and Medical Faculty of University of Oslo, Oslo, Norway
| | - C Porta
- Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', Bari, Italy
| | - B I Rini
- Division of Hematology and Oncology, Vanderbilt University Medical Centre, Nashville, USA
| | - M Schmidinger
- Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Centre, Medical University of Vienna, Austria
| | - C N Sternberg
- Division of Hematology and Oncology, Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, USA
| | - C Rothermundt
- Division of Oncology and Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
| | - P M Putora
- Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland; Department of Radiation Oncology, University of Bern, Bern, Switzerland
| |
Collapse
|
30
|
Siddiqui MS, Lai ZM, Spain L, Greener V, Turajlic S, Larkin J, Morganstein DL. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH. J Endocrinol Invest 2021; 44:195-203. [PMID: 32449093 PMCID: PMC7796881 DOI: 10.1007/s40618-020-01297-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/08/2020] [Accepted: 05/13/2020] [Indexed: 02/08/2023]
Abstract
PURPOSE Ipilimumab, a monoclonal antibody inhibiting CLTA-4, is an established treatment in metastatic melanoma, either alone or in combination with nivolumab, and results in immune mediated adverse events, including endocrinopathy. Hypophysitis is one of the most common endocrine abnormalities. An early recognition of hypophysitis may prevent life threatening consequences of hypopituitarism; therefore, biomarkers to predict which patients will develop hypophysitis would have clinical utility. Recent studies suggested that a decline in TSH may serve as an early marker of IH. This study was aimed at assessing the utility of thyroid function tests in predicting development of hypophysitis. METHODS A retrospective cohort study was performed for all patients (n = 308) treated with ipilimumab either as a monotherapy or in combination with nivolumab for advanced melanoma at the Royal Marsden Hospital from 2010 to 2016. Thyroid function tests, other pituitary function tests and Pituitary MRIs were used to identify those with hypophysitis. RESULTS AND CONCLUSIONS Ipilimumab-induced hypophysitis (IH) was diagnosed in 25 patients (8.15%). A decline in TSH was observed in hypophysitis cohort during the first three cycles but it did not reach statistical significance (P = 0.053). A significant fall in FT4 (P < 0.001), TSH index (P < 0.001) and standardised TSH index (P < 0.001) prior to cycles 3 and 4 in hypophysitis cohort was observed. TSH is not useful in predicting development of IH. FT4, TSH index and standardised TSH index may be valuable but a high index of clinical suspicion remains paramount in early detection of hypophysitis.
Collapse
Affiliation(s)
- M S Siddiqui
- Department of Endocrinology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
| | - Z M Lai
- Department of Endocrinology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
| | - L Spain
- Skin Unit, Royal Marsden Hospital, London, UK
| | - V Greener
- Department of Endocrinology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
| | - S Turajlic
- Skin Unit, Royal Marsden Hospital, London, UK
| | - J Larkin
- Skin Unit, Royal Marsden Hospital, London, UK
| | - D L Morganstein
- Department of Endocrinology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK.
- Skin Unit, Royal Marsden Hospital, London, UK.
| |
Collapse
|
31
|
Acharya A, Agarwal R, Baker M, Baudry J, Bhowmik D, Boehm S, Byler KG, Chen S, Coates L, Cooper C, Demerdash O, Daidone I, Eblen J, Ellingson S, Forli S, Glaser J, Gumbart JC, Gunnels J, Hernandez O, Irle S, Kneller D, Kovalevsky A, Larkin J, Lawrence T, LeGrand S, Liu SH, Mitchell J, Park G, Parks J, Pavlova A, Petridis L, Poole D, Pouchard L, Ramanathan A, Rogers D, Santos-Martins D, Scheinberg A, Sedova A, Shen Y, Smith J, Smith M, Soto C, Tsaris A, Thavappiragasam M, Tillack A, Vermaas J, Vuong V, Yin J, Yoo S, Zahran M, Zanetti-Polzi L. Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19. J Chem Inf Model 2020; 60:5832-5852. [PMID: 33326239 PMCID: PMC7754786 DOI: 10.1021/acs.jcim.0c01010] [Citation(s) in RCA: 109] [Impact Index Per Article: 27.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Indexed: 01/18/2023]
Abstract
We present a supercomputer-driven pipeline for in silico drug discovery using enhanced sampling molecular dynamics (MD) and ensemble docking. Ensemble docking makes use of MD results by docking compound databases into representative protein binding-site conformations, thus taking into account the dynamic properties of the binding sites. We also describe preliminary results obtained for 24 systems involving eight proteins of the proteome of SARS-CoV-2. The MD involves temperature replica exchange enhanced sampling, making use of massively parallel supercomputing to quickly sample the configurational space of protein drug targets. Using the Summit supercomputer at the Oak Ridge National Laboratory, more than 1 ms of enhanced sampling MD can be generated per day. We have ensemble docked repurposing databases to 10 configurations of each of the 24 SARS-CoV-2 systems using AutoDock Vina. Comparison to experiment demonstrates remarkably high hit rates for the top scoring tranches of compounds identified by our ensemble approach. We also demonstrate that, using Autodock-GPU on Summit, it is possible to perform exhaustive docking of one billion compounds in under 24 h. Finally, we discuss preliminary results and planned improvements to the pipeline, including the use of quantum mechanical (QM), machine learning, and artificial intelligence (AI) methods to cluster MD trajectories and rescore docking poses.
Collapse
Affiliation(s)
- A. Acharya
- School of Physics, Georgia Institute of Technology, Atlanta, GA 30332, USA
| | - R. Agarwal
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830, USA
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996, USA
- Graduate School of Genome Science and Technology, University of Tennessee, Knoxville, TN, 37996, USA
| | - M. Baker
- Computer Science and Mathematics Division, Oak Ridge National Lab, Oak Ridge, TN 37830, USA
| | - J. Baudry
- The University of Alabama in Huntsville, Department of Biological Sciences. 301 Sparkman Drive, Huntsville, AL 35899, USA
| | - D. Bhowmik
- Computational Sciences and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
| | - S. Boehm
- Computer Science and Mathematics Division, Oak Ridge National Lab, Oak Ridge, TN 37830, USA
| | - K. G. Byler
- The University of Alabama in Huntsville, Department of Biological Sciences. 301 Sparkman Drive, Huntsville, AL 35899, USA
| | - S.Y. Chen
- Computational Science Initiative, Brookhaven National Laboratory, Upton, NY 11973, USA
| | - L. Coates
- Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
| | - C.J. Cooper
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830, USA
- Graduate School of Genome Science and Technology, University of Tennessee, Knoxville, TN, 37996, USA
| | - O. Demerdash
- Biosciences Division, Oak Ridge National Lab, Oak Ridge, TN 37830, USA
| | - I. Daidone
- Department of Physical and Chemical Sciences, University of L’Aquila, I-67010 L’Aquila, Italy
| | - J.D. Eblen
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830, USA
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996, USA
| | - S. Ellingson
- University of Kentucky, Division of Biomedical Informatics, College of Medicine, UK Medical Center MN 150, Lexington KY, 40536, USA
| | - S. Forli
- Scripps Research, La Jolla, CA, 92037, USA
| | - J. Glaser
- National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830, USA
| | - J. C. Gumbart
- School of Physics, Georgia Institute of Technology, Atlanta, GA 30332, USA
| | - J. Gunnels
- HPC Engineering, Amazon Web Services, Seattle, WA 98121, USA
| | - O. Hernandez
- Computer Science and Mathematics Division, Oak Ridge National Lab, Oak Ridge, TN 37830, USA
| | - S. Irle
- Computational Sciences and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
- Bredesen Center for Interdisciplinary Research and Graduate Education, University of Tennessee, Knoxville, TN 37996, USA
| | - D.W. Kneller
- Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
| | - A. Kovalevsky
- Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
| | - J. Larkin
- NVIDIA Corporation, Santa Clara, CA 95051, USA
| | - T.J. Lawrence
- Biosciences Division, Oak Ridge National Lab, Oak Ridge, TN 37830, USA
| | - S. LeGrand
- NVIDIA Corporation, Santa Clara, CA 95051, USA
| | - S.-H. Liu
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830, USA
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996, USA
| | - J.C. Mitchell
- Biosciences Division, Oak Ridge National Lab, Oak Ridge, TN 37830, USA
| | - G. Park
- Computational Science Initiative, Brookhaven National Laboratory, Upton, NY 11973, USA
| | - J.M. Parks
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830, USA
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996, USA
- Graduate School of Genome Science and Technology, University of Tennessee, Knoxville, TN, 37996, USA
| | - A. Pavlova
- School of Physics, Georgia Institute of Technology, Atlanta, GA 30332, USA
| | - L. Petridis
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830, USA
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996, USA
| | - D. Poole
- NVIDIA Corporation, Santa Clara, CA 95051, USA
| | - L. Pouchard
- Computational Science Initiative, Brookhaven National Laboratory, Upton, NY 11973, USA
| | - A. Ramanathan
- Data Science and Learning Division, Argonne National Lab, Lemont, IL 60439, USA
| | - D. Rogers
- National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830, USA
| | | | | | - A. Sedova
- Biosciences Division, Oak Ridge National Lab, Oak Ridge, TN 37830, USA
| | - Y. Shen
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830, USA
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996, USA
- Graduate School of Genome Science and Technology, University of Tennessee, Knoxville, TN, 37996, USA
| | - J.C. Smith
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830, USA
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996, USA
| | - M.D. Smith
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830, USA
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996, USA
| | - C. Soto
- Computational Science Initiative, Brookhaven National Laboratory, Upton, NY 11973, USA
| | - A. Tsaris
- National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830, USA
| | | | | | - J.V. Vermaas
- National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830, USA
| | - V.Q. Vuong
- Computational Sciences and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA
- Bredesen Center for Interdisciplinary Research and Graduate Education, University of Tennessee, Knoxville, TN 37996, USA
| | - J. Yin
- National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830, USA
| | - S. Yoo
- Computational Science Initiative, Brookhaven National Laboratory, Upton, NY 11973, USA
| | - M. Zahran
- Department of Biological Sciences, New York City College of Technology, The City University of New York (CUNY), Brooklyn, NY 11201, USA
| | | |
Collapse
|
32
|
Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Francesco Ferrucci P, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance A. Cobimetinib plus atezolizumab in BRAF V600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Ann Oncol 2020; 32:384-394. [PMID: 33309774 DOI: 10.1016/j.annonc.2020.12.004] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 12/01/2020] [Accepted: 12/02/2020] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND Emerging data suggest that the combination of MEK inhibitors and immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated whether combining MEK inhibition and immune checkpoint inhibition was more efficacious than immune checkpoint inhibition alone in patients with previously untreated BRAFV600 wild-type advanced melanoma. PATIENTS AND METHODS IMspire170 was an international, randomized, open-label, phase III study. Patients were randomized 1 : 1 to receive cobimetinib (60 mg, days 1-21) plus anti-programmed death-ligand 1 atezolizumab (840 mg every 2 weeks) in 28-day cycles or anti-programmed death-1 pembrolizumab (200 mg every 3 weeks) alone until loss of clinical benefit, unacceptable toxicity, or consent withdrawal. The primary outcome was progression-free survival (PFS), assessed by an independent review committee in the intention-to-treat population. RESULTS Between 11 December 2017, and 29 January 2019, 446 patients were randomized to receive cobimetinib plus atezolizumab (n = 222) or pembrolizumab (n = 224). Median follow-up was 7.1 months [interquartile range (IQR) 4.8-9.9] for cobimetinib plus atezolizumab and 7.2 months (IQR 4.9-10.1) for pembrolizumab. Median PFS was 5.5 months [95% confidence interval (CI) 3.8-7.2] with cobimetinib plus atezolizumab versus 5.7 months (95% CI 3.7-9.6) with pembrolizumab [stratified hazard ratio 1.15 (95% CI 0.88-1.50); P = 0.30]. Hazard ratios for PFS were consistent across prespecified subgroups. In exploratory biomarker analyses, higher tumor mutational burden was associated with improved clinical outcomes in both treatment arms. The most common grade 3-5 adverse events (AEs) were increased blood creatine phosphokinase (10.0% with cobimetinib plus atezolizumab versus 0.9% with pembrolizumab), diarrhea (7.7% versus 1.9%), rash (6.8% versus 0.9%), hypertension (6.4% versus 3.7%), and dermatitis acneiform (5.0% versus 0). Serious AEs occurred in 44.1% of patients with cobimetinib plus atezolizumab and 20.8% with pembrolizumab. CONCLUSION Cobimetinib plus atezolizumab did not improve PFS compared with pembrolizumab monotherapy in patients with BRAFV600 wild-type advanced melanoma.
Collapse
Affiliation(s)
- H Gogas
- First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
| | - B Dréno
- Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France
| | - J Larkin
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - L Demidov
- N.N. Blokhin Russian Cancer Research Center, Ministry of Health, Moscow, Russia
| | - D Stroyakovskiy
- Moscow City Oncology Hospital #62 of Moscow Healthcare Department, Moscow Oblast, Russia
| | - Z Eroglu
- Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
| | | | - J Pigozzo
- Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - P Rutkowski
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - J Mackiewicz
- Department of Medical and Experimental Oncology, Poznan University of Medical Sciences, and Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Center, Poznan, Poland
| | - I Rooney
- Genentech, Inc., South San Francisco, USA
| | - A Voulgari
- Roche Products Ltd, Welwyn Garden City, UK
| | - S Troutman
- Genentech, Inc., South San Francisco, USA
| | - B Pitcher
- Hoffmann-La Roche Ltd., Mississauga, Canada
| | - Y Guo
- Genentech, Inc., South San Francisco, USA
| | - Y Yan
- Genentech, Inc., South San Francisco, USA
| | - M Castro
- Genentech, Inc., South San Francisco, USA
| | - S Mulla
- Hoffmann-La Roche Ltd., Mississauga, Canada
| | - K Flaherty
- Massachusetts General Hospital Cancer Center, Boston, USA
| | - A Arance
- Department of Medical Oncology and IDIBAPS, Hospital Clínic Barcelona, Barcelona, Spain
| |
Collapse
|
33
|
Weber J, Del Vecchio M, Mandalá M, Gogas H, Arance A, Dalle S, Cowey C, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler M, Maio M, Middleton M, Del La Cruz-Merino L, Lobo M, De Pril V, Larkin J, Ascierto P. Nivolumab (NIVO) vs ipilimumab (IPI) en traitement adjuvant du mélanome de stade III/IV opéré : résultats de survie sans récidive (SSR) et de survie globale (SG) à 4 ans de l’essai CheckMate 238. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
34
|
Kirkwood J, Dummer R, Hauschild A, Santinami M, Atkinson V, Sileni VC, Larkin J, Nyakas M, Haydon A, Dutriaux C, Schachter J, Robert C, Mortier L, Banerjee H, Haas T, Tan M, Lau M, Schadendorf D, Long G, Mandala' M. 1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
35
|
Weber J, Del Vecchio M, Mandala M, Gogas H, Fernandez AA, Dalle S, Cowey C, Schenker M, Grob JJ, Sileni VC, Márquez-Rodas I, Butler M, Maio M, Middleton M, Merino LDLC, Lobo M, de Pril V, Larkin J, Ascierto P. 1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1200] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
36
|
Sud A, Jones ME, Broggio J, Loveday C, Torr B, Garrett A, Nicol DL, Jhanji S, Boyce SA, Gronthoud F, Ward P, Handy JM, Yousaf N, Larkin J, Suh YE, Scott S, Pharoah PDP, Swanton C, Abbosh C, Williams M, Lyratzopoulos G, Houlston R, Turnbull C. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol 2020; 31:1065-1074. [PMID: 32442581 PMCID: PMC7237184 DOI: 10.1016/j.annonc.2020.05.009] [Citation(s) in RCA: 355] [Impact Index Per Article: 88.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 05/07/2020] [Accepted: 05/10/2020] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Cancer diagnostics and surgery have been disrupted by the response of health care services to the coronavirus disease 2019 (COVID-19) pandemic. Progression of cancers during delay will impact on patients' long-term survival. PATIENTS AND METHODS We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. We modelled per-patient delay of 3 and 6 months and periods of disruption of 1 and 2 years. Using health care resource costing, we contextualise attributable lives saved and life-years gained (LYGs) from cancer surgery to equivalent volumes of COVID-19 hospitalisations. RESULTS Per year, 94 912 resections for major cancers result in 80 406 long-term survivors and 1 717 051 LYGs. Per-patient delay of 3/6 months would cause attributable death of 4755/10 760 of these individuals with loss of 92 214/208 275 life-years, respectively. For cancer surgery, average LYGs per patient are 18.1 under standard conditions and 17.1/15.9 with a delay of 3/6 months (an average loss of 0.97/2.19 LYGs per patient), respectively. Taking into account health care resource units (HCRUs), surgery results on average per patient in 2.25 resource-adjusted life-years gained (RALYGs) under standard conditions and 2.12/1.97 RALYGs following delay of 3/6 months. For 94 912 hospital COVID-19 admissions, there are 482 022 LYGs requiring 1 052 949 HCRUs. Hospitalisation of community-acquired COVID-19 patients yields on average per patient 5.08 LYG and 0.46 RALYGs. CONCLUSIONS Modest delays in surgery for cancer incur significant impact on survival. Delay of 3/6 months in surgery for incident cancers would mitigate 19%/43% of LYGs, respectively, by hospitalisation of an equivalent volume of admissions for community-acquired COVID-19. This rises to 26%/59%, respectively, when considering RALYGs. To avoid a downstream public health crisis of avoidable cancer deaths, cancer diagnostic and surgical pathways must be maintained at normal throughput, with rapid attention to any backlog already accrued.
Collapse
Affiliation(s)
- A Sud
- Division of Genetics and Epidemiology, Institute of Cancer Research, London
| | - M E Jones
- Division of Genetics and Epidemiology, Institute of Cancer Research, London
| | - J Broggio
- National Cancer Registration and Analysis Service, Public Health England, Wellington House, London
| | - C Loveday
- Division of Genetics and Epidemiology, Institute of Cancer Research, London
| | - B Torr
- Division of Genetics and Epidemiology, Institute of Cancer Research, London
| | - A Garrett
- Division of Genetics and Epidemiology, Institute of Cancer Research, London
| | - D L Nicol
- Urology Unit, Royal Marsden NHS Foundation Trust, London
| | - S Jhanji
- Department of Anaesthesia, Perioperative Medicine and Critical Care, Royal Marsden NHS Foundation Trust, London; Division of Cancer Biology, Institute of Cancer Research, London
| | - S A Boyce
- Department of Colorectal Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford
| | - F Gronthoud
- Department of Microbiology, Royal Marsden NHS Foundation Trust, London
| | - P Ward
- Department of Anaesthesia, Perioperative Medicine and Critical Care, Royal Marsden NHS Foundation Trust, London
| | - J M Handy
- Department of Anaesthesia, Perioperative Medicine and Critical Care, Royal Marsden NHS Foundation Trust, London
| | | | - J Larkin
- Skin and Renal Unit, Royal Marsden NHS Foundation Trust, London; Division of Clinical Studies, Institute of Cancer Research, London
| | - Y-E Suh
- Department of Clinical Oncology, Royal Marsden NHS Foundation Trust, London
| | - S Scott
- RM Partners, West London Cancer Alliance, Royal Marsden NHS Foundation Trust, London
| | - P D P Pharoah
- Department of Public Health and Primary Care, University of Cambridge, Cambridge
| | - C Swanton
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London; Cancer Evolution and Genome Instability Laboratory, University College London Cancer Institute, London
| | - C Abbosh
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London; Cancer Evolution and Genome Instability Laboratory, University College London Cancer Institute, London
| | - M Williams
- Department of Clinical Oncology, Imperial College Healthcare NHS Trust, London; Computational Oncology Group, Imperial College London, London
| | - G Lyratzopoulos
- National Cancer Registration and Analysis Service, Public Health England, Wellington House, London; Epidemiology of Cancer Healthcare and Outcomes (ECHO) Group, University College London, London
| | - R Houlston
- Division of Genetics and Epidemiology, Institute of Cancer Research, London; Department of Clinical Genetics, Royal Marsden NHS Foundation Trust, London, UK
| | - C Turnbull
- Division of Genetics and Epidemiology, Institute of Cancer Research, London; National Cancer Registration and Analysis Service, Public Health England, Wellington House, London; Department of Clinical Genetics, Royal Marsden NHS Foundation Trust, London, UK.
| |
Collapse
|
37
|
Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, Kollmannsberger C, Gravis-Mescam G, Uemura M, Lee JL, Grimm MO, Gurney H, Schmidinger M, Larkin J, Atkins MB, Pal SK, Wang J, Mariani M, Krishnaswami S, Cislo P, Chudnovsky A, Fowst C, Huang B, di Pietro A, Albiges L. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 2020; 31:1030-1039. [PMID: 32339648 PMCID: PMC8436592 DOI: 10.1016/j.annonc.2020.04.010] [Citation(s) in RCA: 266] [Impact Index Per Article: 66.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 03/25/2020] [Accepted: 04/13/2020] [Indexed: 01/31/2023] Open
Abstract
BACKGROUND The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma (aRCC). We report updated efficacy data from the second interim analysis. PATIENTS AND METHODS Treatment-naive patients with aRCC were randomized (1 : 1) to receive avelumab (10 mg/kg) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The two independent primary end points were PFS and overall survival (OS) among patients with programmed death ligand 1-positive (PD-L1+) tumors. Key secondary end points were OS and PFS in the overall population. RESULTS Of 886 patients, 442 were randomized to the avelumab plus axitinib arm and 444 to the sunitinib arm; 270 and 290 had PD-L1+ tumors, respectively. After a minimum follow-up of 13 months (data cut-off 28 January 2019), PFS was significantly longer in the avelumab plus axitinib arm than in the sunitinib arm {PD-L1+ population: hazard ratio (HR) 0.62 [95% confidence interval (CI) 0.490-0.777]}; one-sided P < 0.0001; median 13.8 (95% CI 10.1-20.7) versus 7.0 months (95% CI 5.7-9.6); overall population: HR 0.69 (95% CI 0.574-0.825); one-sided P < 0.0001; median 13.3 (95% CI 11.1-15.3) versus 8.0 months (95% CI 6.7-9.8)]. OS data were immature [PD-L1+ population: HR 0.828 (95% CI 0.596-1.151); one-sided P = 0.1301; overall population: HR 0.796 (95% CI 0.616-1.027); one-sided P = 0.0392]. CONCLUSION Among patients with previously untreated aRCC, treatment with avelumab plus axitinib continued to result in a statistically significant improvement in PFS versus sunitinib; OS data were still immature. CLINICAL TRIAL NUMBER NCT02684006.
Collapse
Affiliation(s)
- T K Choueiri
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, USA.
| | - R J Motzer
- Memorial Sloan Kettering Cancer Center, New York, USA
| | - B I Rini
- Cleveland Clinic, Cleveland, USA
| | - J Haanen
- Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - M T Campbell
- The University of Texas MD Anderson Cancer Center, Houston, USA
| | - B Venugopal
- University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK
| | | | - G Gravis-Mescam
- Institut Paoli-Calmettes, Department of Medical Oncology, Aix-Marseille Université, Inserm, CNRS, CRCM, Marseille, France
| | - M Uemura
- Osaka University Hospital, Osaka, Japan
| | - J L Lee
- University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - M-O Grimm
- Jena University Hospital, Department of Urology, Jena, Germany
| | - H Gurney
- Macquarie University, Sydney, Australia
| | - M Schmidinger
- Clinical Division of Oncology, Department of Medicine I Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - J Larkin
- Royal Marsden NHS Foundation Trust, London, UK
| | - M B Atkins
- Georgetown University Medical Center, Washington, DC
| | - S K Pal
- City of Hope National Medical Center, Duarte, USA
| | | | | | | | | | | | - C Fowst
- Pfizer Italia SRL, Milan, Italy
| | | | | | - L Albiges
- Institut Gustave Roussy, Villejuif, France
| |
Collapse
|
38
|
O'Connell J, Keohane S, McGreal-Bellone A, McDonagh P, Naimimohasses S, Kennedy U, Dunne C, Hartery K, Larkin J, MacCarthy F, Meaney J, McKiernan S, Norris S, O'Toole D, Kevans D. Characteristics and outcomes of acute colitis diagnosed on cross-sectional imaging presenting via the emergency department in an Irish academic medical centre. Ir J Med Sci 2020; 189:1115-1121. [PMID: 31925651 DOI: 10.1007/s11845-019-02162-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Accepted: 12/03/2019] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND AIMS A significant proportion of patients presenting to the Emergency Department with gastrointestinal symptoms that result in cross-sectional imaging receive a radiological diagnosis of colitis. We aimed to review the characteristics, outcomes, and final diagnoses of new emergency department presentations with colitis diagnosed on cross-sectional imaging. METHODS A radiology database was interrogated to identify patients admitted from the Emergency Department of St James's Hospital whose cross-sectional imaging demonstrated colitis. Baseline demographic data, information on inpatient investigations, final diagnoses, and outcomes were recorded. Adverse outcomes were defined as a requirement for surgery, intensive care unit (ICU) stay, or mortality RESULTS: A total of 118 patients, 67% female, were identified with a median age of 64 years (range 16.9-101.2). Median (range) admission duration was 10 days (1-241). Final colitis diagnoses were infectious (28%), undefined (27%), reactive (18%), inflammatory bowel disease (11%), ischaemic (9%), chemotherapy-associated (3%), diverticular (3%), and medication-associated (1%). Colonic perforation, colectomy, and mortality occurred in 1%, 5%, and 13% of the cohort respectively. On univariate analysis, low haemoglobin, low albumin, high lactate, and male gender were associated with adverse outcomes with the following odds ratios (OR) and 95% confidence intervals (95%CI) were low haemoglobin 1.49 [1.15-1.92] P = 0.002, low albumin 1.16 [1.07-1.25] P = 0.0002, lactate 1.65 [1.13-2.42] P = 0.009, and male gender 3.09 [1.23-7.77] P = 0.019. On multivariate analysis, male gender was associated with adverse outcomes. CONCLUSION Patients presenting to the Emergency Department with a colitis, requiring an abdominal CT are a heterogenous group with a proportion having concomitant intra-abdominal pathology resulting in critical illness. Hence their is a significant morbidity and mortality observed in this cohort which should not be extrapolated to a general population of patients presenting with colitis. In this cohort of patients, anaemia, hypoalbuminaemia, and elevated lactate in patients presenting to the ED with acute colitis are significantly associated with adverse outcomes. Early recognition of these prognostic factors may identify the cohort of patients who are best managed in a high-dependency setting.
Collapse
Affiliation(s)
- J O'Connell
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland.
| | - S Keohane
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland
| | - A McGreal-Bellone
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland
| | - P McDonagh
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland
| | - S Naimimohasses
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland
| | - U Kennedy
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland
| | - C Dunne
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland
- Department of Colorectal Surgery, St James's Hospital, Dublin, Ireland
| | - K Hartery
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland
- Department of Colorectal Surgery, St James's Hospital, Dublin, Ireland
| | - J Larkin
- Department of Colorectal Surgery, St James's Hospital, Dublin, Ireland
- Department of Diagnostic Imaging, St James's Hospital, Dublin, Ireland
| | - F MacCarthy
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland
- Department of Colorectal Surgery, St James's Hospital, Dublin, Ireland
| | - J Meaney
- Department of Colorectal Surgery, St James's Hospital, Dublin, Ireland
| | - S McKiernan
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland
- Department of Colorectal Surgery, St James's Hospital, Dublin, Ireland
| | - S Norris
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland
- Department of Colorectal Surgery, St James's Hospital, Dublin, Ireland
| | - D O'Toole
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland
- Department of Colorectal Surgery, St James's Hospital, Dublin, Ireland
| | - D Kevans
- Department of Gastroenterology, St James's Hospital, Dublin, Ireland
- Department of Colorectal Surgery, St James's Hospital, Dublin, Ireland
| |
Collapse
|
39
|
Acharya A, Agarwal R, Baker M, Baudry J, Bhowmik D, Boehm S, Byler KG, Coates L, Chen SY, Cooper CJ, Demerdash O, Daidone I, Eblen JD, Ellingson S, Forli S, Glaser J, Gumbart JC, Gunnels J, Hernandez O, Irle S, Larkin J, Lawrence TJ, LeGrand S, Liu SH, Mitchell JC, Park G, Parks JM, Pavlova A, Petridis L, Poole D, Pouchard L, Ramanathan A, Rogers D, Santos-Martins D, Scheinberg A, Sedova A, Shen S, Smith JC, Smith MD, Soto C, Tsaris A, Thavappiragasam M, Tillack AF, Vermaas JV, Vuong VQ, Yin J, Yoo S, Zahran M, Zanetti-Polzi L. Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19. ChemRxiv 2020:12725465. [PMID: 33200117 PMCID: PMC7668744 DOI: 10.26434/chemrxiv.12725465] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Revised: 07/29/2020] [Indexed: 01/18/2023]
Abstract
We present a supercomputer-driven pipeline for in-silico drug discovery using enhanced sampling molecular dynamics (MD) and ensemble docking. We also describe preliminary results obtained for 23 systems involving eight protein targets of the proteome of SARS CoV-2. THe MD performed is temperature replica-exchange enhanced sampling, making use of the massively parallel supercomputing on the SUMMIT supercomputer at Oak Ridge National Laboratory, with which more than 1ms of enhanced sampling MD can be generated per day. We have ensemble docked repurposing databases to ten configurations of each of the 23 SARS CoV-2 systems using AutoDock Vina. We also demonstrate that using Autodock-GPU on SUMMIT, it is possible to perform exhaustive docking of one billion compounds in under 24 hours. Finally, we discuss preliminary results and planned improvements to the pipeline, including the use of quantum mechanical (QM), machine learning, and AI methods to cluster MD trajectories and rescore docking poses.
Collapse
Affiliation(s)
- A Acharya
- School of Physics, Georgia Institute of Technology, Atlanta, GA 30332
| | - R Agarwal
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996
- Graduate School of Genome Science and Technology, University of Tennessee, Knoxville, TN, 37996
| | - M Baker
- Computer Science and Mathematics Division, Oak Ridge National Lab, Oak Ridge, TN 37830
| | - J Baudry
- The University of Alabama in Huntsville, Department of Biological Sciences. 301 Sparkman Drive, Huntsville, AL 35899
| | - D Bhowmik
- Computational Sciences and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831
| | - S Boehm
- Computer Science and Mathematics Division, Oak Ridge National Lab, Oak Ridge, TN 37830
| | - K G Byler
- The University of Alabama in Huntsville, Department of Biological Sciences. 301 Sparkman Drive, Huntsville, AL 35899
| | - L Coates
- Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831
| | - S Y Chen
- Computational Science Initiative, Brookhaven National Laboratory, Upton, NY 11973
| | - C J Cooper
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830
- Graduate School of Genome Science and Technology, University of Tennessee, Knoxville, TN, 37996
| | - O Demerdash
- Biosciences Division, Oak Ridge National Lab, Oak Ridge, TN 37830
| | - I Daidone
- Department of Physical and Chemical Sciences, University of L'Aquila, I-67010 L'Aquila, Italy
| | - J D Eblen
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996
| | - S Ellingson
- University of Kentucky, Division of Biomedical Informatics, College of Medicine, UK Medical Center MN 150, Lexington KY, 40536
| | - S Forli
- Scripps Research, La Jolla, CA, 92037
| | - J Glaser
- National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830
| | - J C Gumbart
- School of Physics, Georgia Institute of Technology, Atlanta, GA 30332
| | - J Gunnels
- HPC Engineering, Amazon Web Services, Seattle, WA 98121
| | - O Hernandez
- Computer Science and Mathematics Division, Oak Ridge National Lab, Oak Ridge, TN 37830
| | - S Irle
- Computational Sciences and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831
- Bredesen Center for Interdisciplinary Research and Graduate Education, University of Tennessee, Knoxville, TN 37996
| | - J Larkin
- NVIDIA Corporation, Santa Clara, CA 95051
| | - T J Lawrence
- Biosciences Division, Oak Ridge National Lab, Oak Ridge, TN 37830
| | - S LeGrand
- NVIDIA Corporation, Santa Clara, CA 95051
| | - S-H Liu
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996
| | - J C Mitchell
- Biosciences Division, Oak Ridge National Lab, Oak Ridge, TN 37830
| | - G Park
- Computational Science Initiative, Brookhaven National Laboratory, Upton, NY 11973
| | - J M Parks
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996
- Graduate School of Genome Science and Technology, University of Tennessee, Knoxville, TN, 37996
| | - A Pavlova
- School of Physics, Georgia Institute of Technology, Atlanta, GA 30332
| | - L Petridis
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996
| | - D Poole
- NVIDIA Corporation, Santa Clara, CA 95051
| | - L Pouchard
- Computational Science Initiative, Brookhaven National Laboratory, Upton, NY 11973
| | - A Ramanathan
- Data Science and Learning Division, Argonne National Lab, Lemont, IL 60439
| | - D Rogers
- National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830
| | | | | | - A Sedova
- Biosciences Division, Oak Ridge National Lab, Oak Ridge, TN 37830
| | - S Shen
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996
- Graduate School of Genome Science and Technology, University of Tennessee, Knoxville, TN, 37996
| | - J C Smith
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996
| | - M D Smith
- UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830
- The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996
| | - C Soto
- Computational Science Initiative, Brookhaven National Laboratory, Upton, NY 11973
| | - A Tsaris
- National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830
| | | | | | - J V Vermaas
- National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830
| | - V Q Vuong
- Computational Sciences and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831
- Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831
- Bredesen Center for Interdisciplinary Research and Graduate Education, University of Tennessee, Knoxville, TN 37996
| | - J Yin
- National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830
| | - S Yoo
- Computational Science Initiative, Brookhaven National Laboratory, Upton, NY 11973
| | - M Zahran
- Department of Biological Sciences, New York City College of Technology, The City University of New York (CUNY), Brooklyn, NY 11201
| | | |
Collapse
|
40
|
Haanen J, Ernstoff MS, Wang Y, Menzies AM, Puzanov I, Grivas P, Larkin J, Peters S, Thompson JA, Obeid M. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol 2020; 31:724-744. [PMID: 32194150 DOI: 10.1016/j.annonc.2020.03.285] [Citation(s) in RCA: 116] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 03/03/2020] [Accepted: 03/07/2020] [Indexed: 02/08/2023] Open
Abstract
Patients with cancer and with preexisting active autoimmune diseases (ADs) have been excluded from immunotherapy clinical trials because of concerns for high susceptibility to the development of severe adverse events resulting from exacerbation of their preexisting ADs. However, a growing body of evidence indicates that immune-checkpoint inhibitors (ICIs) may be safe and effective in this patient population. However, baseline corticosteroids and other nonselective immunosuppressants appear to negatively impact drug efficacy, whereas retrospective and case report data suggest that use of specific immunosuppressants may not have the same consequences. Therefore, we propose here a two-step strategy. First, to lower the risk of compromising ICI efficacy before their initiation, nonselective immunosuppressants could be replaced by specific selective immunosuppressant drugs following a short rotation phase. Subsequently, combining ICI with the selective immunosuppressant could prevent exacerbation of the AD. For the most common active ADs encountered in the context of cancer, we propose specific algorithms to optimize ICI therapy. These preventive strategies go beyond current practices and recommendations, and should be practiced in ICI-specialized clinics, as these require multidisciplinary teams with extensive knowledge in the field of clinical immunology and oncology. In addition, we challenge the exclusion from ICI therapy for patients with cancer and active ADs and propose the implementation of an international registry to study such novel strategies in a prospective fashion.
Collapse
Affiliation(s)
- J Haanen
- Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, The Netherlands
| | - M S Ernstoff
- Roswell Park Comprehensive Cancer Center, Buffalo, USA
| | - Y Wang
- Department of Gastroenterology, Hepatology & Nutrition, University of Texas MD Anderson Cancer Center, Houston, USA
| | - A M Menzies
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia
| | - I Puzanov
- Roswell Park Comprehensive Cancer Center, Buffalo, USA
| | - P Grivas
- University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, USA
| | - J Larkin
- Royal Marsden NHS Foundation Trust, London, UK
| | - S Peters
- Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV) and Lausanne University, Lausanne, Switzerland
| | - J A Thompson
- University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, USA; National Cancer Institute/NIH, Bethesda, USA
| | - M Obeid
- Department of Medicine, Service of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Vaccine and Immunotherapy Center, Centre Hospitalier Universitaire Vaudois (CHUV), Centre d'Immunothérapie et de Vaccinologie, Lausanne, Switzerland.
| |
Collapse
|
41
|
Peach H, Board R, Cook M, Corrie P, Ellis S, Geh J, King P, Laitung G, Larkin J, Marsden J, Middleton M, Moncrieff M, Nathan P, Powell B, Pritchard-Jones R, Rodwell S, Steven N, Lorigan P. Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement. J Plast Reconstr Aesthet Surg 2020; 73:36-42. [DOI: 10.1016/j.bjps.2019.06.020] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2019] [Accepted: 06/09/2019] [Indexed: 10/26/2022]
|
42
|
Grob JJ, Weber J, Del Vecchio M, Mandala M, Gogas H, Arance A, Dalle S, Lance Cowey C, Schenker M, Chiarion Sileni V, Marquez-Rodas I, Butler M, Maio M, Middleton M, Tang H, Saci A, de Pril V, Lobo M, Larkin J, Ascierto P. Nivolumab (NIVO) versus ipilimumab (IPI) dans le traitement adjuvant du mélanome réséqué de stade III/IV: résultats d’efficacité à 3 ans et analyse de biomarqueurs issus de l’essai de phase 3 CheckMate 238. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
43
|
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2019; 30:1848. [PMID: 31406976 PMCID: PMC6927319 DOI: 10.1093/annonc/mdz221] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
44
|
Liu R, Ball N, Brockill J, Kuan L, Millman D, White C, Leon A, Williams D, Nishiwaki S, de Vries S, Larkin J, Sullivan D, Slaughterbeck C, Farrell C, Saggau P. Aberration-free multi-plane imaging of neural activity from the mammalian brain using a fast-switching liquid crystal spatial light modulator. Biomed Opt Express 2019; 10:5059-5080. [PMID: 31646030 PMCID: PMC6788611 DOI: 10.1364/boe.10.005059] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Accepted: 09/03/2019] [Indexed: 05/27/2023]
Abstract
We report a novel two-photon fluorescence microscope based on a fast-switching liquid crystal spatial light modulator and a pair of galvo-resonant scanners for large-scale recording of neural activity from the mammalian brain. The spatial light modulator is used to achieve fast switching between different imaging planes in multi-plane imaging and correct for intrinsic optical aberrations associated with this imaging scheme. The utilized imaging technique is capable of monitoring the neural activity from large populations of neurons with known coordinates spread across different layers of the neocortex in awake and behaving mice, regardless of the fluorescent labeling strategy. During each imaging session, all visual stimulus driven somatic activity could be recorded in the same behavior state. We observed heterogeneous response to different types of visual stimuli from ∼ 3,300 excitatory neurons reaching from layer II/III to V of the striate cortex.
Collapse
Affiliation(s)
- Rui Liu
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
- Now with GE Healthcare Bio-Sciences Corp, 1040 12th Ave NW, Issaquah, WA, 98027, USA
| | - Neil Ball
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
| | - James Brockill
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
| | - Leonard Kuan
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
| | - Daniel Millman
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
| | - Cassandra White
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
| | - Arielle Leon
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
| | - Derric Williams
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
| | - Shig Nishiwaki
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
| | - Saskia de Vries
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
| | - Josh Larkin
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
| | - David Sullivan
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
| | | | - Colin Farrell
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
| | - Peter Saggau
- Allen Institute for Brain Science, 615 Westlake Ave, Seattle, WA 98109, USA
- Now with Italian Institute of Technology, Via Morego 30, 16163 Genoa, Italy
| |
Collapse
|
45
|
Hayes AJ, Moskovic E, O'Meara K, Smith HG, Pope RJE, Larkin J, Thomas JM. Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma. Br J Surg 2019; 106:729-734. [PMID: 30816996 PMCID: PMC6593779 DOI: 10.1002/bjs.11112] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2018] [Revised: 10/26/2018] [Accepted: 12/11/2018] [Indexed: 02/05/2023]
Abstract
Background For patients with intermediate‐thickness melanoma, surveillance of regional lymph node basins by clinical examination alone has been reported to result in a larger number of lymph nodes involved by melanoma than if patients had initial sentinel node biopsy and completion dissection. This may result in worse regional control. A prospective study of both regular clinical examination and ultrasound surveillance was conducted to assess the effectiveness of these modalities. Methods Between 2010 and 2014, patients with melanoma of thickness 1·2–3·5 mm who had under‐gone wide local excision but not sentinel node biopsy were recruited to a prospective observational study of regular clinical and ultrasound nodal surveillance. The primary endpoint was nodal burden within a dissected regional lymph node basin. Secondary endpoints included locoregional or distant relapse, progression‐free and overall survival. Results Ninety patients were included in the study. After a median follow‐up of 52 months, ten patients had developed nodal relapse as first recurrence, four had locoregional disease outside of an anatomical nodal basin as the first site of relapse and six had relapse with distant disease. None of the patients who developed relapse within a nodal basin presented with unresectable nodal disease. The median number of involved lymph nodes in patients undergoing lymphadenectomy for nodal relapse was 1 (range 1–2; mean 1·2). Conclusion This study suggests that ultrasound surveillance of regional lymph node basins is safe for patients with melanoma who undergo a policy of nodal surveillance.
Collapse
Affiliation(s)
- A J Hayes
- Skin Cancer Unit, Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - E Moskovic
- Department of Radiology, Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - K O'Meara
- Skin Cancer Unit, Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - H G Smith
- Skin Cancer Unit, Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - R J E Pope
- Department of Radiology, Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - J Larkin
- Skin Cancer Unit, Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - J M Thomas
- Skin Cancer Unit, Royal Marsden Hospital NHS Foundation Trust, London, UK
| |
Collapse
|
46
|
Dummer R, Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Mortier L, Robert C, Schachter J, Feng X, de Jong E, Mookerjee B, Kefford R, Kirkwood J, Long G. Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Collinson F, Brown S, Buckley H, Ainsworth G, Howard H, Poad H, Carr G, Banks R, Brown J, Velikova G, Larkin J, Nathan P, Powles T, Vasudev N. PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy283.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv264-iv266. [PMID: 29917046 DOI: 10.1093/annonc/mdy162] [Citation(s) in RCA: 299] [Impact Index Per Article: 49.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
|
49
|
Atkinson V, Hauschild A, Santinami M, Mandala M, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Mortier L, Robert C, Schachter J, Schadendorf D, Feng X, de Jong E, Mookerjee B, Kefford R, Dummer R, Kirkwood J, Long G. Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
Hodi F, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Cowey C, Lao C, Schadendorf D, Wagstaff J, Dummer R, Ferrucci P, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok J. Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.054] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|